Valina Lynn Dawson, Ph.D.
PERSONAL DATA:
Updated: February 12, 2016
Professional Address:
Program in Neuroregeneration and Repair
Institute for Cell Engineering and
Department of Neurology
The Johns Hopkins University
School of Medicine
733 North Wolfe Street, Suite 711
Baltimore, MD 21205
Phone: (410) 614-3361
Fax: (410) 614-9568
Email: vdawson@jhmi.edu
H-INDEX 68
CURRENT APPOINTMENTS
Director, Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The Johns Hopkins
University School of Medicine, Baltimore, MD
Professor, Departments of Neurology, Neuroscience, and Physiology, The Johns Hopkins University School of
Medicine, Baltimore, MD
Vice-Chair, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD
EDUCATION AND TRAINING

Undergraduate
B.S., 1979-1983, University of California at Davis, Davis, CA; Major: Environmental Toxicology

Doctoral
Ph.D., 1985-1989, University of Utah School of Medicine, Department of Pharmacology, Salt Lake City,
UT; Ph.D., Dissertation: Alterations of Muscarinic Receptor Subtypes in Pathways Relating to Memory:
Effects of Lesions and Transplants. Thesis Advisor: Dr. James K. Wamsley.

Postdoctoral
Hospital of the University of Pennsylvania, Department of Neurology, Philadelphia, PA; Postdoctoral
Fellowship, Sponsor: Dr. Marc A. Dichter., 1989-1990.
National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD; Pharmacology Research
Associate Trainingship Fellow, Proctor: Dr. George Uhl, 1990-1992.
National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD; Intramural Research Training
Award, Proctor: Dr. George Uhl, 1992-1993.
Valina L. Dawson, Ph.D.
National Institute on Drug Abuse, Addiction Research Center, Baltimore, MD; Intramural Research Training
Award, Proctor: Dr. Jean Lud Cadet, 1993-1994.
PROFESSIONAL EXPERIENCE
Laboratory for Energy Health Research, University of California at Davis, Davis, CA; Staff Research Associate II
- Analytical Organic Chemist and Toxicologist. 1985
California State Department of Justice, Division of Forensic Toxicology, Sacramento, CA; Forensic Toxicology
Trainee. 1984
Assistant Professor, Departments of Neurology, Neuroscience and Physiology, The Johns Hopkins University
School of Medicine, Baltimore, MD, 1994 –1996
Associate Professor, Departments of Neurology, Neuroscience, and Physiology, The Johns Hopkins University
School of Medicine, Baltimore, MD, 1996-2001
Professor, Departments of Neurology, Neuroscience, and Physiology, The Johns Hopkins University School of
Medicine, Baltimore, MD, 2001- present.
Vice-Chair, Department of Neurology, The Johns Hopkins University School of Medicine, Baltimore, MD, 2001present.
Director, Neuroregeneration and Repair Program, Institute for Cell Engineering, The Johns Hopkins University
School of Medicine, Baltimore, MD, 2002- present.
Director, Neurobiology of Disease Program, Departments of Neurology, The Johns Hopkins University School of
Medicine, Baltimore, MD, 2002- present.
AWARDS AND HONORS
SfN Committee on Women in Neuroscience (2007-2010)
ISI Highly Cited, 2006
SfN Young Investigator Award Committee, Society for Neuroscience (2007-2009)
NINDS Stroke Progress Review Group, Genomics/Proteomics section, Chair, 2006.
NINDS K99-R00 Review Panel, Chair, 2006-present.
Faculty of 1000, 2006-present.
American Heart Steering Committee, 2005-present.
American Academy of Neurology, Frontiers in Clinical Neuroscience, 2005.
ISI Highly Cited, 2004.
McKnight Neuroscience of Brain Disorders, 2004.
Co-Chair, American Heart Association National Review, BS2, 2004.
Reviewing Editor, Journal of Neuroscience, 2003-present.
Leadership Development Program – Johns Hopkins University, 2002.
NINDS NSDA Section Reviewer, 2000-2004.
American Heart Association Establish Investigator Award, 2001.
Mary Lou McIlhany Scholar, 1999-2007
2
Valina L. Dawson, Ph.D.
International Society for Neurochemistry Young Investigator, 1999.
Staglin Music Festival Investigator, 1998.
NARSAD Independent Investigator Award, 1998-2001.
Virginia Davids Scholar, 1998.
Amyotrophic Lateral Sclerosis Association, 1997-1999
Muscular Dystrophy Association, 1997-1999
American Heart Association Grant-In-Aid Award, 1996-1999
National Institutes of Health, NINDS R29 NS33142-01A1, 1995-2000.
Muscular Dystrophy Association, 1995-1997.
Alzheimer's Association Scholar Award, 1994-1997.
NARSAD Young Investigator Award, 1994-1996.
American Heart Association Grant-In-Aid Award, 1994-1996.
AmFAR Scholar Award, 1994-1997
ADAMHA: Intramural Research Training Award. 1992-1993.
National Institute on Drug Abuse Staff Fellow Award, 1992.
Winter Conference on Brain Research Fellowship, Vail, CO, 1991.
National Institutes of Health: PRAT Fellowship, 1990-1992.
National Institutes of Health Training Grant #GMO 7579-07. 1985-1987.
Bekins Scholarship Foundation, 1979-1983
University of California at Davis - Student Orientation Leader Traineeship, 1981.
Italian-American Club Scholarship Foundation, 1979.
Beta Sigma Pi Scholarship Foundation, 1979.
INVENTIONS, PATENTS, COPYRIGHTS

Patents
1. #S5266594-Inhibition of Nitric Oxide Synthase and Use Thereof to Prevent Glutamate Neurotoxicity. V.L.
Dawson, T.M. Dawson, E.D. London, D.S. Bredt and S.H. Snyder. November 30, 1993.
2. #S5587384-Inhibitors of POLY (ADP-ribose) Synthetase and Use Thereof to Treat NMDA Neurotoxicity. J.
Zhang, V.L. Dawson, T.M. Dawson and S.H. Snyder. December 24, 1996.
3. #SRE036397-Inhibitors of POLY (ADP-ribose) Synthetase and Use Thereof to Treat NMDA Neurotoxicity.
J. Zhang, V.L. Dawson, T.M. Dawson and S.H. Snyder. November 16, 1999.
4. #6,358,975 – Method of Using Selective PARP Inhibitors to Prevent or Treat Neurotoxicity. M.J. Eliasson, K.
Sampei, A.S. Mandir; P.D. Hurn, R.J. Traystman, J. Bao, A. Pieper, T.M. Dawson, S.H. Snyder, V.L.
Dawson. March 19, 2002
5. #6,362,160 – Immunophilin-binding agents prevent glutamate neurotoxicity associated with vascular stroke
and neurodegenerative diseases. T.M. Dawson, J.P. Steiner, V.L. Dawson, G.R. Uhl, S.H. Snyder, March 26,
2002.

Copyrights
Doctoral Dissertation: “Alterations of Muscarinic Receptor Subtypes in Pathways Relating to Memory: Effects of
Lesions and Transplants.” V.L. Dawson.
3
Valina L. Dawson, Ph.D.
PUBLICATIONS

Peer-reviewed scientific articles
1.
Dawson, V.L., T.M. Dawson, F.M. Filloux and J.K. Wamsley. “Evidence for Dopamine D-2 Receptors on
Cholinergic Interneurons in the Rat Caudate-Putamen.” Life Sci. 42: 1933-1939 (1988).
2.
Dawson, V.L., F.H. Gage, M.H. Hunt, and J.K. Wamsley. “Normalization of Subtype-Specific Muscarinic
Receptor Binding in the Denervated Hippocampus by Septodiagonal Band Grafts.” Expt. Neurol. 106: 115124 (1989).
3.
Dawson, V.L., and J.K. Wamsley. “Hippocampal Muscarinic Supersensitivity After AF64A Medial Septal
Lesion Excludes M1 Receptors.” Brain Res. Bull. 25: 311-317 (1990).
4.
Dawson, V.L., T.M. Dawson, and J.K. Wamsley. “Muscarinic and Dopaminergic Receptor Subtypes on
Striatal Cholinergic Interneurons.” Brain Res. Bull. 25: 903-912 (1990).
5.
Williams, K.W., V.L. Dawson, C. Romano, M.A. Dichter, and P.B. Molinoff. “Characterization of
Polyamine Sites Having Agonist, Antagonist, and Inverse Agonist Effects at the Polyamine Site of the
NMDA Receptor.” Neuron 5: 199-208 (1990).
6.
Dawson, T.M., V.L. Dawson, L.J. Fisher, F.H. Gage, and J.K. Wamsley. “Functional Recovery of
Supersensitive Dopamine Receptors After Intrastriatal Grafts of Fetal Nigra.” Expt. Neurol. 111: 282-292
(1991).
7.
Dawson, T.M., V.L. Dawson, F.H. Gage, L.J. Fisher, M.A. Hunt and J.K. Wamsley. “Down Regulation of
Muscarinic Receptors in the Rat Caudate-Putamen After Lesioning of the Ipsilateral Nigrostriatal Dopamine
Pathway with 6-Hydroxydopamine (6-OHDA): normalization by Fetal Mesencephalic Transplants.” Brain
Res. 540: 145-152 (1991).
8.
Dawson, V.L., T.M. Dawson, E.D. London, D.S. Bredt, and S.H. Snyder. “Nitric Oxide Mediates Glutamate
Toxicity in Primary Cortical Cultures.” Proc. Natl. Acad. Sci. USA 88: 6368-6371 (1991).
9.
Dawson, V.L., M.A. Hunt and J.K. Wamsley. “Alterations in Cortical Muscarinic Receptors Following
Cholinotoxin (AF64A) Lesion of the Rat Nucleus Basalis Magnocellularis.” Neurobiol. Aging 13: 25-32
(1991).
10. Dawson, V.L., T.M. Dawson, D.A. Bartley, G.R. Uhl, and S.H. Snyder. “Mechanisms of Nitric Oxide
Neurotoxicity in Primary Brain Cultures.” J. Neurosci. 13: 2651-2661 (1993).
11. Kusama, T., C.S. Spivak, P. Whiting, V.L. Dawson, J.C. Schaeffer and G.R. Uhl. “Pharmacology of GABA
Rho1 and GABA Alpha/Beta Receptors Expressed in Xenopus oocytes and COS cells.” Brit. J. Pharmacol.
109: 200-206 (1993).
12. Dawson, T.M., J.P. Steiner, V.L. Dawson, J.L. Dinerman, G.R. Uhl and S.H. Snyder. “Immunosupressant,
FK-506, Enhances Phosphorylation of Nitric Oxide Synthase Protects Against Glutamate Neurotoxicity.”
Proc. Natl. Acad. Sci., USA 90: 9808-9812 (1993).
13. Dawson, V.L., T.M. Dawson, G.R. Uhl and S.H. Snyder. “Human Immunodeficiency Virus-1 Coat Protein
Neurotoxicity Mediated by Nitric Oxide in Primary Cortical Cultures.” Proc. Natl. Acad. Sci., USA 90:
3256-3259 (1993).
14. Dawson, V.L., C.Y. Hsu, T.H. Liu, T.M. Dawson and J.K. Wamsley. “Receptor Alterations in Subcortical
Structures After Bilateral Middle Cerebral Artery Infarction of the Cerebral Cortex.” Expt. Neurol. 128: 8896 (1994).
15. Pogun, S., V.L. Dawson, and M.J. Kuhar. “Nitric Oxide Inhibits [3H]Glutamate Transport in
Synaptosomes.” Synapse 18: 21-26 (1994).
4
Valina L. Dawson, Ph.D.
16. Zhang, J., V.L. Dawson, T.M. Dawson and S.H. Snyder. “Nitric Oxide Activation of Poly (ADP-ribose)
Synthetase in Neurotoxicity.” Science 263: 687-689 (1994)
17. Dawson V.L., H.P. Brahmbhatt, J.A. Mong and T.M. Dawson. “Expression of Inducible Nitric Oxide
Synthase Causes Delayed Neurotoxicity in Primary Mixed Neuronal-Glial Cortical Cultures.”
Neuropharmacology 33: 1425-1430 (1994)
18. Dinerman J.L., J.P. Steiner, T.M. Dawson, V.L. Dawson, and S.H. Snyder. “Cyclic Nucleotide Dependent
Phosporylation of Neuronal Nitric Oxide Synthase Inhibits Catalytic Activity.” Neuropharmacol. 33: 12451252 (1994).
19. Dawson,T.M., K. Hung, V.L. Dawson, J.P. Steiner, S.H. Snyder. “Neuroprotective effects of Gangliosides
May Involve Inhibition of Nitric Oxide Synthase.” Ann. Neurol., 37: 115-118 (1995).
20. Nelson, R.J., G.E. Demas, P.L. Huang M.C. Fishman, V.L. Dawson, T.M. Dawson and S.H. Snyder.
“Behavioral Abnormalities in Male Mice Lacking Neuronal Nitric Oxide Synthase.” Nature 378: 383-386
(1995).
21. Linden D.J., Dawson, T.M., and V.L. Dawson “An Evaluation of the Nitric Oxide/cGMP/cGMP-Dependent
Protein Kinase Cascade in the Induction of Cerebellar Long-Term Depression.” J. Neurosci. 15: 5098-5105
(1995).
22. Bao, J., A.H. Sharp, M.V. Wagster, M. Becher, G. Schilling, C.A. Ross, V.L. Dawson, and T.M. Dawson.
“Expansion of Polyglutamine Repeat in Huntingtin Leads to Abnormal Protein Interactions Involving
Calmodulin.” Proc. Natl. Acad. Sci. USA 93: 5037-5042 (1996).
23. Przedborski S., V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and T.M. Dawson. “Role of
Neuronal Nitric Oxide Synthase in 1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine (MPTP)-Induced
Dopaminergic Neurotoxicity.” Proc. Natl. Acad. Sci. USA 93: 4565-4571 (1996).
24. Adamson, D.C., C. Zink, J. Clements, T.M. Dawson, and V.L. Dawson. “Apoptosis in the CNS of SIV
Infected Rhesus Macaques with Neurologic Disease but not in SIV Infected Rhesus Macaques without
Neurologic Disease.” Molec. Med. 2: 417-428 (1996).
25. Dawson, V.L., V.M. Kizushi, P.L. Huang, S.H. Snyder and T.M. Dawson. “Resistance to Neurotoxicity in
Cortical Cultures from Neuronal Nitric Oxide Synthase Defcient Mice.” J. Neurosci 16: 2479-2487 (1996).
26. Xia Y., V.L. Dawson, T.M. Dawson, S.H. Snyder and J.L. Zweier. “Nitric Oxide Synthase Generates
Superoxide and Nitric Oxide In Arginine-Depleted Cells Leading to Peroxynitrite Mediated Cellular Injury.”
Proc. Natl. Acad. Sci. USA 93: 6770-6774 (1996).
27. Burnett, A.L., R.J. Nelson, D.C. Calvin, J-X Liu, G.E. Demas, S.L. Klien, L.J. Kriegsfeld, V.L. Dawson,
T.M. Dawson and S.H. Snyder. “Nitric oxide Dependent Penile Erection in Mice Lacking Neuronal Nitric
Oxide Synthase.” Molec. Med. 2: 288-286 (1996).
28. Adamson, D.C., B. Wildemann, M. Sasaki, J. McArthur, J. Glass, V.I. Christov T.M. Dawson and V.L.
Dawson. “Immunologic NO Synthase: Elevation in Severe AIDS Dementia and Induction by HIV-1 gp41.”
Science 274: 1917-1921 (1996).
29. Burnett A.L., D.C. Calvin, S.L. Chamness, J.-X. Liu, V.L. Dawson, T.M. Dawson, S.H. Snyder. “Urinary
Bladder-Urethral Sphincter Dysfunction in Mice with Targeted Disruption of Neuronal Nitric Oxide
Synthase Models Idiopathic Voiding Disorders in Humans.” Nature Med., 3: 571-574 (1997).
30. Togashi, H., M. Sasaki, E. Frohman, E. Taira, R.R. Ratan, T.M. Dawson and V.L. Dawson. “Neuronal
(Type I) Nitric Oxide Synthase Regulates NFB Activity and Immunologic (Type II) Nitric Oxide Synthase
Expression.” Proc. Natl. Acad. Sci. USA 94: 2676-2680 (1997).
31. Samdani, A.F., C. Newcamp, A. Resink, F. Facchinetti, B.E. Hoffman, V.L. Dawson and T.M. Dawson.
“Differential Susceptibility to Neurotoxicity is Mediated by Neurotrophins and Neuronal Nitric Oxide
Synthase.” J. Neurosci. 17: 4633-4641 (1997).
5
Valina L. Dawson, Ph.D.
32. Kriegsfeld L.J., T.M. Dawson, V.L. Dawson, R.J. Nelson, and S.H. Snyder. “Aggressive Behavior in Male
Mice Lacking the Gene for Neuronal Nitric Oxide Synthase is Testosterone-Dependent.” Brain Res. 769:
66-70 (1997)
33. Eliasson, M.J.L., K. Sampei, A.S. Mandir, P.D. Hurn, R.J. Traystman, J. Bao, A. Pieper, Z.-Q. Wang, T.M.
Dawson, S.H. Snyder, and V.L. Dawson. “Poly(ADP-Ribose) Polymerase Gene Disruption Renders Mice
Resistant to Cerebral Ischemia.” Nature Med. 3: 1089-1095 (1997).
34. Demas, G.E,. M.J.L. Eliasson, T.M. Dawson, V.L. Dawson, L.J. Kriegsfeld, R.J. Nelson, and S.H. Snyder.
“Inhibition of Neuronal Nitric Oxide Synthase Increases Aggressive Behavior in Mice.” Molec. Med. 3:
611-617 (1997).
35. Nelson, R.J., L.J. Kriegsfeld, V.L. Dawson, and T.M. Dawson. “Effects of Nitric Oxide on Neuroendrocrine
Function and Behavior.” PMID: 9344634 Frontiers in Neuroendocrinol, 18: 463-491 (1997).
36. Gonzalez-Zulueta, M., G. Mukhin, L. Ensz, R.M. Zwacka, J.F. Engelhardt, L.W. Oberley, V.L. Dawson,
and T.M. Dawson. “Manganese Superoxide Dismutase Protects nNOS Neurons From NMDA and Nitric
Oxide Mediated Neurotoxicity.” PMID: 9482791 J. Neurosci. 18: 2040-2055 (1998).
37. Weiss, S.W., D.S. Albers, M. J. Iadarola, T.M. Dawson, V.L. Dawson, D.G. Standaert. “NMDAR1
Glutamate Receptor Subunit Isoforms in Neostriatal, Neocortical and Hippocampal Nitric Oxide Snythase
Neurons.” PMID: 9464997 J. Neurosci. 18: 1725-1734 (1998).
38. Crosbie, R.H., V. Straub, H.Y. Yun, J.C. Lee, J.A. Rafael, J.S. Chamberlain, V.L. Dawson, T.M. Dawson
and Kevin P. Campbell. “mdx Muscle Pathogenesis is Independent of nNOS Perturbations.” PMID: 9536086
Human Molec. Genet., 7: 823-9 (1998).
39. Cooper, J.K., G. Schilling,, M.F. Peters, W.J. Herring, A.H. Sharp, Z. Kaminsky, J. Masone, F.A. Khan, M.
Delanoy, D.R. Borchelt, V.L. Dawson, T.M. Dawson, and C.A. Ross. “Truncated N-terminal fragments of
huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture.” PMID:
9536081 Hum Mol Genet, 7: 783-90 (1998).
40. Yun, H-Y., M. Gonzalez-Zulueta, V.L. Dawson, and T.M. Dawson. “Nitric Oxide Mediates NMDA
Receptor Induced Activation of p21ras.” PMID: 9576960 Proc. Natl. Acad. Sci, USA 95: 5773-5778 (1998).
41. Facchinetti, F., M. Sasaki, D. Reif, M.F. Beal, T.M. Dawson, M.E. Gurney and V.L. Dawson. “Possible
Involvement of Neuronal Nitric Oxide Synthase in the Pathogenesis of a Transgenic Mouse Model of
Familial Amyotrophic Lateral Sclerosis.” PMID: 10338314 Neurosci. 90: 1483-1492 (1999).
42. Klein, S.L., D. Carnovale, A.L. Burnett, E.E. Wallach, H.A. Zacur, J.K. Crone, V.L. Dawson, R.J. Nelson,
and T.M. Dawson. “Impaired Ovulation in Mice with Targeted Deletion of the Neuronal Isoform of Nitric
Oxide Synthase.” PMID: 9848082 Mol. Med. 4: 658-664 (1998).
43. Jumrussirikul, J. Dinerman, T.M. Dawson, V.L. Dawson, U. Ekelund, D. Georgakopoulos, L.P. Schramm,
H. Calkins, S.H. Snyder, J. Hare, R.D. Berger. “Interaction between Neuronal Nitric Oxide Synthase and
Inhibitory G Protein Activity in Heart Rate Regulation in Conscious Mice.” PMID: 9769319 J. Clin. Invest.,
102: 1279-1285 (1998)
44. Adamson, D.C., J.C. McArthur, T.M. Dawson, and V.L. Dawson. “Course of HIV-Associated Dementia:
Correlation’s with gp41, iNOS and Macrophage/Microglial Activation.” PMID: 10203575 Mol. Med. 5: 98109 (1999).
45. Adamson, D.C., K.L. Kopnisky, T.M. Dawson, and V.L. Dawson. “Mechanisms and Structural
Determinants of HIV-1 Coat Protein gp41-Induced Neurotoxicity.” PMID: 9870939 J. Neurosci. 19: 64-71
(1999).
46. Wei, G. V.L. Dawson and J.L. Zweier. “Role of Neuronal And Endothelial Nitric Oxide Synthase in Nitric
Oxide Generation in the Brain Following Cerebral Ischemia.” PMID: 10524226 Biochim. Biophys. ACTA
1544(1): 23-34 (1999).
6
Valina L. Dawson, Ph.D.
47. Mandir, A.S., S. Przedborski, V. Jackson-Lewis, Z.-Q. Wang, C. Simbulan-Rosenthal, M.E. Smulson, B.E.
Hoffman, D.B. Guastella, V.L. Dawson and T.M. Dawson, “Poly (ADP-ribose) Polymerase Activation
Mediates MPTP-induced Parkinsonism.” PMID: 10318960 Proc. Natl. Acad. Sci. USA 96: 5774-5779
(1999).
48. Kriegsfeld L.J., G.E. Demas, S.E. Lee, T.M. Dawson, V.L. Dawson, and R.J. Nelson. “Circadian
Locomotor Analysis of Male Mice Lacking the Gene for Nitric Oxide Synthase (nNOS-/-).” PMID:
10036989 J. Biol. Rhythms 14(1): 19-26 (1999).
49. Toung, T.J., A. Bhardwaj, V.L. Dawson, T.M. Dawson, R.J. Traystman, and P.D. Hurn. “Neuroprotective
FK506 Does Not Alter In Vivo Nitric Oxide Production During Ischemia and Early Reperfusion in Rats.”
MID: 10356112 Stroke 30: 1279-1285 (1999).
50. Peters, M.F., F.C Nucifora, Jr., J. Kushi, H.C. Seaman, J.K Cooper, W.J. Herring, V.L. Dawson, T.M.
Dawson, C.A. Ross. “Nuclear Targeting Of Mutant Huntingtin Increases Toxicity.” PMID: 10479410 Mol.
Cell Neurosci., 14: 121-128 (1999).
51. Liberatore, G.T., V. Jackson-Lewis, A.S. Mandir, J.W. McAuliffe, M. Vila, V.L. Dawson, T. M. Dawson, S.
Przedborski. “Inducible Nitric Oxide Synthase Stimulates Dopaminergic Neurodegeneration in the MPTP
Model of Parkinson’s Disease.” PMID: 10581083 Nature Med 12: 1403-1409 (1999).
52. Engelender, S., Z. Kaminsky, S. Blackshaw, X. Guo, A.H. Sharp, R.K. Amaravi, J.J. Kleiderlein, R.L.
Margolis, J.C. Troncoso, A.A. Lanahan, P.F. Worley, V.L. Dawson, T.M. Dawson, and C.A. Ross.
“Synphilin1: A Protein Associated with Alpha-Synuclein that Promotes the Formation of Cytosolic
Inclusions.” PMID: 10319874 Nature Genetics, 22: 110-114 (1999).
53. Yun H.-Y., V.L. Dawson and T.M. Dawson “Glutamate-Stimulated Calcium Activation of Ras/Erk Pathway
Mediated by Nitric Oxide.” PMID: 10588362 Diabetes Res Clin Pract. 45: 113-115 (1999).
54. Gonzalez-Zulueta, M., A.B. Feldman, L.J. Klesse, R.G. Kalb, J.F. Dillman, L.F. Parada, T.M. Dawson, V.L.
Dawson. “Nitric Oxide Activation of p21ras//Erk-Dependent Signaling is Required for Ischemic
Preconditioning in Neurons.” PMID: 10618436 Proc. Natl. Acad. Sci., USA., 97: 436-441 (2000).
55. Sasaki, M., M. Gonzalez-Zulueta, H. Huang, W.J. Herring, S. Ahn, D.D. Ginty, V.L. Dawson, and T. M.
Dawson. “Dynamic regulation of neuronal NO synthase transcription by calcium influx through a CREB
family transcription factor-dependent mechanism..” PMID: 10900019 Proc. Natl. Acad. Sci. USA 97:861722 (2000).
56. Mandir A.S, M. Poitras A.R. Berliner, W.J. Herring, D.B. Gustella, A. Feldman, G.G. Poirier, Z-Q. Wang,
T.M. Dawson and V.L. Dawson. “NMDA but not Non-NMDA Excitotoxicity is Mediated by Poly (ADPRibose) Polymerase.” PMID: 11050121 J. Neurosci. 20:8005-8011 (2000).
57. Sampei K., Mandir A.S., Asano Y., Wong P.C., Traystman R.J., Dawson V.L., Dawson T.M., Hurn P.D.
“Stroke outcome in double-mutant antioxidant transgenic mice.” PMID: 11062295 Stroke 31:2685-2691
(2000).
58. Zhang Y., Gao J., Chung K.K., Huang H., Dawson V.L., Dawson T.M. “Parkin functions as an E2dependent ubiquitin- protein ligase and promotes the degradation of he synaptic vesicle-associated protein,
CDCrel-1.” PMID: 11078524 Proc Natl Acad Sci USA 97:13354-13359 (2000).
59. Chiavegatto, S., V.L. Dawson, L.A. Mamounas, VE. Koliatsos, T.M. Dawson, and R.J. Nelson. “Brain
serotonin dysfunction accounts for aggression in male mice lacking neuronal nitric oxide synthase.” PMID:
11158630 Proc. Natl. Acad. Sci. USA, 98: 1277-1281, (2001).
60. Aghdasi, B., K.Ye, A. Resnick, A. Huang, H.C. Ha, X. Guo, T.M. Dawson, V.L. Dawson, and S.H. Snyder.
“FKBP12, the 12-kDa FK506-binding protein, is a physiologic regulator of the cell cycle.” PMID: 11226255
Proc. Natl. Acad. Sci., U.S.A. 98: 2425-2430 (2001).
61. Nucifora F.C., Jr, M. Sasaki, M.F. Peters, H. Huang, J.K. Cooper, M. Yamada, H. Takahashi, S. Tsuji, J.
Troncoso, V.L. Dawson, T.M. Dawson, C.A. Ross “Interference by huntingtin and atrophin-1 with CBPmediated transcription leading to cellular toxicity.” PMID: 11264541 Science 291: 2423-8 (2001).
7
Valina L. Dawson, Ph.D.
62. Tanaka, Y., S. Engelender, S. Igarashi, R.K. Rao, T. Wanner, R.E. Tanzi, A. Sawa, V.L. Dawson, T.M.
Dawson and C.A. Ross. "Inducible Expression -Synuclein Sensitizes Cells to Mitochondria-Dependent
Apoptosis." PMID: 11309365 Human Mol. Genetics, 10: 919-926 (2001).
63. Nandagopal, K., T.M. Dawson and V.L. Dawson. "Critical Role for Nitric Oxide Signaling in Cardiac and
Neuronal Ischemic Tolerance." PMID: 11303032 J. Pharmacol. Exp. Ther., 297: 474-478 (2001).
64. Wildemann, B., H. Juergen, K. Stingele, B. Storch-Hagenlocher, J.C. McArthur, T.M. Dawson and V.L.
Dawson. "Identification by mRNA Differential Display of Two Up-regulated Genes as Candidate Mediators
of AIDS Dementia." PMID: 11471556 Molec. Med., 7(3): 193-199, (2001).
65. Guo, X., V.L. Dawson and T.M. Dawson. "Immunophilin Ligands Exert Neuroregeneration and
Neuroprotection in Midbrain Dopaminergic Neurons.” PMID: 11359520 Eur. J. Neurosci. 13: 1683-1693
(2001).
66. Yen, L., M. Gonzalez-Zulueta, A. Feldman, Y. Yuan, H. Fryer, T.M. Dawson, V.L. Dawson, R.G. Kalb.
"Reduction of Functional N-methyl-D-aspartate receptors in neurons by RNase P-mediated cleavage of the
NR1 mRNA.” PMID: 11238723 J. Neurochem., 76: 1386-94 (2001).
67. Goyagi T., S. Goto, A. Bhardwaj, V.L. Dawson, P.D. Hurn, J.R. Kirsch. “Neuroprotective Effect of final
sigma(1)-Receptor Ligand 4-Phenyl-1-(4-Phenylbutyl) Piperidine (PPBP) Is Linked to Reduced Neuronal
Nitric Oxide Production.” PMID: 11441209 Stroke 32(7):1613-1620 (2001).
68. Chung, K.K.K, Y. Zhang, K. L. Lim, Y. Tanaka, H. Huang, J. Gao, C. A. Ross, V. L. Dawson and T. M.
Dawson. "Parkin Ubiquitinates the a-Synuclein-Interacting Protein, Synphilin-1: Implications for Lewy
Body Formation in Parkinson Disease." PMID: 11590439 Nature Med., 7:1144-1150 (2001).
69. Goto, S, R. Xue, N. Sugo, M. Sawada, M.F. Poitras, D.C. Johns, T.M Dawson, V.L. Dawson, B.J. Crain,
R.J. Traystman, S. Mori, P.D. Hurn. “Poly (ADP-ribose)polymerase (PARP-1) Impairs Early and LongTerm Experimental Stroke Recovery.” PMID: 11935067 Stroke 33(4):1101-6 (2002).
70. Yu, S.W., H. Wang, M.F. Poitras, C. Coombs, W.J. Bowers, H.J. Federoff, G.G. Poirier, T.M. Dawson, V.L.
Dawson. “Mediation of Poly(ADP-Ribose) Polymerase-1 Dependent Cell Death by Apoptosis Inducing
Factor,” PMID: 12114629 Science 297:259-263 (2002). *Selected as a Hot Topics Paper by ISI (11/2003),
Selected for the Faculty of 1000, http://www.facultyof1000.com, (3/2004).
71. Cregan SP, A Fortin, JG MacLaurin, SM Callaghan, F Cecconi, SW Yu, TM Dawson, VL Dawson, DS
Park, G Kroemer, RS Slack. “Apoptosis-inducing factor is involved in the regulation of caspase-independent
neuronal cell death.” PMID: 12147675 J Cell Biol 5;158(3):507-17 (2002).
72. Mandir AS, CM Simbulan-Rosenthal, MF Poitras, JR Lumpkin , VL Dawson , ME Smulson , TM Dawson.
“A novel in vivo post-translational modification of p53 by PARP-1 in MPTP-induced parkinsonism.” PMID:
12358742 J Neurochem. 83:186-192, 2002.
73. Dawson, T.M. and V.L. Dawson. “Neuroprotective and Neurorestorative Strategies for Parkinson’s
Disease.” PMID: 12403986 Nature Neuroscience, 5:1058-1061 (2002).
74. Wei, X., M. Sasaki, H. Huang, V.L. Dawson and T.M. Dawson. "The Orphan Nuclear Receptor,
Steroidogenic Factor 1 (SF-1) Regulates Neuronal Nitric Oxide Synthase Gene Expression in Pituitary
Gonadotropes." PMID: 12456803 Mol. Endocrinology, 16:2828-2839 (2002).
75. Nucifora FC Jr, Ellerby LM, Wellington CL, Wood JD, Herring WJ, Sawa A, Hayden MR, Dawson VL,
Dawson TM, Ross CA. “Nuclear Localization of a Non-caspase Truncation Product of Atrophin-1, with an
Expanded Polyglutamine Repeat, Increases Cellular Toxicity.” PMID: 12464607 J Biol Chem.
278(15):13047-13055 (2003).
76. Chung, J.W., K.J. Kim, S.J. Hong, D. Goti, M.F. Stins, V.L. Dawson, T.M. Dawson, K.S. Kim. “37 kDa
Laminin Receptor Precursor is the Receptor for Cytotoxic Necrotizing Factor 1 (CNF1).” J. Biol. Chem. 278:
1857-16862 (2003).
8
Valina L. Dawson, Ph.D.
77. Sheline C.T., H. Wang, A.L. Cai, V.L. Dawson, D.W. Choi. “Involvement of poly ADP ribosyl polymerase1 in acute but not chronic zinc toxicity.” PMID: 14511320 Eur J Neurosci. 18(6):1402-1409 (2003).
78. Chung, K.K.K., V.L. Dawson, and T.M. Dawson “New Insights In Parkinson’s Disease” J. Neurol.
250(Suppl 3):III15-III24 (2003).
79. Pawlyk, A.C., B.I. Giasson, D.M. Sampathu, F.A. Perez, K.L. Lim, V.L. Dawson, T.M. Dawson, R.D.
Palmiter, and J.Q. Trojanowski. "Novel monoclonal antibodies demonstrate biochemical variation of brain
Parkin with age." PMID: 12972409 J. Biol. Chem. 278:48120-48128 (2003).
80. Dawson, T.M. and V.L. Dawson. “Molecular Pathways of Neurodegeneration in Parkinson’s Disease”
PMID: 14593166 Science, 302: 819-822 (2003)
81. Moore, D.J., L. Zhang, T.M. Dawson and V.L. Dawson. “A Missense Mutation (L166P) in DJ-1, Linked to
Familial Parkinson’s Disease, Confers Reduced Protein Stability and Impairs Homo-Oligomerization.”
PMID: 14713311 J. Neurochem.ˆ 87:1588-1567 (2003).
82. Li, H., X. Gu, V.L. Dawson and T.M. Dawson.. “Identification of Calcium and Nitric Oxide Regulated
Genes by Differential Analysis of Library Expression (DAzLE).” PMID: 14701905 Proc. Natl. Acad. Sci.
U.S.A., 101: 647-652 (2004).
83. Hong, S.J., H. Li, K.G. Becker, V.L. Dawson, and T.M. Dawson. “Identification and Analysis of PlasticityInduced Late Response Genes (PLINGS).” PMID: 14766980 Proc. Natl. Acad. Sci. U.S.A., 101:2145-2150
(2004).
84. Samdani, A.F., E.B. Kuchner, L. Rhines, D.C. Adamson, C. Lawson, B. Tyler, H. Brem, V.L. Dawson and
T.M. Dawson. “Astroglia Induce Cytotoxic Effects on Brain Tumors via a Nitric Oxide-Dependent Pathway
both In Vitro and In Vivo.” PMID: 15113479 Neurosurgery 54(5): 1231-8 (2004).
85. Chung K.K., B. Thomas, X. Li, O. Pletnikova, J.C. Troncoso, L. Marsh, V.L. Dawson and T.M. Dawson.
“S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function.” [Epub
Apr 2004] PMID: 15105460 Science 304(5675):1328-31 (2004).
86. Chung K.K., V.L. Dawson and T.M. Dawson. “NO Parkin in Parkinson’s Disease.” Science, 304:1905
(2004).
87. Von Coelln, R., B. Thomas, J. M. Savitt, K.L. Lim, M. Sasaki, E. Hess, V.L. Dawson, T.M. Dawson. “Loss
of Locus Coeruleus Neurons and Reduced Startle in Parkin Null Mice” PMID: 15249681 Proc. Natl. Acad.
Sci. U.S.A., 101:10744-10749 (2004).
88. Seo, S.Y.,Y.B. Chen, I. Ivanovska, A.M. Ranger, S.J. Hong, V.L. Dawson, S.J. Korsmeyer, D.S. Bellows,
Y. Fannjiang and J.M. Hardwick. “BAD is a pro-survival factor prior to activation of its pro-apoptotic
function.” [Epub Jul 2004] PMID: 15231831 J Biol Chem. 249:42240-42249 (2004).
89. Hagberg, H., M.A. Wilson, H. Matsushita, C. Zhu, M. Lange, M. Gustavsson, M.F. Poitras, T.M. Dawson,
V.L. Dawson, F. Northington and M.V. Johnston “PARP-1 gene disruption in mice preferentially protects
males from perinatal brain injury.” PMID: 15312162 J. Neurochem., 90: 1068–1075 (2004).
90. Wang, H., S.W. Yu, D.W. Koh, J. Lew, C. Coombs, W. Bowers, H.J. Federoff, G.G. Poirier, T.M. Dawson,
and V.L. Dawson. “Apoptosis Inducing Factor (AIF) Substitutes for Caspase Executioners in N-methyl-Daspartate Triggered Excitotoxic Neuronal Death.” PMID: 15574746 J. Neurosci. 24: 10963-10973 (2004).
91. Koh, D.W., A.M. Lawler, M.F. Poitras, M. Sasaki, S. Wattler, M.C. Nehls, T. Stöger, G.G. Poirier, T.M.
Dawson and V.L. Dawson. "Failure to Degrade Poly(ADP-ribose) Causes Increased Sensitivity to
Cytotoxicity and Early Embryonic Lethality.” PMID: 15591342 Proc. Natl. Acad. Sci. U.S.A. 101(51):
17699-17704 (2004).
92. Yang S., A. Koteish, H. Lin, J. Huang, T. Roskams, V. Dawson, and A.M. Diehl. “Oval cells compensate
for damage and replicative senescence of mature hepatocytes in mice with fatty liver disease.” PMID:
14767993 Hepatology 39(2): 403-11 (2004)
9
Valina L. Dawson, Ph.D.
93. Moore, D.J., L. Zhang, J. Troncoso, M.K. Lee, N. Hattori, Y. Mizuno, T.M. Dawson and V.L. Dawson.
“Association of DJ-1 and Parkin Through Pathogenic DJ-1 Mutations and Oxidative Stress.” [Epub ahead of
print Nov 3, 2004] PMID: 15525661 Hum. Mol. Genet. 14(1): 71-84 (2005).
94. Lim, K.L., K.C.M. Chew, J.M.M. Tan, C. Wang, K.K.K. Chung, Y. Zhang, Y. Tanaka, W. Smith, S.
Engelender, C.A. Ross, V.L. Dawson, and T.M. Dawson. “Parkin Mediates Nonclassical, ProteasomalIndependent Ubiquitination of Synphilin-1: Implications for Lewy Body Formation.” PMID: 15728840 J
Neurosci., 25(8):2002-2009 (2005).
95. Shimoji, M. L. Zhang, A.S. Mandir, V.L. Dawson and T.M. Dawson “Absence of Inclusion Body Formation
in the MPTP Mouse Model of Parkinson’s Disease.” PMID: 15790534 Brain Res. Mol Brain Res., 134: 103108 (2005).
96. Pol, O., M. Sasaki, N. Jiménez, V.L. Dawson, T.M. Dawson and M.M. Puig. “The Involvement of Nitric
Oxide in the Enhanced Expression of -Opioid Receptors During Intestinal Inflammation in Mice.” [Epub
April 2005] PMID: 15852037 Brit. J. Pharmacol. 145:758-766 (2005).
97. Zhang, L., M. Shimoji, B. Thomas, D.J. Moore, S.-W. Yu, N.. Marupudi, R. Torp, I.A. Torgner, O.P.
Ottersen, T.M. Dawson and V.L. Dawson. “Mitochondrial Localization of the Parkinson’s Disease Related
Gene DJ-1.” [Epub June 2005] PMID: 15944198, Hum. Mol. Genet. 14:2063-2073 (2005).
98. Smith, W.L., R.L. Margolis, J.C. Troncoso, N. West, M.K. Lee, V.L. Dawson, T.M. Dawson, T. Iwatsubo,
and C.A. Ross. “Alpha-synuclein phosphorylation enhances eosinophilic cytoplasmic inclusion formation in
SH-SY5Y cells..” PMID: 15944382, J. Neurosci. 25 5544-5552 (2005).
99. Savitt, J.M., S.S. Jang, W. Mu, V.L. Dawson and T.M. Dawson. “Bcl-x is Required for Proper
Development of the Mouse Substantia Nigra.” PMID: 16033881, J. Neurosci. 25(29):6721-6728 (2005).
100. Kofler J, T. Otsuka ,Z. Zhang, R. Noppens, M.R. Grafe,D.W. Koh, V.L. Dawson, J.M. de Murcia, P.D.
Hurn, .RJ. Traystman. “Differential effect of PARP-2 deletion on brain injury after focal and global cerebral
ischemia.” [Epub Jun 2005] PMID: 15959455, J Cereb Blood Flow Metab. 26(1):135-41 (2006).
101. Chung K.K, V.L. Dawson, T.M. Dawson. “Response to Comment on "S-Nitrosylation of Parkin Regulates
Ubiquitination and Compromises Parkin's Protective Function" Science. 308(5730):1870c, (2005).
102. Sriram, S.R.., X. Li, H. Ko, K.K.K. Chung, E. Wong, K.L. Lim, V.L. Dawson, T.M. Dawson. “Familialassociated Mutations Differentially Disrupt the Solubility, Localization, Binding and Ubiquitination
Properties of Parkin.” [Epub Jul 2005] PMID: 16049031, Hum. Mol. Genet. 14:2571-2586 (2005).
103. Ko, H.S. R. von Coelln, S. Ravichandran, S.W. Kim, K.K.K. Chung, O. Pletnikova, B. Johnson, R. Saffary,
Y. Mizuno, B.J. Park, M.J. Kim, S.H. Kim, V.L. Dawson, and T.M. Dawson. “Accumulation of the
Authentic Parkin Substrate, Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic
Cell Death.” PMID: 16135753, J. Neurosci. 25(35):7968 –7978 (2005).
104. West, A., D. Moore, A. Bugayenko, S. Biskup, C.A. Ross, W.W. Smith, V.L. Dawson and T.M. Dawson. “
Parkinson's Disease Associated Mutations in Leucine Rich Repeat Kinase 2 Augment Kinase Activity.”
PMID: 16269541, Proc. Natl. Acad. Sci. U.S.A., 102:16842-16847 (2005).
105. David, K.K., M Sasaki, S.-W. Yu, T.M. Dawson and V.L. Dawson. “EndoG is Dispensable in
Embryogenesis and Apoptosis,” [Epub Oct 2005] PMID: 16239930 Cell Death Diff., 13:1147–1155 (2006).
106. Smith, W.W., H. Jiang, Z. Pei, Y. Tanaka, H. Morita, A. Sawa, V.L. Dawson, T.M.. Dawson and C.A. Ross.
“Endoplasmic reticulum stress and mitochondrial cell death pathways mediate A53T mutant alphasynuclein-induced toxicity.” [Epub Oct 2005] PMID: 16239241 Hum Mol Genet., 14(24):3801-11 (2005).
107. Wang, C., H.S. Ko, B. Thomas, F. Tsang, K.C.M. Chew, S.P. Tay, M.W.L. Ho, T.M. Lim, T.W. Soong, O.
Pletnikova, J. Troncoso, V.L. Dawson, T.M. Dawson, and K.L. Lim. “Stress-induced Alterations in Parkin
Solubility Promote Parkin Aggregation and Compromise Parkin’s Protective Function.” [Epub Nov 2005]
PMID: 16278233, Hum Mol Genet., 14:3885-3897 (2006).
10
Valina L. Dawson, Ph.D.
108. Smith, W.W., Z. Pei, H. Jiang, D.J. Moore, Y. Liang, A.B. West, V.L. Dawson, T.M. Dawson and C.A.
Ross. “Leucine-rich repeard kinase 2 (LRRK2) interacts with parkin and mutant LRRK2 induces neuronal
degeneration.” PMID: 16352719, Proc. Natl. Acad. Sci. U.S.A., 102:18,676-18,681 (2005).
109. Hara, M.R., B. Thomas, M.B. Cascio, A.S. Huang, S.K. Tankou, B.-I. Bae, M.D. Kornberg, L.D. Hester,
V.L. Dawson, T.M. Dawson, A. Sawa and S.H. Snyder. “Neuroprotection by Pharmacologic Blockade of
the GAPDH Death Cascade.” [Epub Feb 2006] PMID: 16505364, Proc. Natl. Acad. Sci. U.S.A., 103:38873889 (2006).
110. von Coelln, R., B. Thomas, K.L. Lim, J.M. Savitt, R. Saffary, W. Stirling, K. Bruno, E.J. Hess, M.K. Lee,
V.L. Dawson and T.M. Dawson, “Inclusion Body Formation and Neurodegeneration are Parkin-independent
in a Mouse Model of -Synucleinopathy.” PMID: 16597723, J. Neurosci. 26:3685-3696 (2006).
111. Ko, H.S, S.W. Kim, S.R. Sriram, V.L. Dawson, and T.M. Dawson. "Identification of far upstream element
binding protein-1 as an authentic parkin substrate.” [Epub May 2006] PMID:16672220, J. Biol. Chem.
281:16193-16196 (2006).
112. Li, X, M. Nemoto, S.-W. Yu, M. Shimoji, S.A. Andrabi, Z. Xu, J.-F. Haince, G.G. Poirier, T.M. Dawson,
V.L. Dawson, R.C. Koehler. “Early Reperfusion After Focal Cerebral Ischemia Accelerates Translocation
of Apoptosis Inducing Factor to the Nucleus.” PMID:17049179, Neurosci., 144(1):56-65 (2006).
113. Smith, W.W., Z. Pei, H. Jiang, V.L. Dawson, T.M. Dawson2,3,5,6, C.A. Ross. “Kinase activity of mutant
LRRK2 mediates neuronal toxicity.” [Epub Sept 2006] PMID: 16980962, Nat. Neurosci. 9:1231-1233
(2006).
114. Jiang, H., Y-C. Wu, M. Nakamura, Y. Liang, Y. Tanaka, S. Holmes, V.L. Dawson, T.M. Dawson C.A. Ross
and W.W. Smith. “Parkinson’s disease genetic mutations increase cell susceptibility to stress: mutant synuclein enhances H2O2-and Sin-1-induced cell death.” [Epub Sep 2006] PMID:16978743 Neurobiol
Aging. (2007).
115. Biskup, S, D.J. Moore, F. Celsi, S. Higashi, A.B. West, S.A. Andrabi, K. Kurkinen, S.-W. Yu, J.M. Savitt,
H.J. Waldvogel, R.L.M. Faull, P.C. Emson, R. Torp, O.P. Ottersen, T.M. Dawson, and V.L. Dawson.
“Localization of LRRK2 Indicates a Role in Vesicular Trafficking and Membrane Recycling.”
PMID:17120249 Ann. Neurol., 60(5):557-569 (2006).
116. Yu, S.W., S.A. Andrabi, H. Wang, N.S. Kim, G.G. Poirier, V.L. Dawson and T.M. Dawson. “Apoptosis
Inducing Factor (AIF) Mediates Poly (ADP-ribose) (PAR) Polymer Induced Cell Death” [Epub Nov 2006]
PMID: 17116881, Proc. Natl. Acad. Sci. U.S.A. 103: 18314–18319 (2006).
117. Anrabi, S., N.S. Kim, S.W. Yu, N.S. Kim, H. Wang, D. Koh, M. Sasaki, J.A. Klaus, T. Otsuka, Z. Zhang,
R.C. Koehler, P. Hurn, G.G. Poirier, V.L. Dawson and T.M. Dawson. “Poly (ADP-ribose) (PAR) Polymer is
a Novel Death Signal.” [Epub Nov 2006] PMID: 17116882, Proc. Natl. Acad. Sci. U.S.A. 103: 18308–18313
(2006).
118. Li, X, M. Nemoto, Z. Xu, S.-W. Yu, M. Shimoji, S.A. Andrabi, J.-F. Haince, G.G. Poirier, T.M. Dawson,
V.L. Dawson, R.C. Koehler. “Influence of duration of focal cerebral ischemia and neuronal nitric oxide
synthase on translocation of apoptosis-inducing factor to the nucleus.” [Epub Oct 2006] PMID: 17049179
Neurosci. 144(1):56-65 (2007).
119. Thomas, B., R. von Coelln, A.S. Mandir, D.B. Trinkaus, M.J. Farah, K-L Lim, M. F. Beal, V.L. Dawson,
T.M. Dawson. “MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic
neurons in mice is independent of parkin activity.” [Epub Jan 2007] PMID: 17336077 Neurobiol. Dis.
26(2):312-322 (2007).
120. Higashi S, DJ Moore, RE Colebrooke, S Biskup, VL Dawson, H Arai, TM Dawson, PC Emson. “Expression
and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.” [Epub
Nov 2006] PMID: 17101029, J Neurochem. 100(2):368-381 (2007).
121. West, A.B., D.J. Moore, C. Choi, S.A. Andrabi, X. Li, D. Dikeman, S. Biskup, Z. Zhang, K-L. Lim, V.L.
Dawson, T.M. Dawson. “Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding
11
Valina L. Dawson, Ph.D.
and kinase activities to neuronal toxicity.” [Epub Jan 2007] PMID:17200152, Hum. Mol. Genet. 16(2):223232 (2007).
122. Wong, E.S.P., J.M.M. Tan, C. Wang, Z. Zhang, S-P Tay, N. Zaiden, H.S. Ko, V.L. Dawson, T.M. Dawson,
K-L Lim. “Relative Sensitivity of Parkin and Other Cysteine-containing Enzymes to Stress-induced
Solubility Alterations.” [Epub February 2007] PMID: 17329252 J. Biol. Chem. 282(16):12310-12318
(2007).
123. Haince, J-F, S. Kozlov, V.L. Dawson, T.M. Dawson, M.J. Hendzel, M.F. Lavin and G.G. Poirier. “ATM
signaling network is modulated by a novel PAR-dependent pathway in the early response to DNA damaging
agents.” [Epub April 2007] PMID: 17428792, J. Biol. Chem. 282(22):16441-16453 (2007).
124. Poitras M.F., D.W. Koh, S.-W. Yu, S.A. Andrabi, Al.S. Mandir, G.G. Poirier, V.L. Dawson and T.M.
Dawson. “Spatial and Functional Relationship Between Poly(ADP-Ribose) Polymerase-1 and Poly(ADPRibose) Glycohydrolase in the Brain.” [Epub Jul 2007] PMID: 17640816 Neuroscience 148: 198-211
(2007).
125. Higashi, S., S. Biskup A.B. West, D. Trinkaus, V.L. Dawson, R. Faull, H. Waldvogel, H. Arai, T.M.
Dawson, Moore. D.J., P. Emson. “Localization of Parkinson's Disease-Associated LRRK2 in Normal and
Pathological Human Brain.” [Epub Apr 2007] PMID: 17512502, Brain Res. 1155:208-219 (2007).
126. Andres-Mateos, E., C. Perier, L. Zhang, B. Blanchard-Fillion, T.M. Greco, B. Thomas, H.S. Ko, M. Sasaki,
H. Ischiropoulos, S. Przedborski, T.M. Dawson and V.L. Dawson. “DJ-1 Gene Deletion Reveals that DJ-1 is
an Atypical Peroxiredoxin-like Peroxidase” [Epub 2007 Aug] PMID: 17766438 Proc. Natl. Acad. Sci. U.S.A.
104:14807–14812 (2007).
127. Biskup S, D.J. Moore, A. Rea, B. Lorenz-Deperieux, C.E. Coombes, V.L. Dawson, T.M. Dawson, A.B.
West. “Dynamic and redundant regulation of LRRK2 and LRRK1 expression.” [Epub Nov 2007] PMID:
18045479, BMC Neurosci. 8(1):102 (2007).
128. Wong, E.S.P., J.M.M. Tan, W-E Soong, K. Hussein, N. Nukina, V.L. Dawson, T.M. Dawson, A.M. Cuervo,
K-L Lim. “Autophagy-mediated clearance of aggresomes is not a universal phenomenon.” [Epub 2007 Nov]
PMID: 18502787, Hum. Mol. Genet. 17(16):2570-82 (2008).
129. Tan, J.M.M., E.S.P. Wong, O. Pletnikova, D.S. Kirkpatrick, H. Ko, M.W.L. Ho, S.-P. Tay, J. Troncoso, S.P.
Gygi, M.K. Lee, V.L. Dawson, T.M. Dawson and K.-L. Lim.. “Lysine 63-linked ubiquitination promotes
the formation and autophagic clearance of protein inclusions associated with neurodegenerative diseases.”
[Epub Nov 2007] PMID: 17981811 Hum Mol Genet. 17(3):431-9. (2007).
130. Moore, D.J., A.B. West, D.A. Dikeman, V.L. Dawson, T.M. Dawson. “Parkin Mediates the DegradationIndependent Ubiquitination of Hsp70.” [Epub Feb 2008] PMID: 18248624, J Neurochem. 105(5):1806-19
(2008).
131. Wang, L., C. Xie, E. Greggio, L. Parisiadou, H. Shim, L. Sun, J. Chandran, X. Lin, C. Lai, W.-J. Yang, D.J.
Moore, T.M. Dawson, V.L. Dawson, G. Chiosis, M.R. Cookson, and H. Cai. “The Chaperone Activity of
Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2.” PMID:
18367605 J. Neurosci. 28 (13):3384-3391 (2008)
132. Tan, J.M., E.S. Wong, V.L. Dawson, T.M. Dawson, K.L. Lim. “Lysine 63-linked polyubiquitin potentially
partners with p62 to promote the clearance of protein inclusions by autophagy.” [Epub Dec 2007] PMID:
18204306. Autophagy 4: in press (2008).
133. Sen, N., M.R. Hara, M.D. Kornberg, M.B. Cascio, B-I Bae, N. Shahani, B. Thomas, T.M. Dawson, V.L.
Dawson, S.H. Snyder, and A. Sawa. “Nitric oxide-induced nuclear GAPDH activates p300/CBP and
mediates apoptosis.” [Epub June 08] PMID: 18552833 Nat Cell Biol. 10(7):866-73 (2008).
134. Gagne, J-P, M. Isabelle, K.S. Lo, S. Bourassa, M. Hendzel, V.L. Dawson, T.M. Dawson, G. Poirier.
“Proteome-Wide Identification of Poly(ADP-Ribose) Binding Proteins And Poly(ADP-Ribose)-Associated
Protein Complexes” [Epub Nov 08] PMID: 18981049 Nucl. Acids. Res. 36(22):6959-6976 (2008).
12
Valina L. Dawson, Ph.D.
135. Ko, H.S. R. Bailey, W.W. Smith, Z. Liu, J-H. Shin, Y-I. Lee, Y-J. Zhang, H. Jiang, C.A. Ross, D.J. Moore,
C. Patterson, L. Petrucelli, T.M. Dawson and V.L. Dawson. “CHIP Regulates Leucine-Rich Repeat Kinase2 (LRRKK2) Ubiquitination, Degradation and Toxicity.” [Epub 2009 Feb] PMID: 19196961 Proc. Natl.
Acad. Sci. U.S.A. 106(8):2897-902 (2009).
136. Tsang A.H., Y.I. Lee, H.S. Ko, J.M. Savitt, O. Pletnikova, J.C. Troncoso, V.L. Dawson, T.M. Dawson, and
K.K. Chung. “S-nitrosylation of XIAP compromises neuronal survival in Parkinson's disease.” [Epub 2009
Mar] PMID: 19273858 Proc Natl Acad Sci U.S.A. 106(12):4900-5 (2009).
137. Wang, Y., N.S. Kim, X. Li, P.A. Greer, R.C. Koehler, V.L. Dawson, and T.M. Dawson. “Calpain
Activation is not Required for AIF Translocation in PARP-1-Dependent Cell Death (Parthanatos).” [Epub
2009 May] PMID: 19457082 J. Neurochem. 110(2):687-696 (2009).
138. Wang, Y., V.L. Dawson, and T.M. Dawson. “Poly(ADP-ribose) signals to mitochondrial AIF: A key event
in parthanatos.” [Epub 2009 Mar] PMID: 19332058 Exp Neurol. 218:193–202 (2009).
139. David, K.K., S.A. Andrabi, T.M. Dawson, V.L. Dawson. “Parthanatos, a messenger of death.” PMID:
19273119, Front Biosci. 14:1116-28 (2009).
140. Hoang, T., D-K Choi, M. Nagai, D-C Wu, N. Tetsuya, D. Prou, G.L. Wilson, M. Vila, V. Jackson-Lewis,
V.L. Dawson, T.M. Dawson, M-F Chesselet and S. Przedborski. “Neuronal NOS and cyclooxygenase-2
contribute to DNA damage in a mouse model of Parkinson’s disease.” [Epub 2009 July] PMID: 19616617
Free Rad. Biol. Med. in press (2009).
141. Daher, J.P.L., M. Ying, R. Banerjee, R.S. McDonald, M. Dumas Hahn, L. Yang, M.F. Beal, B. Thomas,
V.L. Dawson, T.M. Dawson and D.J. Moore. “Conditional transgenic mice expressing C-terminally
truncated human alpha-synuclein (alphaSyn119) exhibit reduced striatal dopamine without loss of
nigrostriatal pathway dopaminergic neurons.” [Epub July 2009] PMID: 19630976 Mol. Neurodegener. 4:34
(2009).
142. Ng, C-H, S. Mok, C. Koh, X. Ouyang, M. Fivaz, E-K Tan, V.L. Dawson, T.M. Dawson, F. Yu, and K.L.
Lim. “"Parkin Protects Against LRRK2 G2019S Mutant-induced Dopaminergic Neurodegeneration in
Drosophila." J. Neurosci. in press (2009).

Peer-reviewed Pending
1. Dai, C., D. Liang; H. Li; T.M. Dawson and V.L. Dawson, “Functional Cloning of Neuroprotective
Genes.” Proc. Natl. Acad. Sci.
2. Zheng, S. S.J. Hong, R.M. Gronostajski, T.M. Dawson, V.L. Dawson. “NMDA-Induced Neuronal
Survival is mediated through NFI-A, a novel neuronal survival transcription factor” JCI under revision

Peer-reviewed Reviews
1. Dawson, T.M., V.L. Dawson and S.H. Snyder. “Neurological Progress: A Novel Neuronal Messenger
Molecule in Brain: The Free Radical, Nitric Oxide (NO).” Ann. Neurol. 32: 297-311 (1992).
2. Dawson, T.M., and V.L. Dawson. “Nitric Oxide Actions and Pathological Roles.” The Neuroscientist 1: 920 (1994).
3. Dawson, T.M., and V.L. Dawson. “gp120 Neurotoxicity in Primary Cortical Cultures.” Adv.
Neuroimmunol. 4: 167-173 (1994).
4. Dawson, T.M., and V.L. Dawson. “ADP-Ribosylation as a Mechanism for Nitric Oxide's Action in the
Nervous System.” New Horizons 3: 86-92 (1995)
5. Dawson V.L. and T.M. Dawson. “Physiologic and Toxicologic Actions of Nitric Oxide in the Central
Nervous System.” Adv. Pharmacol. 34: 323-342 (1995).
13
Valina L. Dawson, Ph.D.
6. Dawson V.L. “Nitric Oxide: Role in Neurotoxicity.” Clin. Expt. Pharmacol. Physiol. 22: 305-308 (1995).
7. Dawson, V.L. and T.M. Dawson. “Nitric Oxide Actions in Neurochemistry.” Neurochemistry International
29: 97-110 (1996).
8. Dawson, V.L. and T.M. Dawson. “Nitric Oxide in Neuronal Degeneration.” Proc. Soc. Expt. Biol. Med.
211(1): 33-40 (1996).
9. Dawson, V.L. and T.M. Dawson. “Free radicals and neuronal cell death.” Cell Death and Differentiation 3:
71-78 (1996).
10. Dawson, V.L. and T.M. Dawson. “Nitric oxide actions in neurochemistry” Neurochemistry International,
1996, 29: 97-110
11. Dawson, V.L. and T.M. Dawson. “Nitric oxide neurotoxicity.” J. Chem. Neuroanat. 10:179-190 (1996).
12. Yun, H.Y., Dawson, V.L., and T.M. Dawson. “Neurobiology of Nitric Oxide.” Critical Reviews in
Neurobiology, 10: 291-316 (1996).
13. Dawson, T.M., and V.L. Dawson. “NG-nitro-L-arginine delays the development of brain injury during focal
ischemia in the rat.” Editorial Comment in Stroke, 26: 288-289 (1996).
14. Dawson, V.L. “Induction of DNA Fragmentation After 10-120 minutes of Focal Cerebral Ischemia in Rat.”
Editorial Comment in Stroke, 26:1257-8 (1995).
15. Yun, H.-Y, V.L. Dawson and T.M. Dawson. “Nitric Oxide in Health and Disease.” Molec. Psychiatry 2:
300-310 (1997).
16. Samdani, A.F, T.M. Dawson and V.L. Dawson. “Nitric Oxide Synthase in Models of Focal Ischemia.”
Stroke, 28: 1283-1288 (1997).
17. Nelson, R.J., L.J. Kriegsfeld, V.L. Dawson, and T.M. Dawson. “Effects of Nitric Oxide on Neuroendrocrine
Function and Behavior.” Frontiers in Neuroendocrinol, 18: 463-491 (1997).
18. Dawson, V.L. “Tacrolimus (FK506) Attenuates Leukocyte Accumulation After Transient Retinal Ischemia.”
Editorial Comment in Stroke, 29: 1437-1438.
19. Dawson, V.L., J. Kusel and T.M. Dawson. “Nitric Oxide: Diverse Actions in the CNS and PNS.” The
Neuroscientist 4(2): 96-112 (1998).
20. Szabo, C., and V.L. Dawson. “Role of poly(ADP-ribose) synthetase in inflammation and ischaemiareperfusion.” Trends Pharmacol Sci, 19: 287-98 (1998).
21. Dawson, V.L. “Matrix Metalloproteinase Expression Increases after Cerebral Focal Ischemia in RatsInhibition of Matrix Metalloproteinase 9 Reduces Infarct Size.” Editorial Comment in Stroke, 29: 1030.
22. Dawson, V.L., “Role of NO in HIV Dementia” in NeuroAids Vol. 2, Issue 9, October 1999,
http://mednav.com/zone/Naids/zones/Articles
23. Dawson, V.L. “Potent neuroprotectants linked to bifunctional inhibition.” Editorial Comment in Proc. Natl.
Acad. Sci., USA. 96: 10557-10558 (1999).
24. Dawson, V.L. “Of Flies and Mice.” Perspective in Science 288: 631-632 (2000).
25. Zhang Y., Dawson V.L., Dawson T.M. “Oxidative Stress and Genetics in the Pathogenesis of Parkinson's
Disease.” Neurobiol. Dis. 7:240-250 (2000).
26. Mandir, A.S., V.L. Dawson and T.M. Dawson. “Gene therapy to the rescue in Parkinson's disease.” Trends
Pharmacol. Sci. 22:103-105 (2001).
27. Guo, X., J.F. Dillman, III, V.L. Dawson and T.M. Dawson. "Immunophilins: Novel Neuroprotective and
Neuroregenerative Targets." Annals of Neurology, 50:6-16 (2001).
28. Chung, KKK, V.L. Dawson and T.M. Dawson. “The Role of the Ubiquitin Proteasomal Pathway in
Neurodegenerative Disorders” Trends Neurosci 24: S7-S14 (2001).
14
Valina L. Dawson, Ph.D.
29. Lim, K.L., V.L. Dawson and T.M. Dawson, “The Genetics of Parkinson’s Disease.” Curr Neurol Neurosci
Rep 2(5):439-46 (2002).
30. Dawson, T.M. and V.L. Dawson. “Neuroprotective and Neurorestorative Strategies for Parkinson’s
Disease.” Nature Neuroscience, 5:1058-1061 (2002).
31. Dawson, T.M. and V.L. Dawson. “Rare Genetic Mutations Shed Light on the Pathogenesis of Parkinson’s
Disease.” Journal of Clin. Invest., 111:145-51 (2003).
32. Dawson, T.M. and V.L. Dawson. “Molecular Pathways of Neurodegeneration in Parkinson’s Disease”
Science, 302: 819-822 (2003)
33. Yu S.W., Wang H., Dawson T.M., Dawson V.L. “Poly(ADP-ribose) Polymerase-1 and Apoptosis Inducing
Factor in Neurotoxicity.” Neurobiol Dis., 14(3):303-17 (2003).
34. Liang, D., T.M. Dawson and V.L. Dawson. “What Have Genetically Engineered Mice Taught Us About
Ischemic Injury?” Curr. Mol. Med. 4:207-225 (2004).
35. Dawson, V.L. “Maiming Mitochondria in Familial ALS.” News and Views in Nature Med. 10(9):905-906
(2004).
36. Cregan S.P., V.L. Dawson, R.S. Slack. “Role of AIF in caspase-dependent and caspase-independent cell
death.” Oncogene 23(16):2785-96 (2004).
37. Gwinn-Hardy K, Dawson V. “Genomics-proteomics and stroke: introduction.” Stroke 35(11 Suppl 1): 27312734. Epub 2004 Sep 23 (2004).
38. von Coelln, R., V.L. Dawson, T.M. Dawson. “Parkin-associated Parkinson's disease.” Cell Tissue Res. [2004
Jul 30 Epub ahead of print] 318(1):175-84 (2004).
39. Dawson, V.L, and T.M. Dawson. “Deadly Conversations: Nuclear-Mitochondrial Cross-Talk.” J Bioenerg
Biomembr. 36(4):287-294 (2004).
40. Koh, D.W., T.M. Dawson, and V.L. Dawson. “Poly(ADP-ribosyl)ation Regulation of Life and Death in the
Nervous System.” In “Poly-ADP-ribosylation in health and disease” special review, guest ed. L. Virag, Cell
and Molec Life Sci 62:760-768 (2005).
41. Dawson, V.L. “Molecular Mechanisms in Neuronal and Axonal Apoptosis and Necrosis.”
Neurodegeneration and Neuroprotection in Multiple Sclerosis II, Advanced Studies in Medicine, 5:S387S391, www.JHASIM.com, (2005).
42. Chung, K.K.K., T.M. Dawson and V.L. Dawson. “Nitric oxide, S-Nitrosylation and Neurodegeneration.”
Special review on Basic Research on Nitric Oxide, guest ed. G. Keilhoff Cell. Mol. Biol. 51:247-254 (2005).
43. Koh,D.W., V.L. Dawson and T.M. Dawson. “The Road to Survival Goes through PARG.” Cell Cycle 4:3,
e136-e138, [EPUB March 2005], 4: 397-399 (2005).
44. Koh, D.W., T.M. Dawson, and V.L. Dawson. “Mediation of Cell Death by Poly(ADP-Ribose) Polymerase1.” Pharmacol. Res. 52 (1): 5-14 (2005).
45. West A.B., V.L. Dawson, T.M. Dawson. “To die or grow: Parkinson's disease and cancer.” Trends Neurosci.
28:348-52 (2005).
46. Chung KK, T.M. Dawson, V.L. Dawson. “Nitric oxide, S-nitrosylation and neurodegeneration.” Cell Mol
Biol (Noisy-le-grand) Sep 5;51(3):247-54 (2005).
47. Zhang, L., V.L. Dawson, T.M. Dawson. “Role of Nitric Oxide in Parkinson’s Disease “Pharmacol.
Therapeut. [Jul 6, 2005 Epub ahead of print] 109(1-2):33-41 (2006).
48. Moore, D.J., V.L. Dawson, T.M. Dawson. “Lessons from Drosophila models of DJ-1 deficiency.” Sci Aging
Knowledge Environ. Jan 11;2006(2):pe2 (2006).
15
Valina L. Dawson, Ph.D.
49. Lim, K.L. , V.L. Dawson, and T.M. Dawson. “Parkin-mediated lysine 63-linked polyubiquitination: A link to
protein inclusions formation in Parkinson's and other conformational diseases.” Neurobiol Aging. [Epub
ahead of print Oct 5, 2005] 27(4):524-529 (2006).
50. Dawson VL. “Inhibition of Poly(Adenosine Diphosphate-Ribose) Polymerase (PARP) in Experimental
Models of Neurologic Diseases: Cell Death Prevention.” Retina. Dec;25(8 Suppl):S31-S32 (2005).
51. Zhang, L., V.L. Dawson and T.M. Dawson “Role of Nitric Oxide in Parkinson's Disease.” Pharmacol.
Therapeutics, 109:33-41 (2006).
52. Moore, D, V.L. Dawson and T.M. Dawson “Lessons from Drosophila models of DJ-1 Deficiency Science of
Aging Knowledge Environment (SAGE KE, http://sageke.sciencemag.org Jan 11;2006(2):pe2 (2006).
53. Savitt, J.M., V.L. Dawson and T.M. Dawson. “Diagnosis and Treatment of Parkinson's Disease: Molecules
to Medicine.” J. Clin. Investig., 116:1744-1754 (2006).
54. Dawson, V.L. and T.M. Dawson, “Mining for survival genes.” Biochem. Soc. Trans 34(6):1307-9 (2006).
55. Dawson, T.M. and V.L. Dawson. “Taming the clot-buster tPA.” Nature Med., 12:993-994 (2006).
56. Jiang, H., Y-C. Wu, M. Nakamura, Y. Liang, Y. Tanaka, S. Holmes, V.L. Dawson, T.M. Dawson, C.A. Ross
and W.W. Smith. “Parkinson’s disease genetic mutations increase cell susceptibility to stress: mutant asynuclein enhances H2O2-and SIN-1-induced cell death.” PMID: 16978743 Neurobiol Aging. 28:1709-1717
(2007).
57. Harraz, M.M., T.M. Dawson and V.L. Dawson. “Advances in Neuronal Cell Death.” PMID: 18187674,
Stroke 39(2):286-288 (2008).
58. Anrabi, S., T.M. Dawson and V.L. Dawson. "Mitochondrial and Nuclear Cross Talk in Cell Death:
Parthanatos." PMID: 19076445 Ann. New York Acad. Sci., 1147: 233–241 (2008).
59. David, K.K. S.A. Andrabi, T.M. Dawson, and V.L. Dawson. “Parthanatos, a messenger of death.” Front.
Biosci. 14: 1116-1128 (2009).
60. Gupta, A., V.L. Dawson., and T.M. Dawson. “What causes cell death in Parkinson’s Disease?” PMID:
19127586 Ann Neurol 64 Suppl 2:S3-15 (2008).

Book Chapters, Monographs
1. Dawson, V.L., T.M. Dawson and J.K.. “Quantitative Autoradiographic Localization of Drug and
Neurotransmitter Receptors in the Olfactory Bulb.” In: Molecular Neurobiology of the Olfactory Bulb:
Molecular, Membranous, and Cytological Studies, eds. F.L. Margolis and T.V. Getchell, Plenum Press, New
York, NY, pp 99-117 (1988).
2. Wamsley, J.K., T.M. Dawson, V.L. Dawson, M.A. Hunt, L.J. Fisher, and F.H. Gage. “Reversal of
Nigrostriatal-Lesion Induced Receptor Alterations by Grafting of Fetal Mesencephalic Dopaminergic
Neurons.” In Neuroreceptor Mechanism's in Brain, eds. S. Kito, T. Segawa and R. Olsen, Plenum Press, New
York, NY, Adv. Exp. Med. Biol. 287:221-235 (1991).
3. London, E.D., V.L. Dawson, and C.R. Mantione. “Specific Binding Sites for Polyamines in Mammalian
Brain.” In NMDA Related Agents: Biochemistry, Pharmacology and Behavior, eds. T. Nabeshima, T.
Kameyama, and E.F. Domino. Proceedings from a satellite symposium of the 17th Congress of Collegium
Internationale Neuro-Psychopharmacologicum, Nagoya, Japan, NPP Books, Inc., Ann Arbor, MI, Sept. pp
71-78 (1991).
4. Dawson, T.M., V.L. Dawson and S.H. Snyder. “Nitric Oxide as a Mediator of Neurotoxicity.” in Assessing
Neurotoxicity of Drugs of Abuse, ed. L. Erinoff, NIDA Research Monograph Series Volume 136: 253-273
(1993).
16
Valina L. Dawson, Ph.D.
5. Zhang J., V.L. Dawson, T.M. Dawson and S.H. Snyder. “ADP-Ribosylation as a cGMP-Independent
Pathway to Terminate Nitric Oxide Effects.” In Taniguchi Symposia on Brain Science No. 17: Nitric Oxide
Roles in Neuronal Communication and Neurotoxicity. ed. H. Takagi, N. Toda, R.D. Hawkins, CRC Press,
Baco Raton FL pp 223-234 (1994)
6. Dawson, T.M., V.L. Dawson and S.H. Snyder. “Molecular Mechanisms of Nitric Oxide Actions in the
Brain.” In Neurobiology of NO• and •OH. ed. C. Chieuh, Annals of the New York Academy of Science.
738: 76-85 (1994).
7. Dawson, T.M., J. Zhang, V.L. Dawson and S.H. Snyder. “Nitric Oxide: Cellular Regulation and Neuronal
Injury.” In Proceedings of the 5th International Symposium on Neurodegeneration. ed. F.J. Siel, Progress
in Brain Research, 103: 365-369 (1994).
8. Dawson V.L. and T.M. Dawson “Nitric Oxide Neurotoxicity In Primary Neuronal Cultures.” In The
Proceedings of the Nineteenth Princeton Conference. ed. M.A. Moskowitz, Butterworth-Heinemann, Boston,
MA pp 3-17 (1995).
9. Dawson, V.L.and T.M. Dawson “Nitric Oxide Mediates a Componant of gp120 Neurotoxicity in Primary
Cortical Cultures.” in Technical Advances in AIDS Research in the Human Nervous System. ed. E. Major,
Plenum Publishing Corp. pp 163-173 (1995).
10. Dawson V.L. and T.M. Dawson “Mechanisims of Nitric Oxide Neurotoxicity In Primary Neuronal Cultures.”
In World Congress on Alternatives and Animal Use in the Life Sciences: Education, Research and Testing.
ed. A.M. Goldberg, Mary Ann Liebert, Inc Publishers, New York, NY Vol 11 pp 133-139 (1995).
11. Dawson V.L. and T.M. Dawson “Nitric Oxide Toxicity in Central Nervous System Cultures.” in Paradigms
of Neural Injury ed. J.R. Perez-Polo, Academic Press Inc., San Diego CA, pp 26-43 (1996)
12. Dawson, T.M. and V.L. Dawson. “Generation of Isoform Specific Antibodies to the Nitric Oxide
Synthases.” in Nitric Oxide A Volume of Methods in Enzymology. ed. L. Packer, Academic Press, Orlando,
FL, 268: 349-358 (1996).
13. Dawson, T.M. and V.L. Dawson. “Nitric Oxide Synthase: Role as a Transmitter/Mediator in the Brain and
Endocrine System.” in Ann. Rev. Medicine. ed. CH Coggins, EW Hancock and LJ Levitt, Annual Reviews
Inc., Palo Alto, CA 47: 219-227 (1996).
14. Dawson, T.M. and V.L. Dawson. “Protection of The Brain From Ischemia.” in Cerebrovascular Disease,
eds. H. H. Batjer, L. R. Caplan, L. Friberg, R. Greenlee Jr., T. A. Dpoitnik, and W.L. Young, LippincottRaven Publishers, New York, NY 29: 1-7 (1996).
15. Dawson, V.L. and T.M. Dawson. “Nitric oxide actions in the nervous system.” In Neurodegenerative
Diseases: Molecular and Cellular Mechanisms and Therapeutic Advances. ed. G. Fiskum, Plenum Press, NY
pp. 247-262 (1996).
16. Dawson, V.L. and T.M. Dawson. “Pathologic Roles of Nitric Oxide in the Central Nervous System.” in Free
Radicals in Brain Physiology and Disorders.” eds. L. Packer, M. Hiramatsu and T. Yoshikawa, Academic
Press Inc., Orlando, FL, pp 83-99 (1996)
17. Resink, A.M., V.L. Dawson, and T.M. Dawson. “Nitric Oxide Inhibitors: Future Therapies for CNS
Disorders.” in CNS Drugs Review, 6: 351-357 (1996)
18. Dawson, T.M., and V.L. Dawson “Nitric Oxide and Neurotransmission.” in Tissue Oxygen Deprivation:
Developmental Molecular and Integrated Function. ed. GG. Haddad and G. Lister, Marcel Dekker Inc., New
York, NY, pp 669-699 (1996).
19. Dawson, V.L, and T.M. Dawson. “Nitric oxide toxicity in CNS cultures.” in Methods in Neuroscience
Academic Press, San Diego, CA, 30: 26-43 (1996).
20. Dawson, V.L. and T.M. Dawson. “Function of Nitric Oxide in Neuronal Cell Death.” in: Methods in
Neuroscience: Nitric Oxide Synthase - Methods for Characterization and Functional Analysis. ed. M.
Maines, Academic Press, San Diego, CA, 31: 228-240 (1996).
17
Valina L. Dawson, Ph.D.
21. Dawson, T.M. and V.L. Dawson. “NADPH Diaphorase Staining.” in: Methods in Neuroscience: NO
Synthase - Methods for Characterization and Functional Analysis of Nitric Oxide Synthase. ed. M. Maines,
Academic Press, San Diego, CA, 31: 62-67 (1996).
22. Dawson, V.L., and T.M. Dawson. “Therapeutic approaches with nitric oxide synthase inhibitors.” in
Neurodegenerative Diseases: Mitochondria and Free Radicals in Pathogenesis. ed. M.F. Beal, N. Howell and
I. Bodis-Wollner, John Wiley and Sons, Inc, New York, NY pp 513-536 (1997).
23. Gonzalez-Zulueta, M., H.-Y. Yun, V.L. Dawson and T.M. Dawson. “Nitric Oxide Mediates ActivityDependent Neuronal Survival.” in The Biology of Nitric Oxide, Part 6, Eds. S. Moncada, A. Higgs, Portland
Press Ltd. London, pp 16 (1998).
24. Dawson, T.M., M. Sasaki, M. Gonzalez-Zulueta, M., V.L. Dawson, “Regulation of Neuronal Nitric Oxide
Synthase and Identification of Novel Nitric Oxide Signaling Pathways.” In Progress in Brain Research 118:
Nitric Oxide in Brain Development, Plasticity and Disease, eds. RR Mize, TM Dawson, VL Dawson, MJ
Friedlander, Elsevier Press, Amsterdam, Denmark, 118: 3-12 (1998).
25. Dawson, V.L. and T.M. Dawson. “Nitric Oxide in Neurodegeneration.” In Progress in Brain Research 118:
Nitric Oxide in Brain Development, Plasticity and Disease, eds. RR Mize, TM Dawson, VL Dawson, MJ
Friedlander, Elsevier Press, Amsterdam, Denmark, 118: 215-230 (1998).
26. Dawson, V.L. and T.M. Dawson. “Nitric Oxide Neurotoxicity in Models of Ischemic Damage.” in Frontiers
in Cerebrovascular Disease: Mechanisms, Diagnosis, and Treatment. eds. J.T. Robertson and T.S. Jr.
Nowak. Futura Publishing Company, Inc. Armonk, NY pp 149-163 (1998)
27. Dawson, V.L. “Vulnerability and Resistance to Glutamate Excitotoxicity.” ISN News, International Society
for Neurochemistry, 2: 32-36 (1999).
28. Yun, H.-Y., Gonzalez-Zulueta, M. V.L. Dawson and T.M. Dawson. “Nitric Oxide Mediates NMDA
Receptor-Stimulate Calcium Activation of Ras/Erk.” in The Biology of Nitric Oxide, Part 6, Eds. S.
Moncada, A. Higgs, Portland Press Ltd. London, pp 99 (1998).
29. Togashi, H., M. Sasaki, T.M. Dawson, V.L. Dawson. “Neuronal (Type I) Nitric Oxide Synthase Regulates
NFB Activity and Immunologic (Type II) Nitric Oxide Synthase Expression.” in The Biology of Nitric
Oxide, Part 6, eds. S. Moncada, A. Higgs, Portland Press Ltd. London, pp. 12 (1998).
30. Dillman, J.F., V.L. Dawson and T.M. Dawson. “Overview of the Pathway and Functions of Nitric Oxide” in
Chapter 11: “The Nitric Oxide/Guanylate Cyclase Pathway” in Current Protocols in Toxicology Eds. M.
Maines and D. Reed., John Wiley & Sons, Inc., NY, NY, pp. 10.1.1-10.1.7 (1998).
31. Gonzalez-Zulueta, M., V.L. Dawson and T.M. Dawson. “Histochemical Analysis of Nitric Oxide Synthase NADPH Diaphorase Staining” in Chapter 11: The Nitric Oxide/Guanylate Cyclase Pathway Current Protocols
in Toxicology Eds. M. Maines and D. Reed, John Wiley & Sons, Inc., New York, NY, in press (1998).
32. Dawson, V.L. and T.M. Dawson. “Regulation of Nitric Oxide Synthesis and Neurotoxicity,” in Molecular
Biology of the Toxic Response. ed. A. Puga and K. Wallace, TechBook Press, Chapter 15 pp 255-265
(1998).
33. Sasaki, M., T.M. Dawson, and V.L. Dawson. “Blocking Nitric Oxide Toxicity.” in Chapter 7 of Handbook
of Experimental Pharmacology: CNS Neuroprotection. ed. F.W. Marcoux and D.W. Choi, Springer-Verlag,
(1999).
34. Dawson, V.L. and T.M. Dawson. “Poly (ADP-Ribose) Inhibition as a Therapeutic Approach to Focal
Ischemic Insult.” in Pharmacology of Cerebral Ischemia 1998 ed. J. Krieglstein. MedPharm Scientific
Publishers, Stuttgart, Germany pp 289-298 (1998).
35. Dawson, V.L. and T.M. Dawson. “Poly(ADP-Ribose) Polymerase in Ischemia-Reperfusion Injury.” in The
Proceedings of the 21st Princeton Conference. ed. D.W. Choi, American Heart Association, Greenville, TX.
(2000).
18
Valina L. Dawson, Ph.D.
36. Dawson, V.L., Gonzalez-Zulueta, M., Dawson, T.M.. “Nitric oxide mediates ischemic pre-contidioning
through p21Ras activation”. The Biology of Nitric Oxide Part 7, eds. S. Moncada, L. Gustafsson, P. Wiklund,
and E.A. Higgs. Portland Press Ltd. London pp. 29 (2000).
37. Dawson, T.M. and V.L. Dawson. “Nitric Oxide in the Nervous System.” in Encyclopedia of Neuroscience.
eds. G. Adelman and B. Smith, Elsevier Science, Amsterdam, The Netherlands, pp 1473-1476 (1999).
38. Sasaki, M., V.L. Dawson and T.M. Dawson. “The NO Signaling Pathway in the Brain: Neural Injury,
Neurological Disorders and Aggression.” in Cerebral Signal Transduction: From First to Fourth Messengers,
Ed. Maarten E.A. Reith, Humana Press, Totowa, NJ. pp. 151-174 (2000).
39. Gammie, S.C., V.L. Dawson, and R.J. Nelson. “Neuroendocrine Function and Behavior.” in Nitric Oxide:
Biology and Pathobiology ed. LJ. Ignarro, Academic Press pp 429-452 (2000).
40. Gonzalez-Zulueta, M., V.L. Dawson and T.M. Dawson. “Neurotoxic Actions and Mechanisms of Nitric
Oxide.” in Nitric Oxide: Biology and Pathobiology ed. LJ. Ignarro, Academic Press pp 695-710 (2000).
41. Sasaki, M., T.M. Dawson and V.L. Dawson. "Nitric Oxide in Brain Ischemia/Reperfusion Injury." in
Handbook for Experimental Pharmacology: Nitric Oxide. ed B. Mayer, Springer-Verlag, Berlin Heidelberg,
Germany pp. 619-637 (2000).
42. Dawson, V.L. and T.M. Dawson. “Role of PARP in Mediating Acute and Chronic Neuronal Injury and
Neurodegeneration.” In Cell Death: The Role of Poly(ADP-Ribose) Polymerase, ed. C. Szabo, CRC Press,
pgs 23-39 (2000).
43. Dawson, V.L. and T.M. Dawson. “Mechanisms of Ischemic Tolerance.” in The Proceedings of the 21st
Princeton Conference. ed. P Chan, Cambridge University Press, Cambridge UK. pp58-71 (2001).
44. Dawson, V.L. and T.M. Dawson. “p21eas/Erk-dependent Signaling Activates Ischemic Tolerance.” in
Pharmacology of Cerebral Ischemia 1998 ed. J. Krieglstein. MedPharm Scientific Publishers, Stuttgart,
Germany (2000).
45. Poitras, M.F., V.L. Dawson, and T.M. Dawson. “Role of Poly (ADP-Ribose) Polymerase–1 in Neurologic
Disorders.” In Therapeutic Utilities of PARP Inhibitors , Ed. J. Zhang, CRC Press Boca Raton, FL, pps. 19-38
(2002).
46. Sasaki, M., T.M Dawson, V.L. Dawson. “Blocking Nitric Oxide Toxicity.” Ed. F.W. Marcoux and D.W.
Choi, Springer-Verlag, pp 155-176 (2002).
47. Dawson V.L. and T.M. Dawson, "Parkinson's Disease" in Fundamental Neuroscience, eds Larry Squire,
Floyd Bloom, Susan MacConnell, James Roberts, Nicholas Spitzer, and Michael Zigmond, pp 830 (2002).
48. Kofler J, M Sawada, K Hattori, VL Dawson, PD Hurn. Brain injury after cardiac arrest and cardiopulmonary
resusication (CPR). In: Pharmacology of Cerebral Ischemia 2002. Krieglstein J, ed., Medpharm Scientific
Publishers, Stuttgart, Germany, (2002).
49. Yu, S.Y., T.M. Dawson and V.L. Dawson, “Poly(ADP-Ribose) Polymerase and Apoptosis-Inducing Factor
in Excitotoxicity.” In: Pharmacology of Cerebral Ischemia 2002. Krieglstein J, ed., Medpharm Scientific
Publishers, Stuttgart, Germany, pp 47-56 (2002).
50. Wang, H., M. Shimoji, S-W Yu, T.M. Dawson and V.L. Dawson. “Apoptosis Inducing Factor and PARP
Mediated Injury in the MPTP Mouse Model of Parkinson’s Disease.” Parkinson’s Disease: the Life Cycle of
the Dopamine Neuron, ed. H. Federoff, Annals New York Acad. Sci. 991:132-9 (2003).
51. Dawson, T.M. and V.L. Dawson. “Nitric Oxide in the Nervous System.” in Encyclopedia of Neurological
Sciences. eds. M. J. Aminoff and R.B. Daroff, Academic Press, Vol. 3, pp. 632-636 (2003).
52. Lim, K.L., V.L. Dawson and T.M. Dawson, “The Cast of Molecular Characters in Parkinson’s Disease:
Felons, Conspirators and Suspects” Parkinson’s Disease: the Life Cycle of the Dopamine Neuron, ed. H.
Federoff, Annals of the New York Academy of Science, 991:80-92 (2003).
19
Valina L. Dawson, Ph.D.
53. Shimoji, M., T.M. Dawson and V.L. Dawson, “The role of nitric oxide and PARP in cell death.” In
Neurodegenerative Diseases: Neurobiology, Pathogenesis and Therapeutics, eds. F. Beal, A. Lang and A.C.
Ludolph. Cambridge University Press, Cambridge UK, in press (2004).
54. Lim, K.L., V.L. Dawson and T.M. Dawson, "Molecular Biology of Parkin" In Molecular Mechanisms in
Parkinson's Disease ed. P. Kahle and C. Haass, Landes Bioscience /Eurekah.com, Chapter 13, pp. 1-12
(2004).
55. Dawson, T.M. and V.L. Dawson. “Nitric Oxide.” in Encyclopedia of Neurological Sciences. eds. M. J.
Aminoff and R.B. Daroff, Academic Press, Vol. 3, pp. 632-636 (2003).
56. Dawson V.L. and T.M. Dawson, “Intracellular Signaling: Mediators and Protective Responses” In Stroke:
Pathophysiology, Diagnosis, and Management, Fourth Edition. Mohr JP, DW Choi, JC Grotta, B Weir and
PA Wolff ed., Harcourt Inc., Orlando, FL, pp 895-902, (2004).
57. Lim, K.L., V.L. Dawson, T.M. Dawson. “Molecular Biology of Parkin.” In Molecular Mechanisms in
Parkinson’s Disease. Eds. P. Kahle and C. Haass, Landes Bioscience/Eurekah.com, Chapter 13, pp. 1-12
(2004).
58. Dawson, V.L., T.M. Dawson “Nuclear-Mitochondrial Conversations in PARP-1 Dependent Cell Death” In:
Pharmacology of Cerebral Ischemia 2004. Krieglstein J. and S. Klumpp eds., Medpharm Scientific
Publishers, Stuttgart, Germany, pp 113-120 (2004).
59. Hong, S.J, T.M. Dawson and V.L. Dawson, “PARP and the Release of Apoptosis-Inducing Factor from
Mitochondria.” In Poly(ADP-Ribosyl)ation, Bürkle A (Ed.) Landes Bioscience, Georgetown, TX, USA.
ISBN: 1-58706-292-5, (2004).
60. Moore, D.J., A.B. West, V.L. Dawson, and T.M. Dawson. “Molecular Pathophysiology of Parkinson’s
Disease.” In Annual Review of Neuroscience [Jun 30; 2005 Epub ahead of print] 28:55-84 (2005).
61. Ravichandran, S., V.L. Dawson and T.M. Dawson. “Genetics of Parkinson’s Disease.” in Neurogenetics:
Scientific and Clinical Advances, Lynch DR (Ed), Dekker New York, NY in press (2005).
62. Kim, S.W., H.S. Ko., V.L. Dawson and T.M. Dawson. “Recent Advances in our understanding of Parkinson’s
Disease.” Drug Discovery Today: Disease Mechanisms. 2:4270433 (2005).
63. Ravichandran, S., T.M Dawson and V.L. Dawson. “Ubiquintation by Parkin_Implication in Parkinson’s
Disease.” In The Proteasome in Neurodegenerartion Eds. L. Stefanis, J.N. Keller, Springer + Business
Media, ISBN:978-0-387-28499-6; Chapter 13, pp 213-224 (2006).
64. Chung, K.K.K., V.L. Dawson and T.M. Dawson. “S-Nitrosylation in Parkinson's Disease and Related
Neurodegenerative Disorders.” In: Nitric Oxide, Part E, A Volume of Methods in Enzymology, Eds. L.
Packer, E. Cadenas J.N. Abelson and M.I. Simon, Academic Press, Orlando, FL Methods in Enzymology
Chapter 14; 396:139-150 (2005).
65. Hong, S.J., V.L. Dawson and T.M. Dawson, “Identification and evaluation of NO regulated genes by
Differebtial Analysis of primary cDNA Library Expression” In: Nitric Oxide, Part E, A Volume of Methods
in Enzymology, Eds. L. Packer, E. Cadenas J.N. Abelson and M.I. Simon, Academic Press, Orlando, FL
Methods in Enzymology Chpater 30; 396:359-368 (2005).
66. Chung, K.K.K. V.L. Dawson and T.M. Dawson. "Gaseous Signaling: Nitric Oxide (NO) and Carbon
Monoxide (CO) as Messenger Molecules.” In Handbook of Contemporary Neuropharmacology, in press
(2005).
67. Lee, Y.I., T.M. Dawson and V.L. Dawson. “Role of NO in neurodegeneration” in New Encyclopedia of
Neuroscience Third Edition (CD-ROM), ed. L. Squire, G. Adelman, B.H. Smith by Elsevier, Oxford UK,
Chapter 526, ISBN: 0444514325 (2006).
68. Sriram, S.R., V.L. Dawson and T.M. Dawson. “Parkin and Neurodegeneration.” in Protein Degradation, Vol.
4 Eds. R.J. Mayer, A. Ciechanover, Rechsteiner, Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim, in
press (2006).
20
Valina L. Dawson, Ph.D.
69. Savitt, J.M., V.L. Dawson, and T.M. Dawson. “Parkinson Disease: Molecular Insights.” in Molecular
Neurology ed. S.G. Waxman, Elsevier Academic Press, ISBN: 978-0-12-369509-3, Chapter 15, pp221-239
(2007).
70. Koh, D.W., T.M. Dawson, and V.L. Dawson. “Neurobiology of AIF and PARP in Cerebral Ischemia.” in
Handbook of Neurochemistry and Molecular Neurobiology 3rd Edition, Chan PH (Ed.) Springer-Verlag
Berlin Heidelberg, pp.19-33 (2007).
71. West, A.B., V.L. Dawson, T.M. Dawson. “The Role of PARKIN in Parkinson’s Disease” in “Parkinson’s
Disease: Genetics and Pathogenesis,” Ed. T.M. Dawson, Informa Healthcare USA, Inc. ISBN:978-0-84933697-3, Chapter 14, pp. 199-218 (2007).
72. Ying, M., V.L. Dawson and T.M. Dawson. “Genetic Models of Familial Parkinson’s Disease.” In:
Parkinson’s Disease: Molecular and Therapeutic Insight from Experimental Models, Eds. S. Przedborski, R.
Nass, Elsevier Publishing Services, Chennai, India, Chapter 17, pp 225-236 (2008).
73. Kang, H.C., T.M. Dawson and V.L. Dawson, “Excitotoxic programmed cell death involves caspaseindependent mechanisms.” in Acute Neuronal Injury: The Role of Excitotoxic Programmed Cell Death
Mechanisms ed. D.G. Fujikawa, Springer Life Sciences in press (2008).
74. Dawson, V.L. and T.M. Dawson. “Parthanatos: PARP and AIF-dependent programmed cell death.” in
Beyond Apoptosis: Cellular Outcomes of Cancer Therapy. Eds. I.B. Roninson, M.J. Brown, and D.E.
Bredesen, Taylor and Francis Group, LLC, pp143-157 (2008).
75. Lee, Y-I, T.M. Dawson, and V.L. Dawson. “Role of NO in Neurodegeneration.” in Handbook of the
Neuroscience of Aging, ed. Patrick R. Hof and Charles V. Mobbs, San Diego: Academic Press, pp 101-106.
(2009).
76. Lee, B.D., X. Li, T.M. Dawson, and V.L. Dawson. “Measuring the activity of Leucine Rich Repeat Kinase 2
(LRRK2) – a kinase involved in Parkinson’s disease.” In Methods in Molecular Biology: Kinase Inhibitors,
ed. B. Kuster, Humana Press, in press (2009).

Books
“Nitric Oxide and Other Diffusible Signals in Brain Development, Plasticity and Disease”, eds. R. Ranney Mize,
T.M. Dawson, V.L. Dawson and M.J. Friedlander. Progress in Brain Research, Vol. 118, Elsevier Science,
Amsterdam, the Netherlands. 1998.
21
Valina L. Dawson, Ph.D.

Abstracts
1.
Dawson, V.L., T.M. Dawson, D.R. Gehlert and J.K. Wamsley. "High and Low Agonist Affinity States of
Dopamine D-1 and D-2 Receptors: A Quantitative Autoradiographic Study." Soc. Neurosci. Abstr. 12:485,
(1986).
2.
Dawson, V.L., J.K. Wamsley, F.M. Filloux, and T.M. Dawson. "Alterations in Muscarinic M-2 and
Dopamine D-2 Receptors in the Rat Brain Following Intrastriatal Injection of the Cholinotoxin AF64A: An
Autoradiographic Study." Soc. Neurosci. Abstr. 13:1198, (1987).
3.
Dawson V.L., F.H. Gage, and J.K. Wamsley. "Evidence for Reinnervation of Hippocampal Muscarinic
Receptors by Fetal Septal Transplants Following Fimbria-Fornix Lesion." Clinical Research 36:163A,
(1988).
4.
Dawson, V.L., F.H. Gage, and J.K. Wamsley. "Alterations in Muscarinic Binding in Rat Hippocampus
Provides Evidence for Functional Reinnervation of Fimbria-Fornix Lesions." Soc. Neurosci. Abstr. 14:588,
(1988).
5.
Wamsley, J.K., T.M. Dawson, V.L. Dawson, T.H. Liu, C.Y. Hsu and F.M. Filloux. "Receptor Specific
Connections of the Caudate-Putamen: Focus on Dopaminergic and Muscarinic Subtypes." Proc. Int. Basal
Ganglia Soc. III. Sardinia, Italy, (1989).
6.
Dawson, V.L., J.K. Wamsley. "Differential Upregulation of Hippocampal M-1 and M-2 Muscarinic
Receptors After Cholinotoxin (AF64A) Lesion of the Medial Septum or Diagonal Band." Soc. Neurosci.
Abstr. 15:555 (1989).
7.
Wamsley, J.K., F.H. Gage, V.L. Dawson, L.J. Fisher, and T.M. Dawson. "Normalization of Supersensitive
D-1 and D-2 Dopamine Receptors in the 6-OHDA Denervated Rat After Transplantation of Fetal
Mesencephalon." Soc. Neurosci. Abstr. 15:934 (1989).
8.
Dawson, V.L., K. Williams, C. Romano, P.B. Molinoff, and M.A. Dichter. "NMDA-Induced Currents in
Hippocampal Neurons Can Be Modulated by the Polyamine Spermine." Soc. Neurosci. Abstr. 16:541
(1990).
9.
Wamsley, J., T. Dawson, V. Dawson, M. Hunt, L. Fisher and F. Gage. "Reversal of Nigrostriatal-LesionInduced Supersensitivity by Grafting of Fetal Mesencephalic Dopaminergic Neurons." Third International
Symposium of Neurotransmitter Receptors "Neuroreceptor Mechanisms in Brain." Hirioshima, Japan
(1990).
10.
Dichter, M.A., V.L. Dawson, S.R. Zukin, and P.B. Molinoff. "Polyamines: Novel Modulators of the
NMDA Receptor/Channel." Winter Conference on Brain Research, Vail, CO (1991).
11.
Dawson, V.L., T.M. Dawson, E.D. London, D.S. Bredt, and S.H. Snyder. "Glutamate Neurotoxicity is
Mediated by Nitric Oxide." Soc. Neurosci. Abstr. 17:784 (1991).
12.
Dawson, V.L. Dawson, D.S. Bredt, M. Fotuhi, P.M. Wang, G.R. Uhl, and S.H. Snyder. "Nitric Oxide
Synthase/NADPH Diaphorase Neurons: Role in Neurotoxicity." Soc. Neurosci. Abstr. 17:783 (1991).
13.
Bredt, D.S., P.M. Hwang, C. Glatt, T.M. Dawson, M. Fotuhi, V. Dawson, C. Lowenstein, C.D. Ferris, R.R.
Reed, and S.H. Snyder. "Nitric Oxide Synthase: Molecular Characterization and Functional Expression of
the Cloned Gene." Soc. Neurosci. Abstr. 17:349 (1991).
14.
Dawson, V.L., T.M. Dawson, G.R. Uhl, and S.H. Snyder. "Nitric Oxide Mediates Componants of NMDA
and GP120 Neurotoxicities in Primary Striatal Cultures." Soc. Neurosci. Abstr. 18:756 (1992).
15.
Dawson, T.M., J.P. Steiner, V.L. Dawson, G.R. Uhl, and S.H. Snyder. "Nitric Oxide Synthase: NMDA and
the Immunosuppressant, FK-506, Modulate Phosphorylation, Function and Neurotoxicity." Soc. Neurosci.
Abstr. 18:756 (1992).
22
Valina L. Dawson, Ph.D.
16.
Kusama, T., C.E. Spivak, V. Dawson, and G. Uhl. "GABA Rho 1 Expression." Soc. Neurosci. Abstr.
18:656 (1992).
17.
Schwarcz, R., W.O. Whetsell, Jr., E. Aizenman, V. Dawson, and C. Kohler. "Mechanisms of
Excitotoxicity: The In Vivo-In Vitro Dilemma." Winter Conference on Brain Research (1993)
18.
Wasterlain, C.G., A. Charles, V.L. Dawson, I. Hanbauer, and G. Wilcox. "Gas Attack on the Brain:
Functional Aspects of the NO Story." Winter Conference on Brain Research (1993)
19.
Dawson, V.L., T. M. Dawson, K. Hung, J.P. Steiner, and S.H. Snyder. "Gangliosides Attenuate NMDA
Neurotoxicity by Inhibiting Nitric Oxide Synthase." Soc. Neurosci. Abst. (1993)
20.
Dinerman, J.L., J.P. Steiner, T.M. Dawson, V.L. Dawson, and S.H. Snyder. "Regulation of Nitric Oxide
Synthase Activity by Cyclic GMP-Dependent Protein Kinase." American Heart Association (1993)
21.
Dawson, V.L. "Principles and Mechanisms of Neurodegeneration and Neurotoxicity in Primary Cell
Cultures." World Congress on Alternatives and Animal Use in the Life Sciences (1993)
22.
Dawson, V.L. "Nitric Oxide Mediates Componants of NMDA and gp120 Neurotoxicities in Primary
Neuronal Cultures." Technical Advances in AIDS Research in the Human Nervous System, (1993)
23.
Dawson, V.L., J. Zhang, T.M. Dawson, and S.H. Snyder. "Poly(ADP-Ribose)Synthase Inhibitors are
Neuroprotective against NMDA and Nitric Oxide Neurotoxicity." Soc. Neurosci. Abst. (1994)
24.
Dawson, V.L., T.M. Dawson. "Molecular Mechanisms of Glutamate Neurotoxicity in Primary Neuronal
Cultures." American Aging Association, Oxidative Stress '94 (1994)
25.
Dawson, V.L., J. Zhang, T.M. Dawson, and S.H. Snyder. "Molecular Mechanisms of Nitric Oxide
Mediated Toxicity in the Central Nervous System." Biochemistry and Molecular Biology of Nitric Oxide
(1994)
26.
Dawson,V.L. “Nitric Oxide In The Central Nervous System: Physiologic And Pathphysiologic Actions.”
NIH Workshop: Role Of Antioxidants And Free Radicals In Neurobiology (1994).
27.
Dawson, V.L., T.M. Dawson. “The Role of Nitric Oxide in Neurotoxcity.” IVth IBRO World Congress of
Neuroscience (1995).
28.
Dawson, V.L., P.L. Huang, M.C. Fishman, S.H. Snyder, and T.M. Dawson. “Primary cortical cultures
from neuronal NOS null mice are resistant to glutamate neurotoxicity.” Soc. Neurosci. Abst. 21: 520
(1995).
29.
Sasaki, M., H.P. Brahmbhatt, T.M. Dawson, and V.L. Dawson. “Decrements in intracellular NAD and ATP
following exposure of primary neuronal cultures to neurotoxic concentrations of NMDA.” Soc. Neurosci.
Abst. 21: 520 (1995)
30.
Resink, A., H.B. Brahmbhatt, B. Cordell, S.H. Snyder and T.M. Dawson, V.L.Dawson.. "Nitric Oxide
Mediates A Componant Of §-Amyloid Neurotoxicity.” Soc. Neurosci. Abst. 21: 1010 (1995)
31.
Shibata, T., V.L.Dawson, and T.M. Dawson. “The Immunosuppressant, FK506, Provides Neuroprotection
Against Methamphetamine- and MPTP Neurotoxicity.” Soc. Neurosci. Abst. 21:1518 (1995)
32.
Adamson, D.C., T.M. Dawson, C. Zink, J. Clements and V.L. Dawson. “Apoptosis in the CNS of SIV
Infected Rhesus Macaques with Neurologic Disease but not in SIV Infected Rhesus Macaques without
Neurologic Disease.” Soc. Neurosci. Abst. 21: 1740 (1995)
33.
Wildemann, B., V.L. Dawson, D.C. Adamson, J. McArthur, J. Glass, T.M. Dawson. “Immunologic Nitric
Oxide Synthase is Elevated in HIV Infected Individuals with Dementia.” Soc. Neurosci. Abst. 21:1520
(1995)
34.
Bao, J., A.H. Sharp, C.A. Ross, V.L. Dawson and T.M. Dawson. “Partial Purification and Characterization
of the Huntington’s Disease Protein.” Soc. Neurosci. Abst. 21: 488 (1995)
23
Valina L. Dawson, Ph.D.
35.
Demas, GE, SL Klien, LJ Kriegsfeld, RJ Nelson, PL Huang, MC Fishman, VL Dawson, TM Dawson, and
SH Snyder. “Enhanced Sexual Motivation in Mice Lacking the Gene for Neural Nitric Oxide Synthase.”
Conference on Reproductive Behavior (1995).
36.
Kriegsfeld LJ, GE Demas, SL Klien, RJ Nelson, AL Burnett, PL Huang, MC Fishman, VL Dawson, TM
Dawson, and SH Snyder. “Reproductive Behavior in Male MiceLacking the Gene for Neural Nitric Oxide
Synthase.” Conference on Reproductive Behavior (1995).
37.
Klein SL, GE Demas, LJ Kriegsfeld, RJ Nelson, AL Burnett, PL Huang, MC Fishman, VL Dawson, TM
Dawson, and SH Snyder. “Mating in Male Mice Lacking the Gene for Neural Nitric Oxide Synthase
(nNOS) Synthase.” Soc. Neurosci. Abst. 21: 1464 (1995).
38.
Xia Y, VL Dawson, TM Dawson, SH Snyder and JL Zweier. “Arginine Depletion Induces Oxygen Free
Radical Generation From Nitric Oxide In Intact Cells.” Soc. Neurosci. Abst. (1995).
39.
Xia, Y., V.L. Dawson, T.M. Dawson, S.H. Snyder and J.L. Zweier. “Arginine Depletion Induces Oxygen
Free Radical Generation from Nitric Oxide Synthase in Intact Cells.” American Heart Association,
Anaheim, CA (1995).
40.
Nelson, RJ, GE Demas, AL Burnett, SL Klein, LJ Kriegsfeld, PL Huang, MC Fishman, VL Dawson, TM
Dawson, and SH Snyder. “Sustained Reproductive And Aggressive Behavior In Male Mice Lacking
Neuronal Nitric Oxide Synthase.” Fourth International Meeting: Biology of Nitric Oxide (1995).
41.
Crosbie RH, Chamberlain JS, Dawson TM, Dawson VL and Campbell KP. “Nitric Oxide Synthase
Interaction With Dystrophin Glycoprotein Complex.” The American Society for Cell Biology - Mol. Biol.
Cell 6:268A (Suppl) (1995).
42.
Bao, J., A.H. Sharp, M. V. Wagster, M. Becher, G. Schilling, C.A. Ross, V.L. Dawson, T.M. Dawson.
“Protein-Protein Interaction Of Huntingtin Involves Calmodulin.” 61st Symposium: Function &
Dysfunction in the Nervous System, Cold Spring Harbor, (1996).
43.
Dawson V.L., B. Wildemann, M. Sasaki, D.C. Adamson, J. McArthur, J. Glass, and T.M. Dawson.
“Immunologic Nitric Oxide Synthase is Elevated in HIV Infected Individuals With Dementia.” Polk
Symposium, Baltimore MD (1996).
44.
Adamson, D. Cory, B. Wildemann, M. Sasaki, J. McArthur, J. Glass, V.I. Christov, T.M. Dawson, and V.L.
Dawson. “Neuronal Injury In Severe AIDS Dementia is Mediated by HIV-1 Coat Protein, gp41, Induction
Of Immunologic Nitric Oxide Synthase.” 61st Function and Dysfunction in the Nervous System, Cold
Spring Harbor Symposium, (1996).
45.
Dawson V.L., B. Wildemann, M. Sasaki, D.C. Adamson, J. McArthur, J. Glass, and T.M. Dawson.
“Immunologic Nitric Oxide Synthase is Elevated in HIV Infected Individuals With Dementia.” Nitric Oxide
1996, Los Angeles, CA (1996).
46.
Dawson T.M., V. Jackson-Lewis, R. Yokoyama, T. Shibata, V.L. Dawson, and S. Przedborski. “Neuronal
Nitric Oxide Mediates MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydrophyridine) Neurotoxicity.” Nitric
Oxide 1996, Los Angeles, CA (1996).
47.
Dawson, T.M., V.M. Kizushi, P.L. Huang, S.H. Snyder and V.L. Dawson. “Neuronal Nitric Oxide
Synthase-Defcient Mice Are Resistance to Neurotoxicity.” 1st Annual Meeting of the Paul G. Beeson
Physician Faculty Geriatric Scholars, Alliance for Aging Research, Washington DC (1996).
48.
Facchinetti, F., M.E. Gurney, T.M. Dawson, and V.L. Dawson. “Cortical Cell Cultures From a Transgenic
Mouse Model of FALS Are More Vulnerable to AMPA and Kainate Toxicity.” Soc. Neurosci. Abst.
22:1278 (1996).
49.
Sasaki, M. F. Facchinetti, V. Christov, H. Brahmbhatt, M.F. Beal, D. Reif, T.M. Dawson, M.E. Gurney and
V.L. Dawson. “Is Neuronal Nitric Oxide Synthase Involved in the Pathogenesis of a Transgenic Mouse
Model of Familial Amyotrophic Lateral Sclerosis?” Soc. Neurosci. Abst. 22:2142 (1996)
24
Valina L. Dawson, Ph.D.
50.
Bao, J., A.H. Sharp, F. Persichetti, G. Schilling, M.V. Wagster, M. Becher, J. Gusella, M. MacDonald, C.A.
Ross, V.L. Dawson, T.M. Dawson. “Protein-Protein Interactions of Huntingtin Involve Calmodulin.” Soc.
Neurosci. Abst. 22:1894 (1996)
51.
Yun, H.-Y., V.L. Dawson and T.M. Dawson. “Expression of Alternative Forms of Neuronal Nitric Oxide
Synthase (nNOS) in Brain.” Soc. Neurosci. Abst. 22:1565 (1996).
52.
Gonzalez-Zulueta, M., L.M. Ensz, V.L. Dawson and T.M. Dawson. “SOD2 May Account for the
Resistance of nNOS Neurons to Excitotoxicity.” Soc. Neurosci. Abst. 22:803 (1996).
53.
Resink, A., V.L. Dawson, T.M. Dawson. “Tumor Necrosis Factor (TNF) Mediates §-Amyloid Induced
Toxicity Through Interleukin-1§- Converting Enzyme (ICE) Pathway.” Soc. Neurosci. Abst. 22:2115
(1996).
54.
Samdani, A., C. Newcamp, A. Resink, F. Facchinetti, V.L. Dawson and T.M. Dawson. “Nitric Oxide
Mediates Potentiation of Neurotoxicity by Neurotrophins.” Soc. Neurosci. Abst. 22:997 (1996).
55.
Samdani, A., C. Newcamp, A. Resink, F. Facchinetti, V.L. Dawson and T.M. Dawson. “Nitric Oxide
Mediates Potentiation of Neurotoxicity by Neurotrophins.” American Association of Physicians of Indian
Origin Annual Meeting, Boston, MA (1996).
56.
Samdani, A., M. Watts, A.K. Sills, M.Ewend, B.M. Tyler, V.L. Dawson, T.M. Dawson. and H. Brem.
“Nitric Oxide Formed by Glia Inhibits Growth of Human and Experimental Primary Brain Tumors.”
Congress of Neurological Surgeons, Montreal Canada (1996).
57.
Samdani, A., M. Watts, A.K. Sills, M.Ewend, B.M. Tyler, V.L. Dawson, T.M. Dawson. and H. Brem.
“Nitric Oxide Produced by Glia Inhibits Growth of Human and Experimental Metastatic Brain Tumors.”
Congress of Neurological Surgeons, (1997).
58.
Samdani, A., C. Newcamp, A. Resink, F. Facchinetti, V.L. Dawson and T.M. Dawson. “Differential
Susceptibility of Cultures Mediated by Neurotrophins and Neuronal Nitric Oxide Synthase.” 22nd
International Joint Conference on Stroke and Cerebral Vascular Circulation, American Heart Association,
Anaheim, CA (1997).
59.
D. Cory Adamson, J. McArthur, T.M. Dawson, and V.L. Dawson. “Rapid Progression of HIV-associated
Dementia is Associated with CNS iNOS and gp41 Expression.” 4th Conference on Retroviruses and
Opportunistic Infections, Washington D.C. (1997).
60.
Toung, T.J., P.D. Hurn, A. Bhardwaj, V.L. Dawson, T.M. Dawson, and R.J. Traystman.
“Immunosuppressive agent FK506 reduces experimental stroke injury.” BRAIN ‘97, Baltimore, MD.
61.
Asano, Y., A.S. Mandir, P.C. Wong, R.J. Traystman, V.L.Dawson, T.M. Dawson, and P.D. Hurn. “Stroke
outcome in antioxidant transgenics: nNOS, Cu-Zn superoxide dismutase and combined mutants.” BRAIN
‘97, Baltimore, MD.
62.
Dawson, T.M., M. Gonzalez-Zulueta, and V.L. Dawson. “Maganese superoxide dismutase protects nNOS
neurons from NMDA and nitric oxide mediated neurotoxicity.” The Second Annual Meeting of the Paul B.
Beeson Physician Faculty Scholars in Aging Research Program, Wild Dunes Resort, Isle of Palms, SC
(1997).
63.
Yun, H-Y, M. Gonzalez-Zulueta, V.L.Dawson, and T.M. Dawson. “Nitric oxide mediates NMDA receptor
stimulated activation of Ras/Erk.” 5th International Meeting on the Biology of Nitric Oxide, Kyoto, Japan
(1997).
64.
Dawson, V.L., A.S. Mandir, M.J.L. Eliasson, A. Pieper, Z.-Q. Wang, S.H. Snyder, and T.M. Dawson.
“Poly (ADP-Ribose) polymerase null transgenic mice are resistant to models of focal ischemia.” Soc.
Neurosci. Abst. (1997).
65.
Mandir, A.S., S. Prezedboroski, A.B. Naini, M.J.L. Eliasson, A. Pieper, Z.-Q. Wang, S.H. Snyder, V.L.
Dawson, and T.M. Dawson. “Poly (ADP-Ribose) Polymerase (PARP) knockout mice are protected against
neurotoxic effects of methyl-phenyl-tetrahydropyridine (MPTP). Soc. Neurosci. Abst. (1997).
25
Valina L. Dawson, Ph.D.
66.
Eliasson, M.J.L., K. Sampei, A.S. Mandir, P.D. Hurn, R.J. Traystman, A. Pieper, A.J. Verma, Z.-Q. Wang,
T.M. Dawson, S.H. Snyder, and V.L. Dawson. “Poly (ADP-Ribose) polymerase knockout mice are
resistant to cerebral ischemia.” Soc. Neurosci. Abst. (1997).
67.
Herring, W.J., G.A. Oyler, J.M. Hardwick, V. Colomber, C.A. Ross, A. Kakizuka, V.L. Dawson, and T.M.
Dawson. “In vitro modulation of caspase activation and apoptotic cell death by the polyglutamine tract in
Machado-Joseph disease protein.” Soc. Neurosci. Abst. (1997).
68.
Sasaki, M., H. Huang, X. Wei, J.F. Dillman, V.L. Dawson, and T.M. Dawson, “Transcriptional regulation
of nNOS during neuronal development and plasticity is controlled by multiple promoters.” Soc. Neurosci.
Abst. (1997).
69.
Gonzalez-Zuleuta, M., H.-Y. Yun, V.L. Dawson, and T.M. Dawson. “Nitric oxide mediates activitydependent neuronal survival.” Soc. Neurosci. Abst. (1997).
70.
Yun, H.-Y., M. Gonzalez-Zulueta, V.L. Dawson, and T.M. Dawson. “NMDA receptor mediated Ca2+influx activates the Ras/Erk pathway through nitric oxide.” Soc. Neurosci. Abst. (1997).
71.
Bao, J., T.M. Dawson and V.L. Dawson, “Development of a rapid assay for neuronal neutral
sphingomylinase.” Soc. Neurosci. Abst. (1997).
72.
Kopnisky, K.L., D.C. Adamson, T.M. Dawson, and V.L. Dawson. “Characterization of nitric oxide
dependent pathways involved in HIV-1 coat protein toxicity.” Soc. Neurosci. Abst. (1997).
73.
Dawson, V.L., M. Gonzalez-Zulueta, A.F. Samdani and T.M. Dawson. “Mechanisms of resistance to
oxidative injury in models of focal ischemia.” 8th International Symposium on Stroke, Neurotrauma and
Other Neurological Diseases, New Orleans, LA (1997).
74.
Dawson, T.M., M. Gonzalez-Zulueta, H.-Y. Yun, and V.L. Dawson. “Opposing role of nitric oxide as a
trophic molecule and neurotoxin during development and neuronal injury.” 8th International Symposium
on Stroke, Neurotrauma and Other Neurological Diseases, New Orleans, LA (1997).
75.
Gonzalez-Zulueta, M., H.-Y. Yun, V.L. Dawson, and T.M. Dawson. “Nitric oxide mediates activitydependent neuronal survival.” 5th International Meeting on the Biology of Nitric Oxide, Kyoto, Japan
(1997).
76.
Togashi, H., M. Sasaki, E. Frohman, E. Taira, R.R. Ratan, T.M. Dawson, and V.L. Dawson. “Neuronal
(Type I) nitric oxide synthase regulates nuclear factor k B activity and immunologic (Type II) nitric oxide
synthase expression. Kyoto Nitric Oxide Meeting, Kyoto, Japan (1997).
77.
Crosbie R.H., V. Straub, D.P. Venzke, H.Y. Yun, J.S. Chamberlain, V.L. Dawson, T.M. Dawson, and K.P.
Campbell. "Dystrophin and nNOS Double Knockout Mice Maintain Dystrophic Phenotype." FASEB J
11: A1418 (1997).
78.
Mandir, A.S., S. Prezedboroski, A.B. Naini, M.J.L. Eliasson, A. Pieper, Z.-Q. Wang, S.H. Snyder, V.L.
Dawson, and T.M. Dawson. “Poly (ADP-Ribose) Polymerase (PARP) null mice are protected against
MPTP neurotoxicity.” American Academy of Neurology Neurology 50: A133 (1998).
79.
Gonzalez-Zulueta, M., V.L. Dawson, and T.M. Dawson. “Nitric oxide is required for BDNF-mediated
activity-dependent neuronal survival.” Soc. Neurosci. Abst. (1998).
80.
Dawson, T.M., G.A. Oyler, J.M. Hardwick, K. Ueno, V.L. Dawson, and W.J. Herring. “Viral vector
mediated in vivo and in vitro models of ataxin-3 polyglutamine neurotoxicity.” Soc. Neurosci. Abst. (1998).
81.
Herring, W.J., Z.-Q. Wang, A.G. Yakovlev, M. Smulson, T.M. Dawson, and V.L. Dawson. “Viral vector
mediated neuronal expression of poly(ADP-ribose) polymerase in cell death paradigms.” Soc. Neurosci.
Abst. (1998).
82.
Mandir, A.S., D. Guastella, M.F. Poitras, Z.-Q. Wang, P.D. Hurn, R.J. Traystman, T.M. Dawson, and V.L.
Dawson. “Poly (ADP-Ribose) Polymerase (PARP) null mice are protected against neurotoxic effects of
NMDA but not AMPA excitotoxicity.” Soc. Neurosci. Abst. (1998).
26
Valina L. Dawson, Ph.D.
83.
Sasaki, M., H. Huang, S. Ahn, D.D. Ginty, V.L. Dawson, and T.M. Dawson. “Expression of neuronal
nitric oxide synthase (nNOS) is regulated through calcium/cyclic AMP response element.” Soc. Neurosci.
Abst. (1998).
84.
Sawada, M., S. Mori, P.C.M van Zijl, T.M. Dwason, V.L. Dawson, R.J. Traystman, and P.D. Hurn.
“Diffusion and T2 MRI measurement of acute and chronic stroke outcomes in SV129 mice.” Soc. Neurosci.
Abst. (1998).
85.
Kusama-Eguchi, K., J. Bao, V.L. Dawson, K. Watanabe, and T.M. Dawson. “Charateristics and regional
distribution of rat brain neutral sphingomyelinase (NSM).” 71st Annual Meeting of the Japanese
Biochemical Society (1998).
86.
Dawson, V.L. “HIV envelope protein, gp41, Immunologic Nitric Oxide Synthase and HIV Dementia.”
Neuroscience of HIV: Basic Research and Clinical Frontiers, Northwestern University, Chicago, IL (1998).
87.
Dawson, V.L. “Nitric oxide pathways in neuronal signaling and neuronal death.” 3rd International
Conference on the Biochemistry and Molecular Biology of Nitric Oxide, Los Angeles CA (1998).
88.
Dawson, V.L. “Poly(ADP-Ribose) Polymerase in Ischemia-Reperfusion Injury.” the 21st Princeton
Conference. American Heart Association, St. Louis, MO (1998).
89.
Dawson, V.L. and T.M. Dawson. “Poly(ADP-Ribose) Inhibition as a Therapeutic Approach to Focal
Ischemic Insult.” the 7th International Symposia on the Pharmacology of Cerebral Ischemia. Marburg
Germany (1998).
90.
Nucifora, F.C. J.D. Wood, W.J. Herring, M.F. Peters, V.L. Dawson, T.M. Dawson, C.A. Ross. "Nuclear
Localization of Atrophin-1, the DRLPA Gene Product." Molecular Biology of the Cell, 9:185A, (1998).
91.
Roubaud, V., F. Facchinetti, V.L. Dawson, T.M. Dawson, J.L. Zweier. "Oxygen Radical Generation
Following NMDA Receptor Stimulation in Neurons." Free Radical Biology and Medicine 25: S112 (1998).
92.
Goto, S., W.J. Herring, A.S. Mandir, T.M. Dawson, V.L. Dawson, R.J.Traystman, B.J. Crain, Z.Q. Wang,
and P.D. Hurn. “Viral-vector Transfection of Poly(ADP-Ribose) Polymerase in Experimental Stroke.”
Brain ‘99, Copenhagen, Denmark (1999).
93.
Dawson, V.L. "Mechanisms of Sensitivity and Resistance to Neuronal Excitotoxicity." International
Society for Neurochemistry, Berlin, Germany, 1999.
94.
Dawson, T.M., M. Gonzalez-Zulueta, A.B. Felman, J.F. Dillman, R.G. Kalb, L.J. Klesse, L.F. Parada, and
V.L. Dawson. "Ischemic Preconditioning is Mediated by Nitric Oxide Activation of RAS." Fourth Annual
Meeting of the Paul B. Beeson Physician Faculty Scholars in Aging Research, Chantilly, VA, 1999.
95.
Herring, W.J., G.A. Oyler, J.M. Hardwick, Y.A. Lazebnik, V.L. Dawson, T.M. Dawson. "Mutant Ataxin-3
and Caspase-9 Cooperatively Enhance Cell Death." Soc. Neurosci. Abst., 25:1304, (1999).
96.
Sasaki, M., M. Gonzalez-Zulueta, H. Huang, S. Ahn, D.D. Ginty, W.J. Herring, V.L. Dawson, T.M.
Dawson. "Expression of Neuronal Nitric Oxide Synthase is Regulated Through a Calcium/Cyclic AMP
Response Element." Soc. Neurosci. Abst., 25:423 (1999).
97.
Mandir, A.S., M.F. Poitras, D. Guastella, A. Chaudhry, V.L. Dawson, T.M. Dawson. "Mitochondrial SOD
(MnSOD) Heterozygous Mice Are Highly Sensitive to MPTP-Induced Neurotoxicity." Soc. Neurosci. Abst.
(1999).
98.
Guo, X., V.L. Dawson, T.M. Dawson. "Protective Effects of Immunophilin Ligands on Dopaminergic
Neurons." Soc. Neurosci. Abst., 25:335 (1999).
99.
Gonzalez-Zulueta, M., A.B. Felman, J.F. Dillman, R.G. Kalb, L.J. Klesse, L.F. Parada, T.M. Dawson, V.L.
Dawson. "Ischemic Tolerance in Cortical Neuronal Cultures Requires an Intact Ras/MAPK Pathway." Soc.
Neurosci. Abst. (1999).
100. Dillman III, J.F., T.M. Dawson, V.L. Dawson. "Identification of Protein Changes in Ischemic Tolerance
Using Proteomic Approaches." Soc. Neurosci. Abst., 25:1588 (1999).
27
Valina L. Dawson, Ph.D.
101. Chiavegatto, S., T.M. Dawson, V.L. Dawson, R.J. Nelson. "Serotonin is Involved in the Aggressive
Behavior of Male nNOS Null Mice." Soc. Neurosci. Abst., 25:437 (1999).
102. Gao, J., K. Kusama-Eguchi, T.M. Dawson, V.L. Dawson. "Mg2+ -Dependent Neutral Sphingomyelinase
Distribution in the Adult Rat Brain." Soc. Neurosci. Abst., 25:1520 (1999).
103. Wei, X., M. Sasaki, H. Huang, V.L. Dawson, T.M. Dawson. "Expression of Neuronal Nitric Oxide
Synthase is Regulated by Steroidogenic Factor 1 in Hypothalamic-Pituitary Gonadadal Axis." Soc.
Neurosci. Abst., 25:1454 (1999).
104. Nandagopal, K., T.M. Dawson, V.L. Dawson. "N-Methyl-D-Aspartate Receptor-Induced Activation of the
RAP1 GTPASE is Mediated by Nitric Oxide." Soc. Neurosci. Abst., 25:1866 (1999).
105. Poitras, M.F., A.S. Mandir, J. Gao, T.M. Dawson, V.L. Dawson. "Distinct Regional Expression of
Manganese Superoxide Dismutase and Neuronal Nitric Oxide Synthase in Rat Brain." Soc. Neurosci. Abst.,
25:1843 (1999).
106. Guo, X., V.L. Dawson, T.M. Dawson. "Protective Effects of Immunophilin Ligands on Dopaminergic
Neurons." Soc. Neurosci. Abst., (1999).
107. Dawson, V.L., M. Gonzalez-Zulueta, T.M. Dawson. "NO Mediates Ischemic Preconditioning Through
P21Ras Activation." Biology of Nitric Oxide, 6th International Meeting, Stockholm, Sweden, September 58 (1999).
108. Dawson, T.M., M. Sasaki, V.L. Dawson. "Ca2+/cAMP-Mediated Regulation of Neuronal Nitric Oxide
Synthase (nNOS) Through a CREB-Family Transcription Factor Dependent Mechanism. Biology of Nitric
Oxide, 6th International Meeting, Stockholm, Sweden, September 5-8 (1999).
109. Goto, S, A. Bhardwaj, P.D. Hurn, V.L. Dawson, R.J. Traystman, J.R. Kirsch. “Neuroprotective effects of
sigma1-receptor ligand 4-phenyl-1-(4-phenylbutyl)piperidine (PPBP) is linked to reduced neuronal nitric
oxide synthase (nNOS) induced NO production. Annual Meeting of the American Association of
Neurological Surgeons, San Francisco, CA, April 8-13 (2000).
110. Chiavegatto, S., V.L. Dawson , L.A. Mamounas, S.H. Bora, V.E. Koliatsos, T.M. Dawson, R.J. Nelson.
"Altered Gene Expression of Central Serotonin 5-HT1A and 5-HT1B Receptors in Male nNOS Null Mice."
Federation of European Neurosociety, Brighton, United Kingdom (2000).
111. Dawson V.L., “PARP in Experimental Models of Neurologic Disease” 13th International Conference on
ADP-ribosylation Reactions.” Lund Sweden (2000).
112. Gao, J., Y. Zhang, K.K.K. Chung, T.M. Dawson and V.L. Dawson. “Regulation of Mg2+Sphingomyelinase by carboxypeptidase E.” Soc. Neurosci. Abst., (2000).
113. Sasaki, M., Wei, X., Hui, H., Gonzalez-Zulueta, M., Ahn, S., Ginty, D.D., Herring, W.J., Dawson, V.L.,
Dawson, T.M. "Expression of Neuronal Nitric Oxide Synthase Is Regulated Through a Calcium/Cyclic
AMP Response Element." First International Conference: Biology, Chemistry and Their Therapeutic
Applications of Nitric Oxide, San Francisco, California, June, 2000.
114. Nucifora, F.C., Jr., M. Sasaki, M.F. Peters, H. Huang, J. Troncoso, V.L Dawson, T.M. Dawson, and C.A.
Ross. "Polyglutamine interactions block CBP-activated gene transcription and mediate neuronal toxicity
relevant to HD and DRPLA." Hereditary Disease Foundation Meeting, 2000.
115. Wei, X., M. Sasaki, H. Huang, V.L. Dawson, T.M. Dawson. “Nuclear Receptors Regulate Neuronal Nitric
Oxide Synthase Gene Expression In The Central Nervous System.” Soc. Neurosci. Abst., (2000).
116. M. Sasaki, S., H. Huang, J.I. Arima1, D. Guastella, X. Wei, V.L. Dawson, T.M. Dawson. “Expression Of
Neuronal Nitric Oxide Synthase is Regulated Mainly Through the Proximal Promoter.” Soc. Neurosci.
Abst., (2000)
117. Chiavegatto, S., V.L. Dawson, L.A. Mamounas, V.E. Koliatsos1, T.M. Dawson, R.J. Nelson. “Reduced
Sensitivity of Central Serotonin 5-HT1A and 5-HT1B Receptors in Male Nnos Null Mice.” Soc. Neurosci.
Abst., (2000)
28
Valina L. Dawson, Ph.D.
118. Nucifora, F.C., M. Sasaki, H. Huang, J. Troncoso, V.L. Dawson, T.M. Dawson, C.A. Ross. “Huntington
Cellular Toxicity is Mediated via Interference with CBP Regulated Gene Transcription.” Soc. Neurosci.
Abst., (2000)
119. Zhang, Y., J. Gao, K.K.K. Chung, H. Huang, V.L. Dawson, T.M. Dawson. “Functional Characterization of
Parkin.” .” Soc. Neurosci. Abst., (2000)
120. Armellini-Dodel1, D.R., M.O. Lopez-Figueroa, H. Akil, M. Sasaki, V.L. Dawson, S.J. Watson, T.M.
Dawson. “Differential Expression of nNOS Promoters in the Adult Rat Brain.” Soc. Neurosci. Abst., (2000)
121. Dawson V.L., “PARP in Experimental Models of Neurologic Disease” 13th International Symposia on
ADP-Ribosylation, New York, NY (2001).
122. Poitras M.F., Wortel J., Zhong X., Mandir A.S., Norris J., Poirier G.G., Dawson T.M., Dawson V.L.
"Regional, Cellular And Subcellular Distribution of Poly(ADP-ribose) Glycohydrolase in Rate Brain" 13th
Annual International Symposium on ADP-ribosylation Reactions, New York, NY, June, (2001).
123. H. Wang, S-W. Yu, M.F. Poitras, J. Lew, C. Coombs, G.G. Poirier, T.M. Dawson and V.L. Dawson.
"Translocation of Apoptosis-inducing Factor is Involved in NMDA Exciototoxicity and is Poly (ADPRibose) Polymerase Dependent" Soc. Neurosci. Abst (2001)
124. Huiwu Li, Xiujing Gu, Valina L. Dawson, Ted M. Dawson. "Isolation and Characterization of Nitric
Oxide Dependent and Independent Activity Regulated Genes by Differential Analysis of cDNA Library
Expression (DAzLE)." Soc. Neurosci. Abst (2001)
125. X. Wei, M. Sasaki, H. Huang, V.L. Dawson,and T.M. Dawson. "Nueronal Nitric Oxide Synthase Gene
Expression is Dynamically Regulated by Nuclear Receptors in the Central Nervous System." Soc.
Neurosci. Abst (2001)
126. Hidehiko Nakagawa, Ted M. Dawson, Valina L. Dawson. "Preconditioning by Oxygen-Glucose
Deprivation or Membrane Depolarization Induces Differential Regulation of Creb and Erk." Soc. Neurosci.
Abst (2001)
127. Xin Guo, Yi Zhang, Kenny K.K. Chung, Anthony Lanahan, Paul Worley, Valina L. Dawson, and Ted M.
Dawson. "Cloning and Characterization of Paris, a Novel Parkin Interactive Protein." Soc. Neurosci.
Abst(2001)
128. S.-W. Yu, H. Wang, M.F. Poitras, G.G. Poirier, T.M. Dawson, and V.L. Dawson. "Translocation of
Apoptosis-Inducing Factor in MNNG-Treated Fibroblasts is Poly (ADP-Ribose) Polymerase-Dependent."
Soc. Neurosci. Abst (2001)
129. M. F. Poitras, J. Wortel, X. Zhong, A.S. Mandir, J. Norris, G.G. Poirier, V.L. Dawson and T.M. Dawson.
"Regional, Cellular, and Subcellular Distribution of Poly (ADP-Ribose) Glycohydrolase in Rat Brain." Soc.
Neurosci. Abst (2001)
130. Suk J. Hong, Huiwu Li, Jennifer L. Kiluk, Ted M. Dawson, and Valina L. Dawson. "DAzLE Reveals
Numerous NMDA-Induced Genes in Cultured Rat Cortical Neurons." Soc. Neurosci. Abst (2001)
131. A.S. Mandir, C. Simbulan-Rosenthal, M.E. Smulson, M.F. Poitras, V.L. Dawson, T.M. Dawson. "Tumor
Suppressor Protein p53 is a Downstream Target of MPTP-induced Parkinsonism." Soc. Neurosci. Abst
(2001)
132. Kenny K.K. Chung, Yi Zhang, Xin Guo, Yuji Tanaka, Hui Hang, Jun Gao, Christopher A. Ross, Valina L.
Dawson, and Ted M. Dawson. "Parkin Interacts With and Promotes the Ubiquitination of the α-SynucleinInteracting Protein Synphilin-1." Soc. Neurosci. Abst (2001)
133. Hakumäki, J.M., J.M. Savitt, P.C.M. van Zijl, J.D. Gearhart, T. Douglas, T. Dawson, J.A. Frank, V.L. Dawson,
J.W.M. Bulte. ”Magnetic Resonance Imaging of Magnetodendrimer-Labeled Neural Progenitor Cell
Transplants.” 11th Nordic Meeting on Cerebrovascular Diseases and 2nd Biennial Kuopio Symposium on
Ischaemic Stroke, Kuopio, Finland (2001)
29
Valina L. Dawson, Ph.D.
134. Dawson V.L. “Novel Pathways to Neuronal Cell Death or Survival.” 11th Nordic Meeting on
Cerebrovascular Diseases and 2nd Biennial Kuopio Symposium on Ischaemic Stroke, Kuopio, Finland
(2001).
135. Hakumaki, J.M., J.M. Savitt, J.D. Gearhart, T.M. Dawson, V.L. Dawson, J.W.M. Bulte, L. Ifeanyi, J.A.
Frank, P. van Zijl. ‘MRI Detection of Labeled Neural Progenitor Cells in a Mouse Model of Parkinson’s
Disease.” 4th Brain Research Interactive Symposium: Stem Cells in the Mammalian Brain, San Diego, CA
November 8-10, 2001.
136. Tanaka, Y., S. Engelender, S. Igarashi1, R. K. Rao1, T. Wanner, R. E. Tanzi, A. Sawa, V. L. Dawson, T.
M. Dawson and C. A. Ross. “Expression of mutant alpha-synuclein decreases proteasome activity,
increasing sensitivity to mitochondria-dependent apoptosis in inducible PC12 cell lines.” Udall PD Center
Meeting, Bethesda, MD 2001.
137. Chung, K.K.K., Y. Zhang, K.L. Lim, Y. Tanaka, H. Huang, J. Gao, C. A. Ross, V. L. Dawson, and T. M.
Dawson. "Parkin Interacts With and Promotes the Ubiquitination of the a-Synuclein-Interacting Protein
Synphilin-1." Udall Center Meetings, Bethesda, MD August 6-7, 2001.
138. Guo, X. V. L. Dawson, and T. M. Dawson. “Neuroimmunophilin Ligands Exert Neuroregeneration and
Neuroprotection in Midbrain Dopaminergic Neurons.” Immunophilins in the Brain 2: Bridging the GapBasic Research & Clinical Applications. San Diego, CA November 10, 2001.
139. Dawson V.L., “Unraveling the Molecular Mechanisms of Excitotoxic and Ischemic Neuronal Death
Cascades.” Keystone Symposia C1- Stroke-Molecular, Cellular, Pharmacological and Development of
New Therapeutics, Taos, New Mexico, March 2001.
140. Chung J.W., S.J. Hong, K.J. Kim, D. Goti, T. M. Dawson, V.L. Dawson, and K.S. Kim. “Identification of
Cytotoxic Necrotizing Factor 1 (CNF1) Receptor in Human Brain Microvascular Endothelial Cells
(HBMEC).” American Society for. Microbiology 102nd General Meeting, Salt Lake City, UT, 2002.
141. Chung, K.K., V.L. Dawson and T.M. Dawson. “Unraveling the role of parkin’s E3 ubiquitin ligase activity
in Parkinson’s disesase.” Processing Proteins Workshop, Institut des Neurosciences, Le Ptitie-Salpetiere
Hospital, Paris June, 2002.
142. Hoang TQ, Jackson-Lewis V, Mandir AS, Dawson VL, Dawson TM, Chesselet MF, Przedborski SE.
“Blockade of MPTP-induced DNA nick damage in the substantia nigra of mice lacking nNOS.” Soc.
Neurosci. Abst (2002).
143. O. Pol, M. Sasaki, N. Jimenez-Leon ,V.L. Dawson, T.M. Dawson, and M.M. Puig. “The Involvement of
Nitric Oxide in the Enhanced Expression of -Opioid Receptors During Intestinal Inflammation.” Soc.
Neurosci. Abst (2002).
144. Shimoji, M.., L. Zhang, A.S.Mandir, V.L.Dawson, and T.M. Dawson, “Investigation of Inclusion Body
Formation in the MPTP Mouse Model of Parkinson’s disease” Soc. Neurosci. Abst (2002).
145. Liang, D., D. Cheng, X. J. Li, T. M. Dawson, V. L. Dawson. “Expression Cloning of Neuroprotective
Genes.” Soc. Neurosci. Abst (2002).
146. Hong, S.J., T.M. Dawson, and V.L. Dawson, “DAzLE Reveals NMDA Receptor Regulated
Neuroprotective Genes.” Soc. Neurosci. Abst (2002).
147. Wang, H., S-W Yu, M. F. Poitras, J. Kiluk, J. Lew, W. Bowers, H. J. Federoff, G. G. Poirier, T. M. Dawson
and V. L. Dawson, “Apoptosis-Inducing Factor (AIF) Mediates Poly (ADP-Ribose) Polymerase-1
Dependent NMDA Excitotoxicity.” Soc. Neurosci. Abst (2002).
148. Lim, K.L., Y. Tanaka, Y. Zhang, M. Hada, C.A. Ross, V.L. Dawson and T.M. Dawson. “Parkin Mediates
Lysine-63 (K-63)-Linked Ubiquitination Of Synphilin-1: Implications For Lewy Body Formation.” Soc.
Neurosci. Abst (2002).
30
Valina L. Dawson, Ph.D.
149. Kofler, J., K. Hattori, L.J. Martin, V. L. Dawson, P.D. Hurn, and R.J. Traystman. “PARP-1 is
neuroprotective in a murine model of cardiac arrest and cardiopulmonary resuscitation.” Soc. Neurosci.
Abst. (2002).
150. Wei, X., M. Sasaki, H. Hui, Y. Qi, V.L. Dawson and T.M. Dawson. “Identification of COUP-TFI as a
transcriptional repressor of neuronal nitric oxide synthase.” Soc. Neurosci. Abst. (2002).
151. Hoang, T.Q., V.R. Jackson-Lewis, A.S. Mandir, V.L. Dawson, T.M. Dawson, M.F. Chesselet and S.E.
Przedborski. “Blockade of MPTP-induced DNA nick damage in the substantia nigra of mice lacking
nNOS.” Soc. Neurosci. Abst. (2002).
152. West, N.C., A.S. Mandir, X. XU, Y. Xu, B. Das, K. Hirsch, V.L. Dawson, T.M. Dawson and M.K. Lee.
“Effects of MPTP on dopaminergic neurons in a -synuclein transgenic mice.” Soc. Neurosci. Abst.
(2002).
153. Savitt, J.M., J.W.M Bulte, V.L. Dawson, J.D. Gearhart, M.J. Shamblott, J.M. Hakumaku, J. Axelman, and
T.M. Dawson. “Transplantation of differentiated human embryonic germ cells rescues apopmorphineinduced rotation in a mouse model of Parkinson’s disease.” 7th International Congress of Parkinson's
Disease and Movement Disorders, Movement Disorder Society, Miami Beach, FL (2002).
154. Zhang, L., S.J. Hong, M. Shimoji, A. Mandir, V.L. Dawson and T.M. Dawson, “Identification of UpRegulated Genes in the MPTP Model of Parkinson’s Disease. Movement Disorders Society Meeting,
Miami, FL, November, (2002).
155. Dawson, V.L., M. Shimoji, Ph.D., S.-W. Yu, H. Wang, T.M. Dawson, “Apoptosis Inducing Factor and
PARP Mediated Injury in the MPTP Mouse Model of PD.” Parkinson's Disease: The Life Cycle of the
Dopamine Neuron, New York Academy of Sciences Conference, New York, NY 2002.
156. Dawson, T.M., K.L. Lim, Wei, W., Y. Tanaka, Y. Zhang, K.K.K. Chung, C.A. Ross, and V.L. Dawson,
“The Cast of Molecular Characters in PD: Felons, Conspirators and Suspects.” Parkinson's Disease: The
Life Cycle of the Dopamine Neuron, New York Academy of Sciences Conference, New York, NY (2002).
157. Wei, W., K.L. Lim , Y. Tanaka, L. Monfredo, Y. Zhang, K.K.K. Chung, V.L. Dawson, T.M. Dawson, C.A.
Ross. “Cellular Toxicity of A53T a-Synuclein and Polyubiquitination of Synphillin-1: Implications in
Parkinson’s disease.” Parkinson's Disease: The Life Cycle of the Dopamine Neuron, New York Academy
of Sciences Conference, New York, NY (2002).
158. Traystman, R.J., J. Kofler, P.D. Hurn, V.L. Dawson, L.J. Martin, K. Hattori, M. Sawada. “Role of
Poly(ADP-Ribose) Polymerase in Limiting Brain Injury Following Cardiac Arraest and Cardiopulmonary
Resuscitation.” Society for Critical Care Medicine, (2002).
159. Dawson, V. L. “Apoptosis Inducing Factor and PARP Mediated Injury in the MPTP Mouse Model of PD”
Parkinson’s disease: The Life Cycle of the Dopamine Neuron, New York Academy of Sciences
Conference, Princeton, N.J. (2002).
160. Lew, J., S-W Yu, H. Wang, T.M Dawson and V.L. Dawson. “Binding Partners of AIF” Soc. Neurosci
Baltimore Chapter, Baltimore, MD (2002).
161. Wei, W., L. Monfredo, R.L. Margolis, V.L. Dawson, T.M. Dawson, T. Iwatsubo, and C.A. Ross. “Alphasynuclein phosphorylation is required for Lewy body-like inclusion formation in SH-SY5Ycells.” Society
for Neuroscience (2003).
162. Chung, K. K. K., B. Thomas, V.L. Dawson and T.M. Dawson. “Modification of Parkin’s E3 ligase activity
by nitric oxide.” Society for Neuroscience (2003).
163. Savitt, J.M., S. Jang, V.L. Dawson, and T.M. Dawson “Generation of Mice Expressing Cre Recombinase
in Catecholaminergic Cells: A New Method to Determine the Role of Bcl-x in Dopaminergic Cell
Survival.” Society for Neuroscience (2003).
31
Valina L. Dawson, Ph.D.
164. von Coelln, R., K.L. Lim, B. Thomas, J. Savitt, M.K. Lee, V.L. Dawson, T.M. Dawson. “Characterization
of Mice Overexpressing A53T-Alpha-Synuclein on a Parkin-Null Background.” Society for Neuroscience
(2003).
165. Dai, C., D. Liang J. Norris, T.M. Dawson, V.L. Dawson. “A Novel Preconditioning Induced
Neuroprotective Gene.” Society for Neuroscience (2003).
166. Wang, H., S. Yu, M.F. Poitras, J. Norris, G.G. Poirier, T.M. Dawson and V.L. Dawson. “Poly(ADP-ribose)
Polymer Serves as a Death Signal by Triggering Apoptosis-inducing Factor Release.” Society for
Neuroscience (2003).
167. Liang, D., C. Dai, J. Norris, T.M. Dawson, V.L. Dawson “ARL4 is a Neuroprotective Gene.” Society for
Neuroscience (2003).
168. Poitras, M.F., A.B. Ramalingham, D.W. Koh, G.G. Poirier, V.L. Dawson and T.M. Dawson “PARP-1
Dependent Toxicity Is Enhanced By Poly(ADP-Ribose) Glycohydrolase Inhibition.” Society for
Neuroscience (2003).
169. David, K.K., M. Sasaki, S-W. Yu, V.L. Dawson and T.M. Dawson. “Generation of Enodonuculase G
Knockout Mice.” Society for Neuroscience (2003).
170. Koh, D.W., A.B. Ramalingham, T. Otsuka, P.D. Hurn, V.L. Dawson and T.M. Dawson. “Poly(ADPRibose) Glycohydrolase Overexpression is Neuroprotective in Transgenic Mouse Models of Excitotoxic
and Focal Cerebral Ischemic Injury.” Society for Neuroscience (2003).
171. Shimoji, M., S-W.Yu,, H.Wang, T.M. Dawson and V.L.Dawson. “Effect of mitochondrial complex I
inhibitors on apoptosis inducing factor and cell death: in vivo and in vitor studies. Society for Neuroscience
(2003).
172. Yu, S.-W., H. Wang, G.G. Poirier, V.L Dawson and T.M. Dawson. “Poly(ADP-ribose) polymer is a death
signal for the release of apoptosis-inducing factor from the mitochondria.” Society for Neuroscience (2003).
173. Thomas, B., R. von Coelln, K. L. Lim, V.L. Dawson and T.M. Dawson. “Does loss of parkin cause
increased susceptibility to nigral dopaminergic neurons to the parkinsonian neurotoxin 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP)?” Society for Neuroscience (2003).
174. Moore, D.J., L. Zhang, V.L. Dawson and T.M. Dawson. “A familial point mutation (L166P) in DJ-1,
causing autosomal recessive Parkinson’s disease, leads to a decrease in proteins stability by protesomal
degradation and impaired complex formation. Society for Neuroscience (2003).
175. Wang, H. S.-W. Yu, M.F. Poitras, J. Norris, G.G. Poirier, T.M. Dawson and V.L. Dawson. “Poly(ADPribose) Polymer Serves as a Death Signal by Triggering Apoptosis-inducing Factor Release.” Society for
Neuroscience (2003).
176. Savitt, J.M. S Jang, W. Mu, V.L. Dawson, and T.M. Dawson. “Generation of Mice Expressing Cre
Recombinase in Catecholaminergic Cells: A New Method to Determine the Role of Bcl-x in Dopaminergic
Cell Survival.” Society for Neuroscience (2003).
177. O. Pol, M. Sasaki, N. Jimenez, V.L. Dawson, T.M. Dawson and M.M. Puig. “Expression Of Peripheral Opioid Receptor mRNA in iNOS Knockout Mice.” International Symposium on Nitric Oxide-Cyclic GMP
signal transduction, Valencia, Spain (2003).
178. Haince, J.F., V.L. Dawson, T.M. Dawson and G.G. Poirier. Characterization of functional interaction
between ATM protein kinase and poly(ADP-ribose) in DNA double-strand break repair.” DNA damage,
Banff, Canada (2004).
179. Dawson, T.M., A.M. Lawler, M.F. Poitras*, M. Sasaki, S. Wattler, M.C. Nehls, T. Stöger, G.G. Poirier,
V.L. Dawson. “Poly (ADP-Ribose) Metabolism/Signaling in Cell Death.” The Fujihara Seminar, July 2629, 2004 ‘New Challenges in Research on ADP-ribose Metabolism.”
32
Valina L. Dawson, Ph.D.
180. Wei, X. M. Sasaki, V.L. Dawson, T.M. Dawson. “Dynamic duo orchestrates the double-edged sword.”
United States and Canadian Academy of Pathology Annual Meeting, 2004
181. Dawson, TM., K.K.K. Chung, B. Thomas and V.L. Dawson. “S-Nitrosylation Controls the Ubiquitin
Proteasome Degradative Machinery in Parkinson's disease and Related Neurodegenerative Disorders.” 5th
Neurobiology of Aging Conference 2004 to be held at The Hilton San Diego Resort on the 21-22, October
2004.
182. von Coelln, R., B. Thomas, K.L. Lim, E.J. Hess, M.K. Lee, V.L. Dawson, T.M. Dawson. “AlphaSynuclein-induzierte Proteinaggregation und Neurodegeneration in vivo sind Parkin-unabhängig.” Annual
Meeting of the German Neurological Society, Duesseldorf, Germany (2004).
183. Moore, D.J., L. Zhang, J. Troncoso, T.M. Dawson, V.L. Dawson. “Association of DJ-1 and Parkin
Through Pathogenic DJ-1 Mutations and Oxidative Stress.” Society for Neuroscience (2004).
184. Morita, Y., M., Y. Tanaka, W. Wei, S. Engelender, S. Terada, K. Ohtani, H. Ujike, S. Kuroda, V.L.
Dawson, T.M. Dawson and C.A. Ross. “NF-kappaB inhibition attenuates toxicity of A53T alpha-synuclein
in an inducible cell model.” Society for Neuroscience San Diego CA (2004).
185. Li, X., M. Nemoto, S.-W. Yu, T.M Dawson, V.L. Dawson and R.C. Koehler. “Early reperfusion after focal
cerebral ischemia accelerates translocation of apoptosis inducing factor to the nucleus.” American Heart
Assocation, 2004
186. Ravichandran, S., X. Li, K.K.K. Chung, V.L. Dawson, T.M. Dawson. “Familial-associated mutations
differentially disrupt the ubiquitination activity and binding profile of parkin.” Society for Neuroscience San
Diego, CA (2004).
187. Hoang, T.Q., V.R. Jackson-Lewis, A.S. Mandir, V.L. Dawson, T.M. Dawson, S.E. Przedborski, M.-F.
Chesselet. “A role for nitric oxide in rapid alterations of dopamine transporters after MPTP administration
in vivo.” Society for Neuroscience, San Diego, CA (2004).
188. Wei-Smith, W., H. Jiang, Y. Tanaka, Y-C. Wu, H. Morita, M. Nakamura, A. Sawa, V.L. Dawson, T.M.
Dawson and C.A. Ross. “Parkinson’s Disease Cell Model: Inducible Expression of A53T alpha-synuclein
Causes Toxicity in PC12 Cells.” Society for Neuroscience San Diego CA (2004).
189. Dawson, TM., K.K.K. Chung, B. Thomas and V.L. Dawson. “S-Nitrosylation Controls the Ubiquitin
Proteasome Degradative Machinery in Parkinson's disease and Related Neurodegenerative Disorders.” 5th
Neurobiology of Aging Conference 2004, The Hilton San Diego Resort, San Diego CA (2004).
190. Zhang L, M. Shimoji, B. Thomas, D.J. Moorem S.W Yu, R. Torp, I.A. Torgner, O.P. Ottersen, T.M.
Dawson, V.L. Dawson. “Mitochondrial localization of the Parkinson’s disease related gene DJ-1:
implications for pathogenesis.” Society for Neuroscience San Diego CA (2004).
191. Hong, S.J., T.M. Dawson and V.L. Dawson. “A Novel Neuroprotective Gene, Iduna.” Society for
Neuroscience, Washington, D.C. (2005)
192. Andrabi, S.A. , S.W.Yu, H. Wang, N.S. Kim, D.W. Koh, G.G. Poirier, V.L. Dawson, T.M. Dawson. “Poly
(ADP-ribose) (PAR) polymer is a major death signal in PARP-1 neurotoxicity.” Society for Neuroscience,
Washington, D.C. (2005)
193. Kim, N.S., S.W. Yu1, S.A. Andrabi1, J.F. Haince, G.G. Poirier, T.M. Dawson and V.L. Dawson. “PARP-1
Dependent Cell Death in HeLa Cells Is Mediated by Apoptosis Inducing Factor AIF and Poly(ADP-Ribose)
Polymer” Society for Neuroscience, Washington, D.C. (2005)
194. Klaus, J.A , D. Koh, T.M. Dawson, V.L. Dawson, R.C. Koehler. “Protective role of poly(ADP-ribose)
glycohydrolase in transient focal cerebral ischemia.” Society for Neuroscience, Washington, D.C. (2005)
195. Ko, H.S., R. von Coelln, S. Ravichandran, S.W. Kim, K.K.K. Chung, O. Pletnikova, B. Johnson, R.
Saffary, B.J. Park, M.J. Kim, S. Kim, V.L. Dawson and T.M. Dawson. “Accumulation of the Authentic
Parkin Substrate, Aminoacyl-tRNA Synthetase Cofactor, p38/JTV-1, Leads to Catecholaminergic Cell
Death” Society for Neuroscience, Washington, D.C. (2005)
33
Valina L. Dawson, Ph.D.
196. Moore, D.J., A.B. West, V.L. Dawson, T.M. Dawson. “Parkin mediates the multiple mono-ubiquitination
of Hsp70.” Society for Neuroscience, Washington, D.C. (2005)
197. Marupudi, N.I., L. Zhang, M. Shimoji, B. Thomas, D. Moore, S.W. Yu, R. Torp, I. A. Torgner, O.P.
Ottersen, T.M. Dawson and V.L. Dawson. “Characterization of DJ-1, a protein linked to Parkinson’s
disease.” Society for Neuroscience, Washington, D.C. (2005)
198. Smith, W. W., Z. P. Pei, C. Torcassi, T.M. Dawson, V.L. Dawson, L. M. Ellerby and C.A. Ross.
“Expression and interactions off the LRRK2 Parkinson's disease gene product in cells.” Society for
Neuroscience, Washington, D.C. (2005)
199. Pei, Z., W. Smith, W. Duan, H. Jaing, Y. Liang, V.L. Dawson, T.M. Dawson and C.A. Ross. “Cellular
toxicity with expression of E46K -synuclein in an inducible PC12 cell model.” Society for Neuroscience,
Washington, D.C. (2005).
200. Kurkinen, K.M.A., Z. Chi, C. Dai, D. Liang, T.M. Dawson, V.L. Dawson. “Oxygen-glucose deprivation –
induced tolerance upregulated the novel neuroprotective protein, 697-27, in rat cortical cultures. Society for
Neuroscience, Washington, D.C. (2005).
201. Tsang, F. J. Wang. T.M. Dawson, V.L. Dawson and T.W. Soong. “Consequences of overloading iron via
an iron transporter, DMT1, in neuronal apoptosis and -synuclein toxicity: implications in Parkinson’s
disease. Society for Neuroscience, Washington, D.C. (2005).
202. Yu, S. S.A. Andrabi, N. Kim, G.G. Poirier, T.M. Dawson and V.L. Dawson. “Poly (ADP-Ribosyl)ation
and apoptosis – inducing factor as a novel, bidirectional cell death pathway between the nucleus and
mitochondrion. Society for Neuroscience, Washington, D.C. (2005).
203. David, K.O., M. Sasaki, S. Yu, T.M. Dawson and V.L. Dawson. “Endo G is dispensable in apoptosis.”
Society for Neuroscience, Washington, D.C. (2005).
204. Ravichandran, S., X. Li, H. Ko, K.K.K. Chung, E. Wong, K.L. Lim, V.L. Dawson, T.M. Dawson.
“Familial-associated mutations differentially disrupt parkin’s physical and biochemical properties.”
Society for Neuroscience, Washington, D.C. (2005)
205. Trinkaus, D.B., B. Johnson, B. Thomas, Y. Pei, T.M. Dawson and V.L. Dawson. “Does the knock out of
the parkin gene create a sensitivity to proteasome inhibitors in nigral dopaminergic neurons.” Society for
Neuroscience, Washington, D.C. (2005).
206. Thomas, B., N. West, S. A. Andrabi1, W. Stirling, Y Xu, V.L. Dawson, M.K. Lee, T.M. Dawson. “Alpha
Synuclein Knock-out Mice are not protected from 1-Methyl-4-(2’-Aminophenyl)-1, 2, 3, 6Tetrahydropyridine Neurotoxicity.” Society for Neuroscience, Washington, D.C. (2005)
207. West, A.B., D. Moore, S. Biskup, V.L. Dawson, T.M. Dawson. “Characterization of the Leucine-Rich
Repeat Kinase 2 gene.” Society for Neuroscience, Washington, D.C. (2005)
208. Zheng, S., S.J. Hong, R.M. Gronostajski, V.L. Dawson, T.M. Dawson. “Identification of NFI-A as a
Neuroprotective Gene.” Programmed Cell Death, Cold Spring Harbor Laboratory, NY (2005).
209. David, K.K., M. Sasaki, S-W Yu, T.M. Dawson and V.L. Dawson, “ENDOG in Embryogenesis and
Apoptosis.” Programmed Cell Death, Cold Spring Harbor Laboratory, NY (2005).
210. Ravichandran, S., X. Li, H. Ko, S. Ritter, K.K.K. Chung, E. Wong, K.L. Lim, V.L. Dawson, T.M. Dawson..
“Familial-Associated Mutations Differentially Disrupt the Ubiquitination Activity, Binding Profile and
Solubility of Parkin.” Ubiquitin Family 2005 CSHL Meeting.
211. Dawson, TM, AB West, DJ Moore, S Biskup, WW Smith, F Celsi, A Bugayenko, Z Pei, H Jiang, Y Liang,
S Higashi, SA Andrabi, K Kurkinen, SW Yu, JM Savitt, HJ Waldvogel, RLM Faull, PC Emson, R Torp,
OP Ottersen, CA Ross, and VL Dawson. “Parkinson s (PD) Disease Linked Leucine-Rich Repeat Kinase 2
gene (LRRK2): A Mixed Lineage Kinase with a Potential Role in Vesicular Trafficking and Membrane
Recycling.” American Neurological Association 131st Annual Meeting (2006).
34
Valina L. Dawson, Ph.D.
212. Chi, Z., J. Zhang, K.M.A. Kurkinen, D. Liang, N. Gaiano, T.M. Dawson and V.L. Dawson.
“Characterization of 547-6 as a Novel Neuroprotective Gene. Society for Neuroscience, Atlanta, GA (2006)
213. Lee, Y.-I., T.M. Dawson and V.L. Dawson. “The Role of S-nitrosylated Ras in NMDA-Induced Neuronal
Survival. Society for Neuroscience, Atlanta, GA (2006).
214. Tan, J.M.M., E.S.P. Wong, O. Pletnikova, D. Kirkpatric, S.-P. Tay, J. Troncoso, S. Gygi, H. Ko, M.K. Lee,
V.L. Dawson, T.M. Dawson, K.-L. Lim. “Proteasomal-Independent Ubiquitination - A mechanism for the
Formation and Clearance of Protein Inclusions associated with Neurodegenerative Diseases.” Society for
Neuroscience, Atlanta, GA (2006).
215. Smith, W.W., Z. Pei, H. Jiang, Y. Liang, S. Engelender, V.L. Dawson, T.M. Dawson and C.A. Ross.
“LRRK2 Interacts with Synphilin-1.” Society for Neuroscience, Atlanta, GA (2006).
216. Smith, W.W., Z. Pei, H. Jiang, Y. Liang, V.L. Dawson, T.M. Dawson and C.A. Ross. “LRRK2 kinase
activity mediates neuronal toxicity.” Society for Neuroscience, Atlanta, GA (2006).
217. Ko, H.S., S.R. Sriram, S.W. Kim, J.M.M. Tan, V.L. Dawson and T.M. Dawson. “A Transcriptional
Regulator, PARIS, is a Novel Parkin Substrate.” Society for Neuroscience, Atlanta, GA (2006).
218. Xu, Z., K.K. David, M. Sasaki, X. Li, T.M. Dawson, V.L. Dawson, R.C. Koehler. “Effect of Transient
Focal Cerebral Ischemia in Endonuclease G Null Mice.” Society for Neuroscience, Atlanta, GA (2006).
219. Li, X. Xu, Z., Klaus, J.A., Yu, S.-W. Yu, T.M. Dawson, V.L. Dawson, R.C. Koehler. “Contribution of
neuronal nitric oxide synthase to nuclear translocation of apoptosis-inducing factor after transient focal
cerebral ischemia. Society for Neuroscience, Atlanta, GA (2006).
220. Yu, S.-W., D.S. Frydenlund, O.P. Ottersen, T.M. Dawson, V.L. Dawson. “Outer Mitochondrial Membran
Localization of Apoptosis-Inducing Factor: Mechanistic Implication for Release.” Society for
Neuroscience, Atlanta, GA (2006).
221. West, A.B., X. Li, C. Choi, D.J. Moore, S. Biskup, D. Dikeman, S. Andrabi, Z.S. Zhang, K.L. Lim, V.L.
Dawson, T.M. Dawson. “Functional characterization of LRRK2 Kinase Activity.” Society for
Neuroscience, Atlanta, GA (2006).
222. Moore, D.J., D. Dikeman, A.B. West, X. Li, C. Choi, S. Biskup, V.L. Dawson, T.M. Dawson.
“Examination of LRRK2 GTPase activity: Relationship to Kinase Function.” Society for Neuroscience,
Atlanta, GA (2006).
223. Biskup, S., D.J. Moore, F. Celsi, S. Higashi, A.B. West, S. Andrabi, K. Kurkinen, S.W. Yu, J.M Savitt, H.J.
Waldvogel, R.L.M. Faull, P.C. Emson, R. Torp, O.P. Otterson, M.J. Smith, V.L. Dawson, T.M. Dawson.
“Localization of Leucine-Rich Repear Kinase 2 Indicatin a Role in Vesicular Trafficking and Mebrane
Recycling.” Society for Neuroscience, Atlanta, GA (2006).
224. Andres-Mateos, E. C. Perier, L. Zhang, B. Thomas, H. Ko, D. Trinkhaus, H. Ischiropolous, S. Przedborski,
T. M. Dawson, V.L. Dawson. “ DJ-1 Knockouts reveal that DJ-1 is an Atypical Peroxidoxin-like
Peroxidase.” Society for Neuroscience, Atlanta, GA (2006).
225. Zhang, J. Z. Chi, V.L. Dawson, T.M. Dawson. Identification of Signaling Pathways Related to DNA
Damage Induced Cell Death. Society for Neuroscience, Atlanta, GA (2006).
226. Haince JF, Rouleau M, Hendzel MJ, Dawson VL, Dawson TM, Poirier GG. “Targeting poly(ADPribosyl)ation: a promising approach in cancer therapy.” AACR conference on Cancer Susceptibility and
Cancer Susceptibility, Syndromes. Maui, HI (2006)
227. Andrabi SA, Yu SW, Poirier GG, Dawson TM, Dawson VL “Role of poly(ADP-ribose) polymer in
neuronal cell death.” East coast PARP 2006, Quebec Qc, (2006)
228. Haince JF, Kozlov S, Ouellet ME, Dawson VL, Dawson TM, Lavin MF, Poirier GG “Poly(ADPribosyl)ation is a potential modulator of DNA damage signaling.” East coast PARP 2006, Quebec Qc,
Canada (2006).
35
Valina L. Dawson, Ph.D.
229. Dawson, V.L., Zhikai Chi, Suk Jin Hong, Ho Chul Kang, Jianmin Zhang, Sika Zheng, and Ted M. Dawson.
“Identification of New and Novel Survival Molecules Through Preconditioning.” The 26th Princeton
Conference on Cerebrovascular Disease, Houston, Texas, 2008.
230. Chi, Z., J. Zhang, A. Tokunaga, N. Gaiano, T.M. Dawson, and V.L. Dawson, “The novel protein Botch
promotes neurogenesis through regulation of the Notch pathway.” The 1st Annual Maryland Stem Cell
Research Symposium, Baltimore MD (2008).
231. Lee, Y., H.S. Ko, J-H Shin, V.L. Dawson and T.M. Dawson. “The Parkin substrate, AIMP2, mediates cell
death by activation of poly (ADP-ribose) polymerase-1 (PARP-1).” Keystone Symposia Neurodegenerative
Diseases: New Molecular Mechanisms, Keystone, CO (2008).
232. Wang, Y. N. Kim, S. Andrabi, P.A. Greer, V. Dawson, T. Dawson. “Is calpain I critical for PARP-1mediated AIF nuclear translocation and cell death? Society for Neuroscience, Washington, D.C. (2008).
233. Smith, W. W., Z. Liu, Y. Liang, N. Masuda, M. Nakamura, X. Wang, N.A. Jenkins, N. G. Copeland, J.C.
Troncoso2, M. Pletnikov, L.J. Martin, T. Moran, V.L. Dawson, T. M. Dawson, M.K. Lee, D.R. Borchelt,
C.A. Ross. “Synphilin-1 attenuates neuronal degenerative phenotype in a transgenic A53T alpha-synuclein
mouse model.” Society for Neuroscience, Washington, D.C. (2008).
234. Andrabi, S.A., H. Kang, A.B. West, S.J. Hong, Y.-I. Lee, J.-F. Haince, G. G. Poirier, T.M. Dawson, V.L.
Dawson. “Iduna is a novel poly(ADP-ribose) polymer binding neuroprotective protein.” Society for
Neuroscience, Washington, D.C. (2008).
235. Mejias-Estevez, R.M., E. Andres-Mateos, B. Thomas, L. Yang, B.M. Lin, S. Biskup, M.F. Beal, V.L.
Dawson, T.M. Dawson. “Sensitivity of LRRK2 knock-out mice to environmental toxins.” Society for
Neuroscience, Washington, D.C. (2008).
236. Li, X., V.L. Dawson, T.M. Dawson, D.J. Moore. “Development and characterization of phosphorylationspecific antibodies for LRRK2.” Society for Neuroscience, Washington, D.C. (2008).
237. Lin, B.M., M.W. Johnson, D.A. Dikeman, X. Li, N.A. Jenkins, N.G. Copeland, J.C. Troncoso, M.K. Lee,
T.M. Dawson, V.L. Dawson, D.J. Moore. “Evaluation of LRRK2 transgenic mice as a novel model of
Parkinson’s disease.” Society for Neuroscience, Washington, D.C. (2008).
238. Xiong, Y., V.L. Dawson, T.M. Dawson, D. J. Moore. “A yeast model of LRRK2-induced toxicity.” Society
for Neuroscience, Washington, D.C. (2008).
36
Valina L. Dawson, Ph.D.
EDUCATIONAL ACTIVITIES

1.
2.
Invited Lectures
"Nitric Oxide: A Novel Neuronal Messenger Molecule and Neurotoxin." Research Seminar, Department
of Psychiatry, Yale University, New Haven CT (1992).
"Nitric Oxide: A Novel Neuronal Messenger Molecule." Research Seminar, Department of Physiology,
University of Texas Southwestern at Dallas, TX (1992).
3.
"Nitric Oxide Neurotoxicity." Research Seminar, Department of Pharmacology, University of Rochester,
Rochester, NY (1992).
4.
"Nitric Oxide: Neuronal Messenger or Neurotoxin?" Research Seminar, Department of Pharmacology,
University of Colorado, Denver CO (1993).
5.
"Nitric Oxide: Neurotoxin or Neuronal Messenger." 18th International Joint Conference on Stroke and
Cerebral Circulation, Miami, FL (1993).
6.
"Nitric Oxide Neuronal Messenger and Neurotoxin." Cornell University Department of Pharmacology
Visiting Scientist Seminar Series, Ithaca NY (1993).
7.
"Nitric Oxide Synthase Activity Mediates Neurotoxicity" American Society for Neurochemistry
Symposium on Nitric Oxide: Chemistry and Functions, Richmond, VA (1993).
"Nitric Oxide and Neurotoxicity" Upjohn Discovery Seminar Series, Kalamazoo, MI (1993).
8.
9.
"Principles and Mechanisms of Neurodegeneration and Neurotoxicity in Primary Cell Cultures." World
Congress, Baltimore, MD (1993).
10.
"Nitric Oxide Mediates Componants of gp120 Neurotoxicity in Primary Cortical Cultures." Technical
Advances in AIDS Research in the Human Nervous System, Bethesda, MD (1993).
11.
"Nitric Oxide Neurotoxicity In Primary Neuronal Cultures." The Nineteenth Princeton Conference,
Boston, MA (1994).
"Mechanisms Of Nitric Oxide Neurotoxicity In Primary Neuronal Cell Cultures". FASEB Conference on
Endothelial Cell Function, Colorado (1994).
12.
13.
"Mechanisms of gp120 Neurotoxicity." FASEB Conference on Interactions between the Central Nervous
System and the Immune System. Colorado (1994).
14.
"Molecular Mechanisms of Glutamate Neurotoxicity in Primary Cortical Cultures." American Association
of Aging, Oxidative Stress and Aging, Washington D.C. (1994).
15.
"Principles and Mechanisms of Neurodegeneration and Neurotoxicity in Primary Neuronal Cell Cultures."
International Union of Pharmacology Satellite Symposium on In Vitro Neurotoxicity, Val Morin, Quebec,
Canada (1994).
16.
"Molecular Mechanisms of Nitric Oxide Mediated Toxicity in the Central Nervous System." Biochemistry
and Molecular Biology of Nitric Oxide, Los Angeles California (1994).
17.
"NO and Neurodegeneration in Cortical Cultures." Nitric Oxide: Neuropharmacology, St. Sauveur,
Quebec, Canada (1994).
18.
"The Role of NO in Neurodegenerative Disorders." NIH Workshop: The Role of Antioxidants and Free
Radicals in Neurobiology, Miami FL, (1994).
19.
"Nitric Oxide: A Radical Concept in Neuronal Injury" Research Seminar, Department of Physiology,
Johns Hopkins University School of Medicine, Baltimore MD (1994).
20.
“Free Radical Mechanisms of Neurodegeneration.” Neurobiology of Disease, Cold Spring Harbor, New
York (1994).
37
Valina L. Dawson, Ph.D.
21.
"Role of Nitric Oxide in Physiological and Pathophysiological Function." American Physiological
Society-Experimental Biology, Atlanta GA (1995).
22.
"Mechanisms of Nitric Oxide Toxicity" Neurodegenerative Diseases '95: Cellular and Molecular
Mechanisms and Therapeutic Advances, George Washington University Washington DC (1995).
23.
"NO and Neurodegenerative Disorders." The Role of Nitric Oxide in the CNS IV IBRO World Congress
of Neuroscience, Kyoto Japan (1995).
“Nitric Oxide: Physiologic and Pathophysiologic Actions.” University of Iowa, Department of
Pharmacology, (1995).
24.
25.
“Nitric Oxide: Actions and Pathologic Roles in the Nervous System.” Free Radicals in Brain Physiology
and Disorders: An International Conference - Tokyo Symposium, Tokyo Japan (1995).
26.
“Nitric Oxide: Physiologic and Pathophysiologic Actions.” Clinical Neuroscience Research Seminar
Series, Department of Neurology, Johns Hopkins University School of Medicine (1995).
27.
“Free Radical Mechanisms of Neurodegeneration.” Neurobiology of Disease, Cold Spring Harbor, New
York (1995).
28.
“Nitric Oxide Neurotoxicity.” 20th Princeton Conference, Memphis, TN (1996).
29.
“Immunologic Nitric Oxide Synthase And Mechanisms Of Neurodegeneration.” American Society for
Neurochemistry, Philadelphia, PA (1996).
30.
“Nitric oxide in the CNS: From Pathology to Behavior,” Frontiers in Pharmacology Graduate Course,
George Washington University School of Medicine, Department of Pharmacology, Washington, DC
(1996).
“Molecular Mechanisms of Neuronal Cell Death.” INSERM Conferences Philippe Laudat, France (1996).
31.
32.
33.
“Nitric oxide: Neurotoxicity to Behavior.” Department of Anesthesiology Stroke Rounds, Johns Hopkins
University School of Medicine, Baltimore, MD (1996).
“Nitric oxide: Physiology, Pathology and Behavior.” Department of Psychiatry Rounds, Johns Hopkins
University School of Medicine, Baltimore, MD (1996).
34.
“Nitric Oxide in the CNS: Neurotoxicity and Behavior,” IDeA Symposium, University of Kansas Medical
School, Kansas City, Kansas (1996).
35.
“Free Radical Mechanisms of Neurodegeneration.” Neurobiology of Disease, Cold Spring Harbor, New
York (1996).
36.
“NO Neurotoxicity in Stroke, Parkinson’s Disease and HIV Dementia.” Integrated Toxicology Program
Fall Symposium, Duke University (1996).
37.
“Sharing a Lab, Sharing a Problem.” Women in Neuroscience Seminar, Society for Neuroscience Annual
Meeting, Washington, D.C. (1997).
38.
“Reactive Oxygen Species in Neuronal Death: Therapeutic Targets for Neurodegenerative Disease.”
Pharmacology and Molecular Sciences Seminar, Johns Hopkins University School of Medicine (1997).
39.
“Nitric Oxide and Reactive Oxygen Species in the Life and Death of Neurons.” Grand Rounds,
Department of Neurology, Johns Hopkins University School of Medicine (1997).
“Mechanisms of resistance to oxidative injury in models of focal ischemia.” 8th International Symposium
on Stroke, Neurotrauma and Other Neurological Diseases, New Orleans, LA (1997).
40.
41.
“The Role of Nitric Oxide in Neurodegeneration.” Nitric Oxide and Other Diffusible Signals in Brain
Development, Plasticity and Disease. New Orleans, LA (1997).
42.
“Diverse Actions of NO in the Nervous System.” APSET, Medical College of Georgia, Augusta GA
(1997).
43.
“A Molecular Model of Resistance to Cerebral Ischemia.” the 15th Ernst Klenk Conference on “Molecular
Biology of Hypertension”, Cologne, Germany (1997).
38
Valina L. Dawson, Ph.D.
44.
“HIV envelope protein, gp41, Immunologic Nitric Oxide Synthase and HIV Dementia.” International
Busness Communications: HIV Co-Receptors, Washington, DC (1997).
45.
“Nitric Oxide: Physiology and Neuropathology.” Department of Neurology, Stanford University School
of Medicine, CA (1997).
46.
“NO in the Nervous System: Neuronal Survival to Neuronal Death,” Department of Neuroscience Visiting
Lecture, Georgetown University, DC (1998)
“Molecular Models of Resistance to Cerebral Ischemia.” 21st Princeton Conference, St. Louis, MO
(1998).
47.
48.
“Diverse Actions of NO in the Nervous System: Neuronal Survival to Neuronal Death.” Third
International Meeting of NO: Biochemistry and Biology, Los Angeles, CA (1998).
49.
“HIV envelope protein, gp41, Immunologic Nitric Oxide Synthase and HIV Dementia.” Neuroscience of
HIV: Basic Research and Clinical Frontiers, Northwestern University, Chicago, IL (1998).
50.
“Role of Immunologic Nitric Oxide Synthase in HIV Dementia.” Nitric Oxide Symposium, Anatayla,
Turkey (1998).
51.
“PARP Inhibition as a Therapeutic Approach to Focal Ischemic Insult.” 7th International Symposium on
Pharmacology of Cerebral Ischemia, Marburg, Germany (1998).
52.
“Role of PARP in Neuronal Injury.” 16th Annual Neurotrauma Society Meeting, Los Angeles, CA (1998).
53.
“Novel Therapeutic Targets for NO Toxicity.” AGY Therapeutics, San Francisco, CA (1998).
54.
55.
“NO in the Life and Death of Neurons.” Department of Physiology, University of Minnesota (1998).
“PARP in Neuronal Cell Death.” CNS as HIV Reservoir: BBB and Drug Delivery, NINDS AIDS
Program Panel 2, Miami, FL (1999).
56.
“Glutamate Toxicity of Central Neurons: Mechanisms in Acute and Chronic Neuronal Cell Death.”
Central and Peripheral Glutamate Receptors: Role in Cell Toxicity and Tissue Injury. Experimental
Biology ‘99, American Society for Pharmacology and Experimental Therapeutics, Washington, DC
(1999).
57.
"Mechanisms of Sensitivity and Resistance to Neuronal Excitotoxicity." International Society for
Neurochemistry, Berlin, Germany, (1999)
58.
59.
"PARP in Neuronal Cell Death" Symposium on Neuronal Apoptosis, Tubingen, Germany (1999).
"p21Ras/extracellular regulated kinase signaling activates ischemic tolerance." 8th International
Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany (2000).
60.
"New advances in Experimental Stroke." Grand Rounds, Johns Hopkins University School of Medicine,
Department of Neurology (2000).
61.
"What doesn't kill you makes you stronger: pathways to ischemic tolerance." 22nd Princeton Conference,
Redwood City, CA (2000).
62.
“Neuronal Tolerance – Immunity Against Brain Degenertation?” Beyond the Scientific Frontier,
Whitehead Press Seminar 2000, Whitehead Institute for Biomedical Research, Cambridge, MA (2000).
63.
“Ischemic Preconditioning: A Model of Neural Plasticity.” National Institutes of Health,
NINDSNeuroscience Lecture Series, Bethesda, MD (2001).
64.
“Neuroimmunophilins, Mitochondria and Beyond in Neurologic Disease.” Symposia on Emerging
Therapies, American Heart Association Stroke Meeting, Fort Lauderdale, FL (2001).
“Novel Pathways to Neuronal Cell Death or Survival.” 11th Nordic Meeting on Cerebrovascular Diseases
and 2nd Biennial Kuopio Symposium on Ischaemic Stroke, Kuopio, Finland (2001).
“PARP in Experimental Models of Neurologic Disease.” 13th International Symposia on ADPRibosylation, New York, NY (2001).
65.
66.
67.
“Potential for commercial development: views of the future” Science meets business. Special session. 13th
International Symposia on ADP-Ribosylation, New York, NY (2001).
39
Valina L. Dawson, Ph.D.
68.
"Unraveling the Molecular Mechanisms of Excitotoxic Injury." Charite Seminar Series, Berlin, Germany
(2001).
69.
"Unraveling the Molecular Mechanisms of Excitotoxic Injury." Society for Neurotrauma, San Diego, CA
(2001).
70.
"Unraveling the Molecular Mechanisms of Neuronal Cell Death and Survival" Grand Rounds, Yale
University School of Medicine, Department of Neurology, New Haven, CT (2002).
“Unraveling the Molecular Mechanisms of Excitotoxic and Ischemic Neuronal Death Cascades.”
Keystone Symposia C1- Stroke-Molecular, Cellular, Pharmacological and Development of New
Therapeutics, Taos, New Mexico, March 2002.
71.
72.
"Unraveling the Mechanisms of Ischemic and Excitotoxic Neuronal Cell Death" Grand Rounds, Johns
HopkinsUniversity School of Medicine, Department of Neurology, Baltimore, MD (2002).
73.
“Biologic Mechanisms of Stroke.” Stroke in Childhood Topic Symposium, Pediatric Academic Societies
Annual Meeting, Baltimore, MD (2002).
74.
“Unraveling the Cross-Talk Between the Nucleus and the Mitochondria.” 9th International Symposium on
Pharmacology of Cerebral Ischemia, Marburg, Germany (2002).
75.
"Unraveling the Molecular Mechanisms of Neuronal Cell Death and Survival" 16th Annual Center for
Neuroscience at the University of Pittsburgh (CNUP), Oglebay Resort and Conference Center Wheeling,
West Virginia (September 13-15, 2002).
76.
“Apoptosis Inducing Factor and PARP Mediated Injury in the MPTP Mouse Model of PD” Parkinson’s
disease: The Life Cycle of the Dopamine Neuron, New York Academy of Sciences Conference, Princeton,
N.J. (2002).
77.
“Unraveling the Mechanisms of Ischemic and Excitotoxic Neuronal Cell Death.” Child Neurology
Society, Stroke Symposium Washington, D.C. (2002).
78.
“Mitochondrial-Nuclear Cross-Talk in Excitotoxic Injury.” The Fifth U.S.-Taiwan Neuroscience
Symposium on Neuroprotection - Neuroprotection after Oxidative Stress: from Molecular Repair to
Functional Genomics. Orlando, FL (November, 2002).
“Mitochondrial-Nuclear Signal Integration in Neuronal Cell Death.” The Third Annual Neurobiology of
Aging Symposium. Orlando, FL (November, 2002).
"Nuclear-Mitochondrial Cross-Talk in Experimental Stroke and Parkinson's disease." Gordon Research
Conference on Oxidative Stress. CA (2003).
79.
80.
81.
“Mitochondrial-Nuclear Signal Integration in Neuronal Cell Death.” Translational Research Conference,
Oncology Center, Johns Hopkins Medical Institution, Baltimore, MD (2002).
82.
“Mitochondrial-Nuclear Signal Integration in Neuronal Cell Death.” Department of Comparative Medicine
Conference, Johns Hopkins Medical Institution, Baltimore, MD (2002).
83.
“Parkinson’s disease and Stroke” Strategies to Investigate the Pathophysiology of Ganglion Cell and Optic
Nerve Degeneration, National Eye Institute, NIH, Airlie, VA (2002).
84.
“Mortally Wounded but Still Talking.” Winter Conference on Brain Research, Salt Lake City, UT (2003).
85.
“PARP mediated cross-talk between the nucleus and mitochondria in models of neuronal injury.” Keynote
Lecture. Advances in Cardiovascular Medicine: PARP as Therapeutic Target, Academy of Sciences of
Lisboa and The William Harvey Research Institute, Lisbon Portugal (2003) *Keynote Lecture.
“PARP in Experimental Models of Neurologic Disease.” in Novel Enzyme Targets for the Treatment of
Neurological Disease, Biotechnology Industry Organization, BIO 2003, Washington, D.C.
“Poly-ADP-ribosylation and apoptotic cell death.” Federation of the European Biochemical Societies
Advanced Course on Poly-ADP-ribosylation, Debrecen Hungary (2003).
86.
87.
88.
“Pathophysiology of poly- ADP-ribosylation in the CNS.” Federation of the European Biochemical
Societies Advanced Course on Poly-ADP-ribosylation, Debrecen Hungary (2003).
40
Valina L. Dawson, Ph.D.
89.
“Signals for Death or Survival in Stroke and Parkinson’s Disease.” Grand Rounds, Department of
Neurology, Weill Medical College of Cornell University, New York, NY (2003).
90.
“Mechanisms of PARP-1 Dependent AIF Mediated Cell Death.” Apoptosis in Biochemistry and Structural
Biology, Keystone Symposia Meeting, Keystone, CO (2004).
91.
“PAR is a Novel Nuclear Death Signal.” Gordon Research Conference on Cell Death, Big Sky, Montana
(USA) (2004).
"Deadly conversations in mitochondrial-nuclear pillow-talk" Mitochondria and Neuroprotection Meeting,
Fort Lauderdale, FL (USA) (2004).
92.
93.
“Emerging Concepts in Life and Death Decisions in the Nervous System.” 4th International Congress on
Genetics and Regeneration in Neuroscience Terni, Italy (2004) *Keynote Lecture
94.
“Life and Death in the Nervous System.” MARC-USTAR Program, University of Maryland, Baltimore,
MD (2004).
95.
“Nuclear-mitochondrial conversations in PARP-1 dependent neurotoxicity.” 10th International
Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany (2004).
96.
“Ischemic Preconditioning.” American Society for Neurochemistry, New York, NY, (2004).
97.
“Unraveling the mechanisms of neuronal preconditioning: Identification and characterization of novel
neuroprotective proteins.” Society for Neuroscience Symposium "Ischemic Tolerance - Endogenous
Mechanisms of Cerebral Protection", Society for Neuroscience, San Diego, CA (2004).
“Unraveling Survival Strategies” Mechanisms of Brain Resiliency & Repair, National Institute on Drug
Abuse Mini-Convention: Frontiers in Addiction Research, San Diego, CA (2004).
“Poly(ADP-Ribosyl)ation for Survival and Death in Neurons.” Medicinal Chemistry Seminar Series,
College of Pharmacy, Department of Pharmacology and Toxicology, University of Arizona Health
Sciences Center, Tucson, AZ (2004).
98.
99.
100.
“New Signals in the Life and Death of Neurons.” Neuroscience Seminar Series, Stanford University, Palo
Alto, CA (2004).
101.
“Molecular mechanisms in neuronal/axonal apoptosis and necrosis.” Neurodegeneration And
Neuroprotection in Multiple Sclerosis II, New York City, NY (2004).
“Inspiration to Innovation: Lessons the Survival and Death of Neurons.” Voyage & Discovery Seminar
Series, Johns Hopkins, Homewood Baltimore, MD (2005).
“Harnessing the Protective Power of the Brain.” Frontiers in Clinical Science Plenary Session, American
Academy of Neurology, 57th Annual Meeting, Miami, FL (2005).
102.
103.
104.
“Poly(ADP-Ribosyl)ation in the Survival and Death of Neurons.” Molecular and Cellular Bioenergetics
Gordon Conference, Kimball Union Academy, Meriden, NH. (2005).
105.
“Poly(ADP-Ribosyl)ation in the Survival and Death of Neurons.” 14th International Meeting on ADP
Ribosylation Reactions, "PARP2005: Bench to Bedside" Newcastle upon Tyne - Gateshead England
(2005).
106.
“Inspiration to Innovation: Lessons from Preconditioning for Neuronal Survival.” Gordon Conference on
"Neurotrophic Factors" at Salve Regina College, Newport, Rhode Island (2005).
107.
“Putting the on Breaks on Cell Death and Accelerating Survival.” Harvard/McLean Udall Neuroscience
Seminar Series, Boston, MA (2005).
108.
“Poly(ADP-Ribosyl)ation in the Survival and Death of Neurons.” Abbott Laboratories, Chicago, IL
(2005).
109.
“Turning on Genes to Protect the Brain.” European Science Foundation, Functional Genomics and
Disease, Symposium 8: Neurogenomics and Disease, Oslo, Norway (2005).
110.
“Poly(ADP-Ribosyl)ation in the Life and Death of Neurons” University of Bergen, Bergen, Norway
(2005).
41
Valina L. Dawson, Ph.D.
111.
“Life and Death Decisions in the Nervous System.” Department of Physiology, Johns Hopkins University
School of Medicine, Baltimore, MD (2005).
112.
“Poly(ADP-ribose) is a novel cell death signal.” 2006 Keystone Symposium on Metabolomics: From
Bioenergetics to Apoptosis, Snowbird, Utah (2006)
113.
“Discovering the Dance of Death in Parkinson’s Disease.” Neuroscience Symposium, Georgetown
University, Washington D.C. (2006).
“Life and Death Signaling by PAR in the Brain” Van Andel Research Institute Han-Mo Koo Memorial
Seminar Series, Grand Rapids, MI (2006).
114.
115.
"Life and Death Decisions in the Brain" Neurosciences Critical Care Division Acute Neurosciences
Research Seminar, Johns Hopkins University School of Medicine, Baltimore, MD (2006).
116.
“New Life and Death Signals in the Brain.” Neuroscience Seminar Series, University of Louisville,
Louisville, KY (2006).
117.
"Genetic Clues to Unravel the Mystery of Parkinson's Disease." University of Oslo, Norway (2006).
118.
119.
“PAR: A Novel Death Signal in the Brain.” University of Oslo, Norway (2006).
“Unraveling the Pathobiology of DJ-1.” World Parkinson Congress, Washington, D.C. (2006).
120.
“Parkin is a dual function E3 ligase - implications for Parkinson's disease.” NIH/JHU Protein Trafficking
workshop, Annapolis, MD (2006).
“Life and Death Choices in the Brain.” Neuroscience Seminar Serier, Loma Linda University, Loma
Linda, CA (2006).
“Genetic Clues to the Mystery of Parkinson Disease.” National Parkinson Foundation 4th Annual YoungOnset Parkinson Network Conference, Reston, Virginia (2006).
121.
122.
123.
“Turning on genes to protect the brain” International Symposium On Neurodegeneration and
Neuroprotection, Muenster, Germany (2006).
124.
“The peroxynitrite/PARP pathway in stroke and neuroinjury.” Keynote lecture, Nitric Oxide And
Nitrosative Stress In The Cardiovascular System, Semmelweis Symposium, Budapest, Hungary (2006).
125.
"Genetic Clues to the Mystery of Parkinson's Disease." Grand Rounds Department of Neurology,
University of Pennsylvania, Philadelphia, PA (2006).
126.
“Parthanatos, a Novel Key Regulator of Neuronal Cell Death.” Grand Rounds Department of Neurology,
Albert Einstein College of Medicine in New York, NY (2007).
127.
“Rare insights into Neurodegeneration in Parkinson’s disease.” Clinical Neuroscience Seminar Series,
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore MD (2007).
128.
“Turning on genes to protect the brain” 2007 McKnight Conference on Neuroscience, Aspen CO (2007).
129.
“Proteins behaving badly: clues to Parkinson’s disease.” Protein Folding Diseases Symposia, University of
Massachusetts at Amherst, Amherst, MA (2007).
130.
“Parthanatos is a Key Regulator of Cell Death: PARP-1 and AIF Signaling.” 2007 Keystone Symposium
on Apoptotic and Non-Apoptotic Cell Death Pathways, Monterey, CA (2007).
“Genes and Parkinson’s disease.” Neuroscience Graduate Program, Oregon Health & Science University,
Portland OR (2007).
131.
132.
“LRRK2 in Parkinson’s disease.” The Movement Disorder Society’s 11th International Congress of
Parkinson’s disease and Movement Disorders, Istanbul, Turkey (2007).
133.
“Mitochondria and Nuclear Cross Talk in Cell Death: Parthanatos” Mitochondria and Oxidative Stress in
Neurodegenerative Disorders, The New York Academy of Sciences, New York, NY (2007).
134.
“Turning on genes to protect the brain” ACCM Research Talks, Dept. Anesth./Critical Care Med., Johns
Hopkins University, School of Medicine (2007).
135.
“Parthanatos is a Key Regulator of Cell Death: PARP-1 and AIF Signaling.” Dept. of Environmental
Health Sciences Johns Hopkins University School of Public Health (2007).
42
Valina L. Dawson, Ph.D.
136.
“Parthanatos is a Key Regulator of Cell Death: PARP-1 and AIF Signaling.” Clinical Neuroscience
Seminar Series, Department of Neurology, Johns Hopkins University School of Medicine (2008)
137.
“Mining for survival genes” Stroke – From Molecules to Rehabilitation, Keynote Lecture. NevroNor,
Oslo, Norway (2008)
138.
“New Neuroprotective Signaling Molecules” 5th International Conference on Cerebral Ischemia and
Stroke "Neuroprotection and Neurorepair" Magdeburg, Germany (2008).
“Parthanatos is a Key Regulator of Cell Death: PARP and AIF Signaling.” Spring Neuroscience Day
Bluegrass chapter of the Society for Neuroscience, Lexington KY (2008).
139.
140.
“Genetic Clues to the Mystery of Parkinson Disease.” Nu Rho Psi lectures, Johns Hopkins University
(2008).
141.
“Parthanatos: A Novel Type of Cell Death.” First Annual Post-Baccalaureate Poster Day, National
Institute on Ageing Gerontology Research Center, Baltimore, MD (2008).
142.
“Dissecting Neuronal Death and Survival Signaling.” Neuroscience Seminar Series Program in
Neuroscience, Uniformed Services University of the Health Sciences, Bethesda, MD (2008).
143.
“Neuroprotective Signaling Pathways.” Burke Medical Research Institute, White Plains, NY (2008).
144.
“Genetic Clues to the Mystery of Parkinson Disease.” Gladstone Institute of Neurological Disease,
Department of Neurology University of California, San Francisco, CA (2008).
145.
“New Neuroprotective Signaling Pathways.” Brain Ischemia and Stroke Conference, Rome, Italy (2008).
146.
147.
“Genetic Clues to the Mystery of Parkinson Disease.” ERBI Fondazione Santa Lucia, Rome, Italy (2008).
“What Genetic Mutations Reveal About Parkinson’s disease.” Department of Physiology, Johns Hopkins
University School of Medicine, Baltimore, MD (2008).
148.
“Survival and Death Choices Regulated by mIRs.” Keystone Symposia Neurodegenerative Diseases: New
Molecular Mechanisms, Keystone, CO (2009).
149.
“Clues about Parkinson's disease from genetic mutations.” CDD Conference 2009 on Neurodegeneration,
Consiglio Nazionale delle Ricerche P.le Aldo Moro 7, 00185 Rome, Italy (2009)
150.
“Parkin, PARIS and mitochondrial stability - insight into Parkinson’s disease?” Neurodegeneration
Conference, University of Leicester, Leicester, England (2009).
151.
“A novel neurprotective protein, Botch, regulates neurogenesis through Notch.” University of Maryland,
Baltimore MD (2009).
152.
“Stem Cells” A Woman’s Journey, Baltimore, MD (2009)
153.
“LRRK2 Therapeutic Opportunities.” 2nd World Parkinson Congress, Glasgow, UK (2010)

Presentations to the Lay Public
Nitric Oxide and Schizophrenia. National Alliance for Research on Schizophrenia and Depression, New
York, NY (1996).
Nitric Oxide and Schizophrenia. National Alliance for the Mentally Ill, Washington, DC (1996).
Rebuilding the Brain. Breakers, Palm Beach, FL (2005)
Genetic Clues to the Mystery of Parkinson's Disease. 4th Annual Young-Onset Parkinson Network
Conference, National Parkinson Foundation, Reston, Virginia (2006)
Stroke. The American Alliance for Health, Physical Education, Recreation and Dance (AAHPERD) and the
American Heart Association National Convention, Baltimore, MD (2007)
New Opportunities to Repair the Brain. Legacy Lunch, Department of Neurology, Johns Hopkins, Baltimore
MD (2007)
Changes to the Maryland Stem Cell Commission, WYPR Maryland Morning with Sheilah Kast, March 9,
2009.
43
Valina L. Dawson, Ph.D.
Stem Cells, A Womans Journey, Johns Hopkins University

Teaching, Classroom Instruction
Course Director:
1996-present: Molecular Mechanisms of Cell Death: Necrosis to Apoptosis, JHU Medical School (ME:440.710)
Instuctor/Lecturer:
1994: Neuropathology Course, Free radicals and ALS. JHU Medical School
1994: Neurobiology of Disease, Cold Spring Harbor, NY
1995: Organ Systems, Endocrinology Discussion, JHU Medical School
1995: Neurobiology of Disease, Cold Spring Harbor, NY
1996: Organ Systems, Journal Club, JHU Medical School
1996: Organ Systems, Endocrinology Discussion, JHU Medical School
1996: Molecular Mechanisms of Neurologic Disease, Cold Spring Harbor, NY
1996: Biology of Neuropsychiatric Disorders, JHU Medical School
1997: Organ Systems, Journal Club, JHU Medical School
1997: Organ Systems, Endocrinology Discussion, JHU Medical School
1998: Cell Cycle, Cell and Molecular Medicine Program, JHU Medical School
1998: Biology of Neuropsychiatric Disorders, JHU Medical School
1999: Organ Systems, Endocrinology Discussion, JHU Medical School
1999: Molecules and Cells, Cell Physiology, Journal Club and Discussion, JHU Medical School
2000- Biology of Neuropsychiatric Disorders, JHU Medical School
2000- Organ Systems, Endocrinology Discussion, JHU Medical School
2001- Organ Systems, Endocrinology Discussion, JHU Medical School
2003- Neuroscience & Cognition II, Stroke (Global Function) JHU Medical School
2005- Neuroscience & Cognition II, Stroke (Global Function) JHU Medical School
2007- Neuroscience & Cognition II, Stroke (Global Function) JHU Medical School
2007- Neurobiology of Disease, Genes and Parkinson’s disease, Oregon Health and Sciences University,
Portland, OR

Thesis Committees
199519961996199719971998199919992000200120022002200520052005200620062007-
Cecilia Lobato, Department of Neuroscience
Jennifer Lewis, Department of Biological Chemistry and Molecular Biology
Sami Jaffery, Department of Neuroscience
Mikael Eliasson, Department of Neuroscience
Jennifer Nagy, Department of Biological Chemistry and Molecular Biology
Micheal Lai, Cell and Molecular Medicine Program
Tsing-Tsing, Department of Biological Chemistry
Crystal Watkins, Department of Neuroscience
Eric Nakamura, Cell and Molecular Medicine
Eileen Emson, Human Genetics Graduate Program
Adam Resnick, Department of Neuroscience
Sathya Ravichandran, Cell and Molecular Medicine
Sika Zheng, Department of Neuroscience
Cheng Dai, Department of Physiology
Karen Kate David, Cell and Molecular Medicine Graduate Training Program
Zhikai Chi, Department of Neuroscience
Xiaojie Li, Cell and Molecular Medicine Graduate Training Program
Eunhye Park, Cell and Molecular Medicine Graduate Training Program
44
Valina L. Dawson, Ph.D.
2007200720072009
Oral Examination Committees
19951996199619961997199719971997199819981998199819981999199919992001200220022002200320052005
Meghan Smith, Cell and Molecular Medicine Graduate Training Program
Sarah Texel, Department of Neuroscience
Yunjong Lee, Department of Physiology
Sean Byrne, Department of Physiology
Cecilia Lobato, Department of Neuroscience
Jennifer Lewis, Department of Biological Chemistry and Molecular Biology
Carlos Aizenman, Department of Neuroscience
Sami Jaffery, Department of Neuroscience
Mikael Eliasson, Department of Neuroscience
Jennifer Nagy, Department of Biological Chemistry and Molecular Biology
Perry Shieh, Department of Neuroscience
Yu Tzu, Department of Neuroscience
Micheal Lai, Cell and Molecular Medicine Program
Patrick Burnett, Department of Neuroscience
Nicole Striker, Department of Neuroscience
Patricia Finklestat, Department of Neuroscience
Xiaoling Li, Department of Biological Chemistry
Qianfei Wang, Cell and Molecular Medicine Graduate Program
Virote Sriuranpong, Cell and Molecular Medicine Graduate Program
Hong-Erh Liang, Department of Immunology
Felim MacGabhann, Biomedical Engineering
Bonnie Lonze Department of Neuroscience
Adam Resnick, Department of Neuroscience
Sathya Ravichandran, Cell and Molecular Medicine
Emmanual Karaginkus, Biomedical Engineering
Yen-Ching Wu, Department of Neuroscience (chair)
Annaka Lorinez, Pathobiology Graduate Training Program
Awards and Honors to Trainees
1995
1996
1996
1997
1998
1998
1998
1998
1998
1998
1998
1998
1998
1999
1999
2000
2000
National Research Service Award to Jun Bao
Howard Hughes Medical Student Fellowship to Amer Samdani
Boehringer Ingelheim Fonds Postdoctoral Fellows Award to Mirella Gonzalez-Zulueta
Clinician Development Award to W. Joey Herring
Clinician Development Award to Allen S. Mandir
David Israel Macht Medical Student Scholar Award to D. Cory Adamson
Barry Wood Postdoctoral Scholar Award to Mirella Gonzalez-Zulueta
National Research Service Award to James Dillmann III
Spinal Cord Foundation Scholar Award to James Dillman, III
Howard Hughes Student Fellowship Award to Carmen Coombs
Howard Hughes Student Fellowship Award to Robert Fekete
First Prize, Johns Hopkins University Graduate Student Association Poster Presentations to D. Cory
Adamson
Canadian Heart and Stroke Foundation Scholar Award to Marc Poitras
Howard Hughes Student Fellowship Award to Robert Fekete
Barry M. Goldwater Scholarship to Robert Fekete
Howard Hughes Student Fellowship Award to Robert Fekete
Howard Hughes Student Fellowship Award to Karen Hirsch
45
Valina L. Dawson, Ph.D.
2002
2003
2003
2003
2004
2004
2004
2005
2005
2005
2005
2005
2006
2006
2006
2006
2006
2006
2007
2007
2008
2008
2008
2008
2008
2009
2009
Christopher Reeve Scholarship to David Koh
American Heart Association Postdoctoral Fellowship to Dong Liang
American Heart Association Predoctoral Fellowship to Sika Zheng
Society for Neuroscience Fellowship Award to Karen Kate David
American Heart Association Predoctoral Fellowship to Cheng Dai
Parkinson’s Disease Foundation Viola Kerr Postdoctoral Fellowship to Li (George) Zhang
Cayman Chemical Travel Award to Society for Neuroscience meeting to Seong Woon Yu
Barry M. Goldwater Scholarship to Catherine Choi
Emily and Thomas Meren Scholars Award to Neena Marupudi
Keystone Travel Award, Stem Cells, Hong Kong to Karen Kate David
American Heart Association Postdoctoral Fellowship to NoSoo Kim
National Research Service Award to Andrew B. West
American Heart Association Predoctoral Fellowship to Zhikai Chi
American Heart Association Postdoctoral Fellowship to Shaida Andrabi
The Best Oral Presentation Award by a Student or a Post-Doctoral Fellow, East Coast PARP 2006
Conference, Quebec City, Canada to Shaida Andrabi
Singapore Millenium Foundation Ltd Postdoctoral Fellowship to Jeanne Tan
Peter Gruber International Research Award, Society for Neuroscience, to Saskia Biskup
K99/R00 NINDS to Andrew B. West
HHMI Cloister Program to Jasmine Lew
American Heart Association Postdoctoral Fellowship to Jianmin Zhang
MDTEDCO Postdoctoral Fellowship to Majed Harraz
American Heart Association Postdoctoral Fellowship to Amos Fatokun, *Highest score for a postdoctoral
fellowship, Mid-Atlantic Affiliate.
American Heart Association Postdoctoral Fellowship to Yingfei Wang
American Heart Association Postdoctoral Fellowship to Majed Harraz
Woodrow Wilson Research Fellowship Program to Karthik Rao
Keystone Scholarship to Ishrat Ahmed
William D. McElroy Award for Meritorious Research to Ishrat Ahmed
ORGANIZATIONAL ACTIVITIES

Scientific Meetings, Chair
Neurodegenerative Diseases: New Molecular Mechanisms (J5-2009) Organizer(s): Valina L. Dawson and
David M. Holtzman Keystone Resort, Keystone, Colorado • February 17 - February 22, 2009

Scientific Sessions, Chair
Excitatory Amino Acids: Neurotoxicity. Society for Neuroscience Annual Meeting, Washington D.C. (1993).
Nitric Oxide and Free Radicals in Neurotoxicity. International Union of Pharmacology Satellite Symposium
on In Vitro Neurotoxicity, Val Morin, Quebec, Canada (1994).
Oxidative Stress/Cellular Metabolism. Neurodegenerative Diseases '95: Cellular and Molecular Mechanisms
and Therapeutic Advances, George Washington University, Washington, D.C. (1995).
Nitric Oxide and Neuronal Disorders. Free Radicals in Brain Physiology and Disorders: An International
Conference - Tokyo Symposium, Tokyo, Japan (1995).
Degenerative disease: Other-Molecular Biology. Society For Neuroscience Annual Meeting, Washington,
D.C. (1996)
Response of the Nervous System to Ischemia and Injury. 8th International Symposium on Stroke,
Neurotrauma and Other Neurological Diseases, New Orleans, LA (1997).
NO and Regulation of Cerebral Blood Flow and Airway Function. Third International Meeting of NO:
Biochemistry and Biology, Los Angeles, CA (1998).
46
Valina L. Dawson, Ph.D.
Plenary session 6-Approaches to Therapeutic Development: Neurologic Diseases, Heart Attack, Stroke,
Septic Shock, Respiratory Diseasea, Arthritis. 13th International Symposia on ADP-Ribosylation, New York,
NY (2001).
The secret life of mitochondria. Winter Conference on Brain Research, Salt Lake City, UT (2003).
Poly (ADP-ribosyl)ation reactions: Basic Mechanisms. Poly(ADP-ribose)polymerases as Novel Therapeutic
Targets, Lisbon (2003).
Genomics-Proteomics Relationship to Stroke, 33rd Princeton Conference on Stroke, Baltimore MD (2004).
Neurodegenerative Diseases, Mitochondria and Neuroprotection Symposium, Fort Lauderdale, FL (2004).
Neuroprotection, 4th International Congress on Genetics and Regeneration in Neuroscience Terni, Italy
(2004).
Mechanisms of ischemic damage, 10th International Symposium on Pharmacology of Cerebral Ischemia,
Marburg, Germany (2004)
Mechanisms of Neuronal Cell Death. Programmed Cell Death, Cold Spring Harbor, NY (2005).
Bioenergetics and Neuronal Cell Death, Keystone Symposia on Metabolomics: Bioenergetics to Apoptosis,
Snowbird, UT (2006).
Update on the molecular pathogenesis and protein interactions in Parkinson's disease, The Movement
Disorder Society 11th International Congress of Parkinson’s Disease and Movement Disorders, Istanbul,
Turkey (2007).
Neural Stem Cells, 2009 World Stem Cell Summit, Baltimore, MD (2009)

Advisory Committees
Advisory Committee, XVIII International Symposium on Cerebral Blood Flow and Metabolism, Baltimore,
MD (1997).
Advisory Committee, 8th International Symposium on Stroke, Neurotrauma and Other Neurological
Diseases, New Orleans, LA (1997).
Advisory Committee, 9th International Symposium on Stroke, Neurotrauma and Other Neurological
Diseases, Martin, Slovakia (1999).
1st International Conference on the Biology, Chemistry and Therapeutic Applications of Nitric Oxide. San
Francisco, CA (2000) Scientific Advisory Board
Princeton Conference 2002, Los Angeles, CA (2002) Scientific Advisory Board
9th International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany (2002), Scientific
Advisory Board
Scientific Advisory Board, 36th Winter Conference on Brain Research, Snowbird UT (2002)
10th International Symposium on Pharmacology of Cerebral Ischemia, Marburg, Germany (2002), Scientific
Advisory Board (2004)
33rd Princeton Conference on Stroke, Baltimore MD (2004)
2004 Terni Conference on Cerebrovascular Disease and Stroke, President, Terni, Italy (2004)
Scientific Advisory Board, Winter Conference on Brain Research, Snowbird UT (2004-2005)
American Heart Association, Mid-Atlantic Affiliate Peer Review Consortium Steering Committee (2005 –
present)
47
Valina L. Dawson, Ph.D.
Scientific Advisory Board, Senator Paul D. Wellstone Muscular Dystrophy Center, Johns Hopkins
University School of Medicine. (2005-present)
Scientific Advisory Board, International Symposium On Neurodegeneration and Neuroprotection, Muenster,
Germany (2006).
NINDS Stroke Progress Review Group, Genomics/Proteomics section, Chair (2006)
Steering Committee, UAMRMC Military Operational Medicine Research Program, Neurotoxin Exposure
Treatment Research Program, (2006)
SfN Young Investigator Award Committee, Society for Neuroscience (2007-2009)
SfN Committee on Women in Neuroscience (2007-2010)
Scientific Advisory Board, Brain Ischemia and Stroke Conference, Rome Italy, (2008)

Grant Review, National
1993
1994
1994
1994
1994
1995
1995
1996
1997
1998
1998
1998
1998-2002
National Science Foundation
Amyolateral Sclerosis Association National Review
NIH, National Institute on Aging: Program Project Grant Review
American Paralysis Association
New York Academy of Sciences: Conference proposal review
NIH, Child Health: Program Project Grant Review
NIH, NIMH: Program Project Grant Review
Alzheimer’s Association
Spinal Cord Foundation
NIH, Child Health: Program Project Grant Review
Amyotrophic Lateral Sclerosis Association National Review
BCDN-3, NIH Ad hoc, 10/98
NeurotoxinExposure Research Treatment Program. Department of Defense, American Institute of
Biological Sciences
1999United States-Israel Binational Science Foundation
1999
MDCN, NIH 3/98
1999
Board of Scientific Counselors Ad Hoc
1999
National Institute of Mental Health Review #0822
1999
Alzheimer’s Association
1999
Amyolateral Sclerosis Association National Review
2000
National Institute of Neurologic Disease and Stroke, NSDA Study Section, Ad Hoc 10/00
2000
National Institute of Heart and Lung, Lung Biology and Pathology Study Section, Ad Hoc 06/00
2000
Muscular Dystrophy Association
2001-2004 National Institute of Neurologic Disease and Stroke, NSD-A Study Section member
2001National Institute of Neurologic Disease and Stroke, Chairman - Special Emphasis Panel, ZNSI
SRB-W (03) June 15, 2001.
2003National Institute of Neurologic Disease and Stroke, Chairman
2001-2002 Muscular Dystrophy Association, National Council
2001-2004 American Heart Association, Beginning Grant-in-Aid Study Section, National
2001-2004 American Heart Association, Mid-Atlantic Study Section
2004-2005 American Heart Association, National, Brains Sciences 2 Study Section – Co-Chair
2004-2005 National Institute of Neurologic Disease and Stroke, NSD-A Ad Hoc
2006
American Heart Association, National, Brains Sciences 3
2006-present NINDS K99-R00 Review Panel, Chair
48
Valina L. Dawson, Ph.D.

Grant Review, International
1996
1997
1998
2000
2001
2002
2004
2004
2008

The Israel Science Foundation
The Israel Science Foundation
Research Grants Council, Hong Kong, China
Welcome Trust Foundation, England
Welcome Trust Foundation, England
Welcome Trust Foundation, England
Welcome Trust Foundation, England
Research Grants Council, Hong Kong, China
Parkinson's Disease Society (PDS), United Kingdom
Editorial Board Appointment
1997- 2003: Stroke, Associate Editor,
1996- present: NITRIC OXIDE Biology and Chemistry, Associate Editor
2000- present: Neurobiology of Disease, Associate Editor
2003- present: Journal of Neuroscience, Reviewing Editor
2004- present: Journal of Cerebral Blood Flow and Metabolism, Associate Editor
2007- present: Journal of Molecular Medicine, Reviewing Editor
2007: Proceeding National Acadamy of Sciences, Guest Editor

Ad Hoc Manuscript Reviews
Science
Nature
Nature Medicine
Nature Neuroscience
Nature Reviews Drug Discovery
Nature Reviews Molecular Cell Biology
Nature Reviews Neuroscience
Neuron
Proceedings of the National Academy of Sciences, USA
American Journal of Physiology
Annals of Neurology
Biochemical Pharmacology
Brain Research
British Journal of Pharmacology
Cardiovascular Research
Cancer Research
Cell Death and Differentiation
CNS Drugs
Comparative Biochemistry and Physiology
European Journal of Neuroscience
European Journal of Pharmacology
Experimental Dermatology
Experimental Neurology
FEBS Letters
49
Valina L. Dawson, Ph.D.
FASEB Journal
Glia
Human Molecular Genetics
Journal of Biological Chemistry
Journal of Cell Biology
Journal of Cerebral Blood Flow and Metabolism
Journal of Chemical NeuroAnatomy
Journal of Clinical Investigation
Journal of Leukocyte Biology
Jounal of Molecular Medicine
Journal of Neurochemistry
Journal of Neuroimmunology
Journal of Neuroscience
Journal of the Neurological Sciences
Journal of Pharmalcologic and Experimental Therapeutics
Journal of Thoracic and Cardiovascular Surgery
Journal of Virology
Molecular and Cellular Neuroscience
Molecular Chemistry and Neuropatholgy
Nature Reviews Drug Discovery
Nature Reviews Molecular Cell Biology
Neurobiology of Aging
Neurobiology of Disease
NeuroImmunoModulation
Neurologist
Neuropharmacology
Neuropathology and Applied Neurobiology
Neuroscience
Neuroscience Letters
Nitric Oxide: Biology and Chemistry
Oncogene
Oncology
Pharmacology Biochemistry and Behavior
Research Communications in Molecular Pathology and Pharmacology
Stroke
Survey of Opthalmology: An International Reveiw Journal
Synapse
Trends in Cell Biology
Trends in Moleclar Medicine
Trends in Neuroscience
Trends in Pharmacologic Science

Institutional Committees
1994-1996
Department of Neurology Incentive Plan Committee
50
Valina L. Dawson, Ph.D.
1996-present
1998-2005
2001-2004
2001-2004
2001, 2002
2003-2004
2003-2004
2003-present
2004-present
2003-present
2004-present
2006-present
2009-present

Administrative, Institutional
1996-2005:
1996-present:
1998-present:
1998-present:
1999-2004:
2005-present
2001-present:
2003-2004
2004-present

Executive Committee, Department of Neuroscience
Executive Committee, Graduate Program in Cell and Molecular Medicine
Women Leadership Council – Steering Committee
Admissions Committee, Department of Neuroscinece
Search Committee, Department of Neuroscience
Radiology Director – Search Committee
Conflict of Interest Committee
Progress Committee, Department of Neuroscience
Apointments and Promotions Committee, Department of Neurology
Advisory Board, Institute for Cell Engineering
Advisory Board, Gene Vector Center
Executive Committee, Department of Neurology
Embryonic Stem Cell Research Oversight Committee (ESCRO), Johns Hopkins University
School of Medicine
Director of Clinical Neuroscience Seminar Series, Department of Neurology, JHU Medical
School
Executive Committee, Department of Neuroscience, JHU Medical School
Policy Committee, Cell and Molecular Medicine Program, JHU Medical School.
Education Committee Coordinator, Cell and Molecular Medicine Program, JHU Medical School.
Rotation Coordinator, Cell and Molecular Medicine Program, JHU Medical School.
Thesis Progress Committee, Cell and Molecular Medicine Program, JHU Medical School.
Vice Chairman for Faculty Development, Department of Neurology
Conflict of Interest Committee
Chair, Promotions Committee, Department of Neurology
Professional Societies
Society for Neuroscience
Women in Neuroscience
American Association for the Advancement of Science
American Neurologic Association
American Heart Association
The New York Academy of Sciences

Consultantships
AGY Therapeutics, San Francisco, CA - Scientific Advisory Board, 1998-2002
Abbott Laboratories, Abbott Park, IL – Consultant, 2005
51